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ABSTRACT 
 
 Endometrial adenocarcinomas are considered rare tumours in domestic 
animals, though, in the cat, these are often described as the uterine tumours most 
frequently diagnosed. In fact, in recent years we have been witnessing to an 
increase in the number of publications in the topic, raising the question of the 
increasing prevalence of these tumours. Nevertheless, knowledge of these 
neoplasms is still scarce. The present study foresaw to contribute to the 
understanding of feline endometrial adenocarcinomas (FEA). 
The study of neoplastic disease of the genital tract in companion animal is of 
great interest, either from the prospect of fertility or from the clinicopathological point 
of view. Thus, we believe that this work will contribute to the recognition of FEA as 
an entity with clinical relevance that should be considered for the differential 
diagnosis within the causes for uterine disease. 
In the present study, the morphological and histopathological features of FEA 
are described and the immunohistochemical profile of the papillary serous type 
determined, regarding a broad panel of antibodies. Normal uterine samples in 
follicular and luteal stages of the feline estrous cycle are also used as controls, to 
establish the normal pattern of expression, because seldom existed available 
descriptions for most of the antibodies/markers used herein. We believe that the 
findings report in this study would greatly facilitate the routine histopathological 
diagnosis. Dedifferentiation markers are suggested with the immunophenotyping of 
the tumours under study. Also, putative molecular mechanisms underlying 
carcinogenesis and proliferation of the cat endometrium are unveiled. 
Regarding the immunophenotype of the papillary serous FEA, data gathered 
herein suggests that proliferation in those tumours accompanies estrogen receptor 
α (ER-α) down-regulation, possibly following activation of pathways mediated by 
local growth factors. Moreover, FEA retained combined expression of cytokeratin 
(CK) 7 and CK20, as evidenced in normal endometrial epithelia, although the CK7 
expression was decreased. Cyclooxygenase – 2 (COX-2) scores were decreased 
in FEA; however, evidence for the loss of compartmentalization in COX-2 
expression by the neoplastic epithelium most likely reflects the involvement of this 
enzyme in feline endometrial carcinogenesis. The majority of the cases under study 
were positive to c-erbB-2 immunolabeling; however, a decrease in the expression 
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of this protein was observed compared to the follicular stage of normal 
endometrium. Comparing the results of c-erbB-2 scoring with those of the 
proliferation marker Ki-67, it was suggested that the former might not be involved in 
FEA proliferation events. Data also suggest that the expression of c-erbB-2 in the 
endometrium is influenced by functional changes occurring during the estrous cycle 
and feline endometrial carcinogenesis. 
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RESUMO 
 
Os adenocarcinomas do endométrio são considerados tumores raros nos 
animais domésticos, embora na gata sejam muitas vezes descritos como os 
tumores uterinos mais frequentemente diagnosticados. De fato, nos últimos anos 
temos vindo a assistir a um aumento no número de publicações sobre o tema, 
levantando a questão do aumento da prevalência destes tumores. No entanto, o 
conhecimento dessas neoplasias ainda é escasso. O presente estudo pretende 
contribuir para a compreensão dos adenocarcinomas do endométrio da gata (FEA). 
O estudo das doenças neoplásicas do trato genital dos animais de 
companhia é de grande interesse, quer na perspetiva da fertilidade, quer do ponto 
de vista clínico-patológico. Assim, acreditamos que este trabalho contribuirá para o 
reconhecimento dos FEA como uma entidade com relevância clínica que deve ser 
considerada no diagnóstico diferencial da doença uterina. 
No presente estudo descrevemos as características morfológicas e 
histopatológicas dos FEA, assim como o perfil imunohistoquímico do tipo papilar 
seroso, em relação a um amplo painel de anticorpos. Amostras de úteros normais 
nas fases folicular e lútea do ciclo éstrico da gata são também utilizadas como 
controlos, para estabelecer o padrão normal de expressão, pois raramente existem 
descrições disponíveis para a maior parte dos anticorpos / marcadores aqui 
utilizados. Acreditamos que as conclusões do nosso trabalho facilitarão o 
diagnóstico histopatológico de rotina. Marcadores de indiferenciação são sugeridos 
com a imunofenotipagem dos tumores em estudo. Além disso, sugerimos 
mecanismos moleculares considerados como subjacentes à carcinogénese e 
proliferação do endométrio da gata. 
Em relação ao imunofenótipo dos FEA papilares serosos, os dados aqui 
recolhidos sugerem que a proliferação desses tumores acompanha a subregulação 
do recetor de estrogénios α (ER-α), possivelmente após a ativação de vias 
mediadas por fatores de crescimento locais. Adicionalmente, os FEA mantiveram a 
expressão combinada das citoqueratinas (CK) 7 e CK20, como evidenciado no 
epitélio do endométrio normal, embora a expressão da CK7 estivesse diminuída. 
Os scores da ciclooxigenase - 2 (COX-2) encontravam-se diminuídos nos FEA; no 
entanto, a perda de compartimentalização da COX-2 no epitélio neoplásico reflete 
provavelmente o envolvimento desta enzima na carcinogénese do endométrio da 
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gata. A maioria dos casos em estudo foram positivos para a imunomarcação com 
o anticorpo anti-c-erbB-2; no entanto, foi observada uma diminuição na expressão 
desta proteína em comparação com a fase folicular do endométrio normal. 
Comparando os resultados do score de c-erbB-2 com aqueles do marcador de 
proliferação Ki-67, foi sugerido que o primeiro não deverá estar envolvido em 
eventos de proliferação FEA. Os dados também sugerem que a expressão de c-
erbB-2 no endométrio é influenciada por alterações funcionais que ocorreram 
durante o ciclo éstrico e a carcinogénese do endométrio da gata. 
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SYMBOLS, ABBREVIATIONS AND ACRONYMS 
 
CEH – Cystic endometrial hyperplasia 
CEH/P – Cystic endometrial hyperplasia / pyometra complex 
c-erbB-2 (HER2) – Human epidermal growth factor receptor type 2 
CI – Confidence interval 
CK – Cytokeratin 
cm – Centimeter 
COX – Cyclooxygenase 
DAB – 3,3’- diaminobenzidine 
DGE – Deep glandular epithelium 
EGF – Epidermal growth factor 
EGFR – Epidermal growth factor receptor 
ER – Estrogen receptor 
FEA – Feline endometrial adenocarcinoma (s) 
FS – Folicular stage 
FSH – Follicle stimulating hormone 
GnRH – Gonadotropin releasing hormone 
HPF – High power field 
IGF-1 – Insulin-like growth factor 1 
kDa – KiloDalton 
L – Litre 
LH – Luteinizing hormone 
LS – Luteal stage 
ml - Milliliters 
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mm – Millimeters 
μm - Micrometers 
mRNA – Messenger ribonucleic acid 
n – Number 
NE – Normal epithelium 
OVH – Ovariohysterectomy  
PBS – Phosphate buffered saline 
PCNA – Proliferating cell nuclear antigen 
PDP – Progesterone-dependent secretory protein 
pg – Picogram 
PG – Prostaglandin (s) 
PLA2 – Phospholipase A2 
PR – Progesterone receptor 
SE – Surface epithelium 
SGE – Superficial glandular epithelium 
TGF-α – Transforming growth factor alpha 
TNF- α – Tumour necrosis factor alpha  
VEGF – Vascular endothelial growth factor 
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GENERAL INTRODUCTION 
 
The survival of a species depends on homeostasis of all organic systems, the 
reproductive tract being one of the most important. In the past few decades, 
diseases of the reproductive tract have not changed much but the understanding of 
the molecular events underlying those diseases, the new advanced methods of 
treatment and the predictive value of morphological and molecular markers in the 
outcome of reproductive system pathology largely improved. A great emphasis has 
been given to production animals since its reproduction is essential to continued 
supply of food. However, with the increasing social (and economic) importance of 
companion animals, a lot of effort was taken to understand and treat diseases of the 
reproductive tract of dogs and cats (Foster, 2007). 
The ultimate role of the female reproductive tract is to provide location for the 
conception, to guarantee the embryo survival, and to succeed on the development 
and release of viable offspring (Foster, 2007; Ponnampalam et al., 2004). Diseases 
of the reproductive tract disrupt all these biological functions. 
In order to understand the pathology of an organic system or a particular 
organ, it is of utmost importance to recognize its normal physiology and morphology. 
Therefore in this chapter, we will focus in the morphological and physiological 
aspects of the normal reproductive tract of queens. 
 
ANATOMY OF THE GENITAL TRACT 
 
The reproductive tract of queens, as in other mammal females, consists of 
paired ovaries for the oogenesis – the primary reproductive organs -, and a tubular 
duct system – the secondary reproductive organs - to facilitate fertilization of ova 
and to support pregnancy (Rastogi, 2007; Williamson, 1988). 
During ovarian development - a gene regulated mechanism – the germ cells 
undergo meiosis and the supporting cells surround the oocytes to become the cells 
of the follicles. The development of the paramesonephric (Müllerian) ducts 
determines the differentiation of the tubular genitalia according to a female 
phenotype, originating the uterine tube, uterus and upper part of the vagina. The 
genital tubercle develops into the distal vagina and vulva (Inomata et al., 2009). 
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OVARIES 
The normal ovaries are located caudal and laterally to the caudal poles of the 
kidneys; their macroscopic appearance varies with the stage of the estrous cycle 
(Davidson and Baker, 2009). 
The ovary has two main functions namely the development and release the 
ova and to produce hormones, such as estrogen and progesterone. Ovarian 
hormones influence animal behaviour and affect all organic systems. The 
hypothalamus and pituitary gland control the ovarian function through the release of 
gonatropin releasing hormone (GnRH), follicle stimulating hormone (FSH) and 
luteinizing hormone (LH) (Foster, 2007). 
 
TUBULAR GENITALIA 
Four regions compose the uterine tube: infundibulum (which surrounds the 
ovary), ampulla, isthmus and the uteral-tubal junction. Fertilization occurs in the 
uterine tube; afterwards, the conceptus moves into the uterus (Foster, 2007). In 
carnivores, for a short period after the entrance in the uterus, the young embryo free 
floats within the uterine cavity, allowing the implantation of multiple embryos at 
equidistant distances from each other (Lamm and Makloski, 2012). 
The uterus develops from the paramesonephric ducts of the embryo (König 
and Liebich, 2007). As age and physiological activity influence uterine anatomy 
(König and Liebich, 2007), general descriptions of uterine anatomy usually refer to 
mature and non-pregnant uterus (König and Liebich, 2007).  
Cats have a bicornuate uterus, Y-shaped, with two horns longer than the 
uterine body (Foster, 2007). The uterus is an abdominopelvic organ, located from 
the pelvis to the kidneys, dorsal to the intestines (König and Liebich, 2007). It 
receives the uterine tubes anteriorly and opens to the vagina posteriorly (Sisson, 
1910). Two major double folds of peritoneum attach the uterus (as well as the 
ovaries and the uterine tubes) to the lumbar wall of the abdomen and the lateral 
walls of the pelvic cavity – the broad ligaments of the uterus (König and Liebich, 
2007; Sisson, 1910). The uterine horns are entirely located in the abdomen, pressed 
up against the sublumbar muscles by the intestine (Sisson, 1910). The dorsal border 
is attached to the broad ligament, while the ventral border remains free (Sisson, 
1910). The dorsal surface of the uterine body is related to the colon and rectum, 
whereas its ventral surface is related to the bladder (Davidson and Baker, 2009; 
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Sisson, 1910). The cervix of the uterus is the most posterior segment in contact to 
the vagina (Sisson, 1910). It is located slightly cranial to the bladder trigone, with 
which is ventrally related along with the urethra, and is best seen when under 
hormonal influence, either by estrogens or progesterone (Davidson and Baker, 
2009). The cervix of the queen cannot be directly observed by gynaecologic 
examination due to a thin and undistensible cranial vagina (Zambelli et al., 2015). 
The broad ligaments extends from the sublumbar region and the lateral pelvic 
walls to the dorsal border of the uterine horns and the lateral margins of the uterine 
body. The outer layer of each forms a fold – the round ligament of the uterus – which 
blends to the parietal peritoneum; the anterior extremity is located above the 
extremity of the uterine horns and is free. The vessels and nerves that irrigate the 
uterus travel through the broad ligament. The principal arteries that supply the 
uterus are the uterine and the uterine branch of the ovarian artery. Additionally, there 
is a branch of the internal pubic artery. The homologous veins accompanies the 
arteries. The lymphatics drain to the internal iliac and lumbar lymph nodes. The 
nerves are derived from the sympathetic through the uterine and the pelvic plexuses 
(Sisson, 1910). 
The cervix is oriented obliquely between the uterine body and vagina, forming 
an obtuse angle with the vagina. It is located 40–45 mm anterior to the vulva 
(Zambelli and Cunto, 2005). The major functions of the cervix include: providing a 
functional barrier, protecting the uterus from the external environment; holding the 
products of conception during pregnancy; and transport the sperm during breeding 
(Chatdarong et al., 2006; Foster, 2007; Zambelli and Cunto, 2005). The feline cervix 
cannot be visualized unless with endoscopy (Zambelli et al., 2015). In cats, the 
cervix tends to open dorsally and has a relatively smooth mucosa (Foster, 2007). 
The mucosa of the uterine cervix is elevated into longitudinal folds that may become 
subdivided into secondary and tertiary folds (Bacha and Bacha, 2012). 
The vestibule has 1-2 cm in length and is large in comparison to the vagina; 
the latter has a narrow lumen, which is further constricted by a prominent dorsal 
median fold. The vaginal fornix is located ventrolateral to the cervix (Zambelli and 
Cunto, 2005). Vaginal and cervical modifications during the stages of the estrous 
cycle are described regarding anatomical variations (Zambelli et al., 2004). 
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EXTERNAL GENITALIA 
The vulva is the terminal part of the genital tract and includes the vestibule, 
labia, and clitoris (Sisson, 1910). Amongst with the vagina, the vulva protects the 
uterus and cervix, reducing the contamination. These stuctures also provide a 
passageway to foetus at parturition (Foster, 2007). 
 
HISTOLOGY OF THE GENITAL TRACT 
 
OVARIES 
The ovary is a compact organ, consisting of two portions – cortex and medulla 
- surrounded by an outer layer of epithelium. The cortex is composed by follicles in 
different stages of development, stromal connective tissue, interstitial glands and 
blood vessels, whereas the medulla presents many large blood vessels, lymphatics, 
nerves and loosely connective tissue. In this region, remnants of the mesonephric 
tubules – the rete ovarii – are observed (Bacha and Bacha, 2012). 
Within the ovary, follicular units composed of specialized cells surround each 
ova (or oocyte). The follicle plays a major function in the normal development of the 
oocyte. The process by which follicles mature is referred to as folliculogenesis, 
which is under the control of the hypothalamic-pituitary-ovary axis. The ovary itself 
produces several growth factors also responsible for follicular development. During 
folliculogenesis, follicular morphology changes according to oocyte growth and 
differentiation of surrounding cells (Bristol-Gould and Woodruff, 2006). 
Follicles are classified as primordial, primary, secondary and antral follicles, 
according to their timeline evolution (Reynaud et al., 2009; Uchikura et al., 2010). 
Throughout the follicular progression, there is an increase of the follicle diameter, 
oocyte diameter and zona pellucida thickness (Reynaud et al., 2009). Primordial / 
primary follicles are characterized by oocytes surrounded by a single layer of 
granulosa cells. Secondary follicles contain two or more layers of granulosa cells 
and a theca cell is deposited on the side opposite to the basement membrane from 
granulosa cells (Bristol-Gould and Woodruff, 2006; Uchikura et al., 2010). The theca 
differentiates into a cellular, vascular inner layer, the theca interna, and an outer 
layer of connective tissue, the theca externa (Bacha and Backa, 2012). Oocyte in 
antral follicles are surrounded by multi-layered granulosa cells; the main 
characteristic of these follicle is the appearance of a fluid-filled antrum. Multi-oocyte 
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follicles are characterized by two or more oocytes. Throughout the estrous cycle, 
follicles can be generally classifies as quiescent, growing or atretic (Bristol-Gould 
and Woodruff, 2006; Uchikura et al., 2010). Although many primordial follicles begin 
the process of growth and differentiation, few become mature. The majority undergo 
a degenerative regression, becoming atretic (Bacha and Bacha, 2012). 
The oocyte release at ovulation following the rupture of the follicular walls – 
ovulation – leads to the formation of a blood clot within the follicular space, which 
will be posteriorly infiltrated by mural granulosa cells – corpus hemorrhagicum – that 
will transform, together the thecal cells, into luteal cells – corpus luteum. The 
regression of the corpus luteum leaves a scar called corpus albicans (Bacha and 
Bacha, 2012). 
 
TUBULAR GENITALIA 
The structure of the uterine wall includes three layers: the endometrium, the 
myometrium and the perimetrium (Bacha and Bacha, 2012). The endometrium is 
lined by a simple cuboidal or columnar layer of epithelial cells, supported by a 
stromal component, the lamina propria, where variable numbers of straight, simple, 
branched glands are also present and open into the lumen (Aughey and Frye, 2001; 
Bacha and Bacha, 2012; Foster, 2007). The glandular epithelium is similar to the 
surface epithelium (Junqueira and Carneiro, 2004). Connective tissue from the 
lamina propria, mainly composed by fibres of collagen type III, is rich in fibroblasts 
and extracellular matrix is abundant (Junqueira and Carneiro, 2004). The 
inflammatory and immune cells residing in the endometrium (Foster, 2007) varies 
according to the stage of estrous cycle. The work of Tavares Pereira (2012) showed 
that the pattern distribution of resident B and T lymphocytes and macrophages are 
different according to the layer of endometrium and also that their numbers change 
during the oestrus cycle, suggesting that immune cells distribution may be related 
with the functions of the organ (Tavares Pereira, 2012). 
The endometrium can be divided in three anatomical layers: 1) a superficial 
area, encompassing the area of the surface epithelium and the opening of glandular 
crypts (equivalent to the superficial component of the named stratum functionalis in 
humans); 2) a basal area, surrounding the deep endometrial glands, closer to the 
myometrium (equivalent to the named stratum basalis in humans); and 3) an 
intermediate, between the former two layers (equivalent to the remainder of the 
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stratum functionalis), with a variable number of glandular elements depending on 
the stage of the estrous cycle (Payan-Carreira et al., 2014). 
The myometrium is composed of a deep inner layer and an outer layer of 
circular and longitudinal smooth muscle, respectively. These two layers are 
separated by the stratum vasculare, a layer of connective tissue with large blood 
vessels (Aughey and Frye, 2001; Bacha and Bacha, 2012).  
The perimetrium or serosa is the outer loose connective tissue layer, which 
is continuous with the broad ligament (Aughey and Frye, 2001). 
The cervix is lined by simple columnar epithelium with goblet cells. Glandular 
tissue fades in the cervix, extending to the cervical outer orifice. The muscularis is 
composed by an inner circular and an outer longitudinal layer of smooth muscle 
(Bacha and Bacha, 2012). 
The mucosa of the vagina is lined by a stratified squamous epithelium. The 
inner layer of the muscularis is thick and consists of circularly arranged smooth 
muscle, while the outer layer is thin and consists of longitudinally organized smooth 
muscle. In the queen, a thin layer of longitudinal muscle occurs internal to the 
circular layer. An adventitia or serosa is present (Bacha and Bacha, 2012). ). The 
cervical and vaginal epithelia undergo histologic variations during the stages of the 
estrous cycle (Mills et al., 1979). 
 
EXTERNAL GENITALIA 
The mucosal epithelium of the vulva is stratified squamous. The major 
vestibular glands are bilateral, mucus-secreting, tubuloacinar glands in the 
submucosa. Minor vestibular glands are small, branched, tubular, mucous glands 
distributed through the vestibular mucosa. The integument of the labia (lips of the 
vulva) has a structure like that of the external skin. It is well endowed with both 
sebaceous and tubular apocrine glands. The clitoris consists of erectile tissue 
(corpus cavernosum clitoridis), a glans, and a prepuce (Bacha and Bacha, 2012). 
 
FELINE ESTROUS CYCLE 
 
The estrous cycle refers to the physiological cyclic changes, both organic and 
behavioral, induced by different hormonal profiles. Regular estrous cycles start after 
sexual maturity, which in domestic cats is achieved when the female attains 
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approximately 80% of the adult body weight, normally between 5 and 12 months of 
age, if the photoperiod is adequate (Feldman and Nelson, 2004; Schmidt, 1986). 
The age at the onset of estrous cycles also depends on the breed and on the as the 
date of birth (Schmidt, 1986). Cats are seasonally polyestrous (Feldman and 
Nelson, 2004; Kutzler, 2007; Schmidt, 1986), the seasonality being determined by 
day length (Gimenez et al., 2009; Kutzler, 2007; Leyva et al., 1989). Cats are long 
day breeders. Therefore, in the North Hemisphere, a prolonged anestrus occurs 
from September to January, when the length of the day is shorter (Kutzler, 2007). 
However, anestrus may be minimal or non-existent in household animals, 
maintained with fourteen hours of light and moderate environmental temperatures 
(Tsutsui and Stabenfeldt, 1993). Additionally, audiovisual and olfactory signs 
presented by the females in estrus affect queens’ behavior (da Silva et al., 2006).  
Cats show a distinctive peculiarity on their estrous cycle: in felids, ovulation 
is not spontaneous but triggered by mating (Kutzler, 2007; Schmidt, 1986; Wildt et 
al., 1981). However, in some cases (that may reach up to 25%) spontaneous 
ovulations can occur, mainly in very young or older queens living in larger groups, 
possible triggered by visual and pheromone stimuli (Goericke-Pesch, 2010; 
Gudermuth et al., 1997). 
Consequently, cats may present two types of estrous cycle: the anovulatory 
cycles, when ovulation is not achieved, and the ovulatory cycles, often associated 
with mating (FIGURE 1). The anovulatory cycle is characterized by successive 
follicular stages (representing the proestrus and estrus), that lasts for 1 to 7 days 
(although it may last up to 16-20 days, according to Fontbonne and Garnier, 1998), 
separated by a short interestrous interval (ranging from 9 to 19 days), equivalent to 
the period of atresia of one follicular wave and the emergence of the subsequent 
one; in these cycles, no luteal stage exists (Tsutsui and Stabenfeldt, 1993). 
The ovulatory cycle occurs when mating or spontaneous ovulation take place 
(Borges et al., 2015). This cycle is characterized by periods of ovarian follicular 
development coincident with sexual activity – follicular stage -, where estrogens 
dominate, alternating with periods of dominance of progesterone, produced byactive 
corpora lutea is active – the luteal stage (or diestrus) (Tsutsui and Stabenfeldt, 
1993). In cats, the non-pregnant diestrus last for 35-40 days, and in that case the 
interestrous interval is about 45 to 50 days. But if the female conceives, 
progesterone dominance is maintained for an average of 65 days, until parturition. 
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During the reproductive season, the female may resume cyclic ovarian activity in 
about 3 weeks (Fontbonne and Garnier, 1998; Verhage et al., 1976). 
 
FIGURE 1: Draft of the anovulatory and ovulatory cycles in cats. In pink are depicted the follicular 
stages and in yellow the luteal stage. 
 
MORPHOLOGICAL CHANGES CHARACTERIZING THE FELINE ESTROUS CYCLE STAGES 
The phases of the estrous cycle are characterized based on clinical and 
behavioral signs and hormonal changes (Feldman and Nelson, 2004; Malandain et 
al., 2011; Mills et al., 1979), which can be surveyed through changes in vaginal 
cytology features and ultrasonography in vivo, or by direct inspection of the ovaries 
at laparoscopy or after the surgical excision of the genital tract. These are reliable 
tools for staging of the estrous cycle (Davidson and Baker, 2009; Malandain et al., 
2011; Schmidt et al., 1983; Wildt et al., 1981).  
 
ENDOCRINOLOGY OF FELINE ESTROUS CYCLE 
In the beginning of the breeding season, follicular growth is stimulated at the 
ovaries, in response the positive stimulus of hypophyseal FSH. In consequence of 
the follicular development during proestrus and estrus, blood estrogen 
concentrations increase, and in the follicular stage they may exceed 20 pg/ml (Wildt 
et al., 1981). LH coordinates the later stages of follicle maturation and ovulation. In 
cats, pre-ovulatory surge of LH is triggered by the coitus, and is dependent on 
multiple, recurrent stimulation at the level of the vagina. A sustained elevation in 
estradiol concentration is a prerequisite for ovulatory LH release (Banks and 
Stabenfeldt, 1982). A reduced number of copulations might fail to elicit an LH 
adequate response, impairing ovulation or only allowing partial ovulation 
(Concannon et al., 1980). Ovulatory LH response, in amount and duration, varies 
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within animals and intra-individually (Banks and Stabenfeldt, 1982; Glover et al., 
1985). 
In anovulatory cycles, successive waves of follicles arise at the ovaries, 
inducing the occurrence of sequential follicular stages, separated by short periods 
devoid of the stimulation of sex steroids.  
In the ovulatory cycles, after ovulation estradiol values decline significantly 
(Banks and Stabenfeldt, 1982; Shille et al., 1983), closely followed by the increased 
in the progesterone secretion. In cats, the progesterone levels peak around day 21; 
thereafter, in non-pregnant cycles, the progesterone drops and reach the basal 
levels between days 35 and 40 (Fontbonne and Garnier, 1998). 
 
MORPHOLOGICAL CHANGES IN THE OVARIES AND UTERUS DURING THE ESTROUS CYCLE 
Grossly, two stages may be found in the non-pregnant estrous cycle of the 
cat: (1) the follicular stage, also named as proliferative or estrogenic - the beginning 
of the proliferative stage occurs when the follicular teca interna starts to secrete 
estrogens, which plasma concentrations gradually rise (Shille et al., 1979; 
Chatdarong et al., 2005); (2) the luteal stage, also named as secretory or 
progestagenic. 
These two stages are characterized by diverse features (whether at a macro 
or microscopic level) in different segments of the genital tract of the queen that may 
be used to grossly stage the cycle; besides the use of vaginal cytology, which gives 
the measure of the estrogen impregnation in the tissues, the most often used are 
the inspection and the histology of the ovaries and uterus. 
The follicular growth may be perceived at the ovarian surface. In the ovaries, 
follicles growth from less than 1 mm in early proestrus to 1.5 mm at the start of the 
estrus (Feldman and Nelson, 2004) (FIGURE 2 A). They appear as multiple cavitary 
structures, which size varies with the development stage (Chatdarong et al., 2005; 
Gatel et al., 2015; Karja et al., 2002; Liman et al., 2013). At ovulation, they became 
less tense and when the follicular wall is ruptured, and their content evades, the 
follicular walls collapse slightly. Afterwards, proliferating lutein/luteinic cells occupy 
the follicular cavity and forms the corpora lutea. These are seen as compact round 
structures at the ovarian surface, in dark red color, giving the ovary the appearance 
of a berry (FIGURE 2 B). 
12 | Contribution to the Study of Feline Endometrial Adenocarcinoma  
 
  
FIGURE 2: Macroscopic features of the feline ovary. In the follicular stage (A), multiple follicles are 
visible at cut surface. (B) In the luteal stage, a corpus luteum is evident. 
 
The histological evaluation of the ovary sustains and details the gross 
changes described before (FIGURE 3 A-B). The follicles are lined by single to multiple 
layers of granulosa cells. In the ovarian cortex, a large number of pre-antral follicles 
are frequently found. Starting in proestrus, antral follicles increase in size as the 
follicular cavity enlarges. Around ovulation time, a small number of flatted granulosa 
cells are disposed around the antrum. Large, well-developed corpora lutea, 
containing prismatic lutein cells characterize the active corpora lutea, bulging at the 
ovarian surface; these are the main structures observed during the luteal stage. In 
the early luteal stage, luteal cells are closely packed and have amphophilic to 
eosinophilic cytoplasm; in the late luteal stage, luteal cells become vacuolated. 
Regressing corpora lutea also lost prominence at the surface of the ovary. Small, 
atretic corpora lutea from previous cycles may also be present in the ovary (Liman 
et al., 2013). 
The uterine gross morphology does not vary much between the follicular and 
the luteal stage (Chatdarong et al., 2005; Gatel et al., 2015) (FIGURE 4 A-B). In 
general, the uterus shows a slightly curved shape and a wavy luminal cavity 
(Chatdarong et al., 2005) with scant fluid present (Davidson and Baker, 2009). 
During the normal estrous cycle, the macroscopic width of the uterine horns is 
maximum in the luteal stage (Davidson and Baker, 2009; Chatdarong et al., 2005). 
In this stage, the uterine horns became coiled or markedly curved, as the cycle 
progress from early to mid-luteal stage, accompanying the changes in progesterone 
concentration (Chatdarong et al., 2005). 
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FIGURE 3: Microscopic features of the feline ovaries during the follicular stage (A) and the luteal stage 
(B). Bar = 300 μm. Multiple follicles and a complete corpus luteum (and half of one in the right bottom) 
are observed, respectively. 
 
FIGURE 4: Macroscopic features of the feline uterus during the follicular stage (A) and the luteal stage 
(B). The uterine horns are curved and their width is maximum in the luteal stage. 
 
The major differences between the stages on respect to the uterus are 
observed microscopically (FIGURE 5 A-B). During the follicular stage, as it happens 
in other mammalian species, the endometrium is thin, lined a single layer of cuboidal 
or prismatic cells. In the early follicular stage, the surface epithelial cells are 
columnar and eosinophilic, contrasting to the vacuolated appearance in the late 
stage (Liman et al., 2013). Uterine glands are simple and straight (Chatdarong et 
al., 2005; Rastogi, 2007), the epithelium composed by prismatic cells (Liman et al., 
2013). The beginning of the follicular stage is characterized by endometrial growth, 
which was previously lost (Bacha and Bacha, 2012; Junqueira and Carneiro, 2004). 
A B
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FIGURE 5: Microscopic features of the feline uterus during the follicular stage (A) and the luteal stage 
(B). Bar = 300 μm. The endometrium reach is maximum thickness in the luteal stage; the endometrial 
glands show a secretory acidophilic activity. 
  
In the luteal stage, the surface epithelium is composed by high columnar 
cells, with pseudostratification or single cells (Chatdarong et al., 2005; Liman et al., 
2013). The glands grow in diameter and are abundantly coiled, following 
progesterone stimulus (Chatdarong et al., 2005; Liman et al., 2013; Rastogi, 2007). 
The epithelial cells of deep glandules are taller than those of superficial glandules 
and surface epithelium (Liman et al., 2013). During this period, secretory acidophilic 
activity of the endometrial glands reach the maximum, coinciding with the peak in 
blood progesterone luteum (Bacha and Bacha, 2012; Liman et al., 2013). In this 
stage, the endometrium reach is maximum thickness, as the result of the growth of 
the mucosa and secretion accumulation (Junqueira and Carneiro, 2004). 
Additionally, the myometrium, which also respond to hormonal production, is thick 
and composed by hypertrophied smooth muscle cells (Liman et al., 2013). 
Despite this division in phases, cyclic structural changes are progressive and 
continuous; the division of the estrous cycle in stages depends on the differential 
secretion of ovarian hormones, which is reflected in different functional and clinical 
conditions (Junqueira and Carneiro, 2004). In TABLE 1, we present a resume of the 
follicular and luteal stages of the feline estrous cycle (adapted from Chatdarong et 
al., 2005; Junqueira and Carneiro, 2004). 
 
 
 
 
A B
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TABLE 1: Resume of the Principal Features of the Follicular and Luteal Stages of the Estrous Cycle 
(adapted from Chatdarong et al., 2005; Junqueira and Carneiro, 2004). 
 FOLLICULAR STAGE LUTEAL STAGE 
PITUITARY HORMONES FSH LH 
OVARY DESCRIPTION 
Follicular growth; dominant 
follicle reach preovulatory 
stage 
Ovulation and development of 
corpus luteum 
OVARY HORMONES Estrogens Progesterone 
UTERINE FEATURES Growth of the endometrium 
Additional growth of the 
endometrium; the glands 
become maximum coiled 
UTERINE GROSS 
MEASUREMENTS 
Length: 4.46 ± 0.77 cm 
Width: 0.56 ± 0.11 cm 
Length: 4.74 ± 0.87 cm 
Width: 0.70 ± 0.16 cm 
UTERINE MICROSCOPIC 
MEASUREMENTS (THICKNESS) 
Endometrium: 461.63 ± 
206.00 μm 
Myometrium: 629.74 ± 288.02 
μm 
Endometrium: 398.70 ± 
160.39 μm 
Myometrium: 619.33 ± 191.40 
μm 
 
CYCLIC CHANGES OF LOCAL FACTORS IN THE ENDOMETRIUM: THE ENDOMETRIAL CYCLE 
 The endometrium undergoes a series of precisely determined morphological 
changes in response to the stimulation of the ovarian sex steroids, coordinated by 
the effects of estrogens or progesterone over their own receptors at the 
endometrium which triggers a dynamic interplay of local factors that ultimately 
determines the endometrial pattern of proliferation, differentiation, apoptosis, 
regeneration or resident immune cells infiltration, among other (Strowitzki et al., 
2006). These are commonly named, in humans, as the endometrial cycle. This 
phenomena also exist in other mammal species, including the cat. 
The feline endometrium undergoes cyclic changes throughout the estrous 
cycle responding to the ovarian steroid hormones. The proliferative stage is under 
the influence of estrogen whereas after ovulation, progesterone controls the 
secretory stage. This shift in hormonal balance promotes the transition between the 
proliferative pattern of the endometrium to a secretory lining, with the corresponding 
morphological changes. If conception is achieved, the endometrium remains as 
decidua, which becomes part of the placenta. On the other hand, if the endometrium 
doesn’t receive the conceptus undergoes reabsorption. 
 The orchestration of the endometrial cycle is determined by the availability 
and activation of estrogen and progesterone receptors (ER and PR, respectively) in 
the organ, which in their turn influence a myriad of smaller molecules, such as 
interleukins and growth factors. The information regarding the molecules playing a 
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role in the endometrial cycle in cats is still limited, whether concerning the normal, 
physiological cycle or the diseased endometrium. 
There are two forms of estrogen receptors ER-α and ER-β, without which 
reproductive functions are severely impaired. The overall proliferative response to 
estrogen is the result of a balance between ER-α and ER-β signaling. The ligand-
dependent pathway of activating ER is not exclusive, however, since growth factor 
signaling leads to activation of kinases that may phosphorylate and thereby activate 
ER or associated co-regulators in the absence of ligand (Heldring et al., 2007). The 
amount of nuclear ER in feline uterus increases during proestrus and estrus and 
decreases after coitus. This suggest that progesterone decreases ER in feline 
uterus (Li et al., 1992; West et al., 1976; West et al., 1977).  
The uterus respond to progesterone, increasing the growth and secretion of 
endometrial glands (West et al., 1976; West et al., 1977). Progesterone has both an 
antiestrogenic and progestagenic effect within the uterine epithelial cells. 
Progesterone receptors can be cytoplasmic or nuclear and progesterone is able to 
influence subcellular compartmentalization of PR (Li et al., 1992). 
Estrogen receptors also have important interrelationships with the 
progesterone receptor system in modulation of responses (Katzenellenbogen, 
1996). The studies of Kraus and collaborators (1995) showed that PR occupied by 
its ligand can suppress estradiol-stimulated ER activity, through interference with 
the ability of ER to interact with the transcription complex below in the molecular 
cascade.  
Progesterone diminishes PR, however progesterone doesn’t deplete totally 
the levels of ER and PR (Li et al, 1992). During pregnancy, the fall in the amount of 
nuclear ER in the uterus is probably related to the rise in progesterone more than 
the fall in estrogen.  The increasing serum levels of progesterone observed after 
coitus diminishes cytoplasmic PR and raises nuclear PR; the continued presence of 
high levels of progesterone results in downregulation of PR system (Verhage et al., 
1984).  
It has been proposed that estradiol effects were mediated by ER localized in 
the uterine epithelial cells of the cat endometrium, whereas the existing PR would 
mediate the progesterone effects in the stromal compartment. However the putative 
crosstalk between epithelial and stromal compartment was proposed as being 
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involved in estrogen and progesterone effects in cycling feline endometrium (Li et 
al., 1992). 
  Prostaglandin (PG) synthesis is under the regulation of ovarian sex steroids 
in feline endometrium, as it also occurs in other species. Epithelial cells are the main 
source of PGF2α, whereas stromal cells mainly secrete PGE2. However, ovarian 
steroids amplification of PG synthesis is limited to epithelial cells. Estrogens 
significantly raise PGF2α, enhanced by progesterone, which means that it is involved 
in a local regulation at the diestrus in cats. It is proposed that PGE2 secretion 
increased by progesterone promotes a luteotrophic effect on feline corpora lutea 
(Siemieniuch et al., 2010). In another study, using only spontaneously ovulated 
queens, a higher expression levels of the genes involved in PG synthesis were 
related to the highest progesterone level at the mid diestrus (Siemieniuch et al., 
2013), reinforcing the idea that estrogens and progesterone affect PG synthesis in 
the feline endometrium. However, ovarian sex steroids did not altered PGF2α output 
neither its synthase at the gene expression level. Technical issues have been 
pointed as the main reason for the discrepancies between both studies. On the 
contrary, the combination of exogenous estrogen and progesterone (added to 
endometrial explants, imitating normal period shortly after ovulation) augmented 
PGE2 secretion at estrus and mid dioestrus, whereas progesterone alone 
(mimetizing the luteal stage) augmented PGE2 secretion at estrus. This supports 
the idea that PGE2 is a luteotrophic factor released by the endometrium at the time 
of progesterone dominance (Siemieniuch et al., 2013). 
The mechanisms underlying the PG synthesis dependency on steroid 
hormone activation are still poorly understood; however, it is proposed that the rate-
limiting step in PG production may be the availability of arachidonic acid and that 
different molecular mechanisms may apply for steroids affecting synthesis and 
secretion of PG by cat endometrium (Siemieniuch et al., 2013).  
 Oxytocin is secreted by early/developing corpus luteum in cultured luteal cells 
and these cells express its receptors. The feline uterus also presents oxytocin 
receptors, suggesting that it responds to the ovarian produced oxytocin. These 
receptors are abundantly expressed during estrus and early/developing luteal stage, 
especially in stromal cells, being an important driver in the pathway of PGE2 
synthesis. The importance of PGE2 in differentiation of stromal cells into decidua 
and implantation suggests that oxytocin has a major role in fostering implantation. 
18 | Contribution to the Study of Feline Endometrial Adenocarcinoma  
 
Furthermore, PGE2 is essential for changes in uterine vasculature during 
implantation and can be important for prevent luteolysis. The epithelial cells also 
secret PGF2α through oxytocin receptors (Siemieniuch et al., 2011). 
Tumour necrosis factor alpha (TNF-α) enhances PG secretion in feline 
epithelial cells but not stromal cells, under the influence of phospholipase A2 (PLA2) 
and cyclooxygenase-2 (COX-2). In the luteal stage, TNF-α immunolabelling is lower 
and restricted mostly to the stromal cells and into a lesser extend to surface and 
glandular epithelium, whereas in estrus the immunoreaction is moderate to strong 
and develops both in surface and in epithelial cells (Fontinha et al., 2015; Jursza et 
al., 2014). In feline endometrium, TNF-α receptors were only localized in epithelial 
cells (Jursza et al., 2014). 
Epidermal growth factor (EGF) and transforming growth factor alpha (TGF-
α) seem to be involved in an autocrine/paracrine way. These growth factors were 
found in normal feline endometrium, during treatment with estradiol and 
progesterone, as well as in pregnant uterus (Boomsma et al., 1997).   
Chatdarong and collaborators (2005) tried to establish a correlation between 
the PCNA (proliferating cell nuclear antigen) index and the stage of the estrous cycle 
in cats, as it is proposed in other species. However, PCNA expression in feline 
uterus seems to be unrelated to the stages of the estrous cycle (Chatdarong et al., 
2005).  
Interestingly, several molecules were identified in the feline endometrium 
specifically in each steroid-associated stage. A progesterone-dependent secretory 
protein (PDP), an uterine specific protein, was synthetized in feline endometrium 
and released into the uterine lumen during early stages of pregnancy, which has be 
hypothesize to play a role during attachment and implantation (Boomsma and 
Verhage, 1987). Progesterone-dependent uterine secretory protein is diffusely 
localized in the cytoplasm of the epithelial cells of the deep uterine glands, where it 
is synthesized (Verhage et al., 1989). It was also identified a high molecular weight 
protein dependent on estrogens (CUPED) in the cat endometrium, present in 
secretory granules of epithelial cells of uterine glands and in the lumen of deep 
uterine glands, during periods of estrogen dominance (estrus). This protein is also 
maintained high during the period extending from peri-ovulation and the first few 
days of pregnancy, being suggested that, although it may act at the time of sperm 
transport through the uterus and by the time of the unplanted blastocyst, its main 
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role would relate to the nutrition of developing blastocysts, to coating the uterine 
epithelium in preparation for implantation and in sperm capacitation or in maintaining 
sperm viability (Murray et al., 1986; Murray et al., 1985; Murray and Verhage, 1985). 
 Survivin, Bcl-2 and Bax are apoptosis-related proteins; apoptosis is an 
important mechanism in endometrial homeostasis. These proteins are expressed in 
feline endometrium with cyclic variations, playing an important role in endometrial 
growth and regression. The maximum intensity of Bcl-2 immunolabeling is observed 
in late proliferative stage, decreasing in the early luteal stage. This is in accordance 
with the shift in Survivin and Bax expression, which arise during the secretory stage. 
Survivin is expressed in the cytoplasm and nucleus of superficial and deep uterine 
glands in the luteal stage, whilst it is only located in the cytoplasm during follicular 
stage and anestrus. These findings suggest that Survivin may be involved in 
controlling uterine cell survival and proliferation during feline estrous cycle. Survivin 
is also expressed in particular stromal cells, endothelial and smooth muscle cells of 
blood vessels, suggesting that this protein plays a significant role in angiogenesis. 
Bcl-2 was only found in the cytoplasm of either epithelial or stromal cells of feline 
endometrium, evidencing increased expression during the follicular stage, 
suggestive of an anti-apoptotic role for Bcl-2 in feline uterus. Bax immunoreaction 
was demonstrated predominantly in the cytoplasm of the glandular epithelial cells in 
the luteal stage; the protein has a diffuse pattern of expression. These findings are 
consistent with the role of this protein in the increasing of apoptotic susceptibility. 
Stromal cells of feline endometrium with a Bcl-2/Bax positive phenotype represent 
macrophages (Liman et al., 2013). Studies on apoptosis performed by our group 
demonstrated a higher expression of activated Caspase 3 in the proliferative stage 
of feline normal endometrium (Fontinha, 2014). 
   
UTERINE PATHOLOGY IN THE QUEEN 
 
Impairment of the reproductive function and the clinical syndromes related 
with uterine inflammatory conditions are the more representative causes for uterine 
disease in feline practice. Abnormalities of reproductive function generally follow 
disturbances of the normal hormonal and physiologic patterns. Such disturbances 
can arise from a number of uterine diseases. The most common lesions of uterine 
pathology can be grossly divided in congenital abnormalities, displacement, 
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hypertrophy, hyperplasia and metaplasia, inflammation and neoplasia (Van Dijk et 
al., 2007).  
Developmental anomalies are rare in cats. In one study of 53,258 female cats 
around United States and Canada, 0.09% of the queens had a gross uterine, namely 
unicornuate uterus, segmental uterine horn agenesis and uterine horn hypoplasia 
(McIntyre et al., 2010). These kind of abnormalities can be found as an extraordinary 
finding during hysterectomy or laparotomy, but they also can be at the origin of 
ambiguous abdominal pain and distension, as a consequence of fluid accumulation 
upstream the obstruction point (Colaço et al., 2012). 
Cystic endometrial hyperplasia is a frequent condition in cats (Kempisty et 
al., 2013). This lesion generally arises from disturbances at the functioning of the 
endometrial glands and frequently progress to pyometra so they are commonly 
known as the cystic endometrial hyperplasia/pyometra complex (Agudelo, 2005; 
Schlafer and Gifford, 2008). The first stage of the disease is characterized by 
progesterone-induced cystic dilatation of the glandular endometrium. Evolution into 
pyometra is facilitated by the progesterone environment, but also depends on 
estrogen influences (Agudelo, 2005). 
However, other causes besides cystic endometrial hyperplasia can induce 
pyometra making this disease a common feature in queens, and frequently the 
reason for uterus ablation. In a study of 139,075 female Swedish insured cats, 791 
were diagnosed with pyometra (Hagman et al., 2014). In our experience, 
ovariohysterectomy surgical specimens clinically diagnosed with pyometra are 
rarely sent to the laboratory for morphological evaluation. 
Regarding oncological diseases, adenocarcinomas of the endometrium are 
considered the most frequently diagnosed uterine neoplasia in this species (Argyle, 
2008; Van Dijk et al., 2007). Compared with the amount of work performed on feline 
mammary diseases, few references are available concerning feline uterine 
pathology. The lack of knowledge in this area of veterinary medicine endorsed our 
commitment to the present work. We looked forward to describe and understand the 
morphology, histology and immunoprofile of feline endometrial adenocarcinomas 
(FEA), hopping that this will become the beginning of a journey that promises to be 
helpful to pathologists, surgeons and especially to cats. In the next chapter, we will 
review all the general aspects of FEA. 
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AIMS 
 
The general aim of the present work was to understand the biopathology of 
FEA, including their epidemiologic aspects and histomorphological features. 
 
Specific aims of our study included: 
1) The characterization of the state of the art regarding FEA, recognizing 
epidemiologic data, clinical signs, diagnosis, available treatment and 
prognosis of the disease. 
 
2) The description of the histological aspects of FEA of the papillary serous type, 
especially considering features generally related to prognosis. 
 
3) The immunohistochemical characterization of the expression of several 
molecules in FEA of the papillary serous type, in comparison with normal 
endometrium in proliferative and luteal stages of the feline estrous cycle. 
Those included proteins extensively studied in the human endometrial 
neoplasms: 
 
a. Steroid hormones receptors; 
b. Cytokeratins 7 and 20; 
c. Ki-67; 
d. Cyclooxygenase-2; 
e. C-erbB-2. 
 
With the study of the patterns of expression of these proteins in feline normal 
and neoplastic endometrium, we intend to initiate the characterization of 
some of the molecular events underlying endometrial carcinogenesis in cats. 
Moreover, some of these proteins might be used as markers in the 
histological diagnosis of FEA.
   
Contribution to the Study of Feline Endometrial Adenocarcinomas | 23 
 
REFERENCES 
 
Agudelo CF (2005). Cystic endometrial hyperplasia-pyometra complex in cats. A 
review. Veterinary Quarterly. 27(4):173-182. 
Argyle DJ (2008). Tumors of the reproductive tract. In: Argyle DJ, Brearley MJ, Turek 
MM (Eds.), Decision Making in Small Animal Oncology, Wiley-Blackwell Publishing, 
Ames, Iowa, pp. 317. 
Aughey E and Frye FL (2001). Female reproductive system. In: Aughey E and Frye 
FL (Eds.), Comparative Veterinary Histology with Clinical Correlates, Manson 
Publishing, London, pp. 183-207. 
Bacha WJ and Bacha LM (2012). Female reproductive system. In: Bacha WJ and 
Bacha LM (Eds.), Color Atlas of Veterinary Histology, 3rd Ed., Wiley-Blackwell, Iowa, 
pp. 243-265. 
Banks DH and Stabenfeldt G (1982). Luteinizing hormone release in the cat in 
response to coitus on consecutive days of estrus. Biology of Reproduction. 
26(4):603-611. 
Boomsma RA, Mavrogianis PA, Verhage HG (1997). Immunocytochemical 
localization of transforming growth factor alpha, epidermal growth factor and 
epidermal growth factor receptor in the cat endometrium and placenta. The 
Histochemical Journal. 29(6):495-504. 
Boomsma RA and Verhage HG (1987). Detection of a progesterone-dependent 
secretory protein synthesized in cat endometrium. Biology of Reproduction. 
37(1):117-126. 
Borges P, Fontbonne A, Payan-Carreira R (2015). New approaches for hormonal 
contraception in female cats. In: Kevins C (Ed.), Felines: Common Diseases, 
Clinical Outcomes and Developments in Veterinary Healthcare, Nova Science 
Publishers, Hauppauge, New York, pp. 47-68. 
Bristol-Gould S and Woodruff TK (2006). Folliculogenesis in the domestic cat (Felis 
catus). Theriogenology. 66(1):5-13. 
24 | Contribution to the Study of Feline Endometrial Adenocarcinoma  
 
Chatdarong K, Lohachit C, Kiartmanakul S, Axnér E, Forsberg L (2006). Cervical 
patency during non-ovulatory and ovulatory cycles in domestic cats. 
Theriogenology. 66(4):804-810. 
Chatdarong K, Rungsipipat A, Axnér E, Forsberg CL (2005). Hysterographic 
appearance and uterine histology at different stages of the reproductive cycle and 
after progestogen treatment in the domestic cat. Theriogenology. 64(1):12-29. 
Colaço B, Pires MA, Payan-Carreira R (2012). Congenital Aplasia of the 
UterineVaginal Segment in Dogs. In:  Perez-Marin (Ed.) A Bird's-Eye View of 
Veterinary Medicine. InTech. Available from: http://www.intechopen.com/books/a-
bird-s-eye-view-of-veterinarymedicine/congenital-atresia-of-the-uterine-vaginal-
segment-in-dogs. Accessed 08th May 2015.   
Concannon P, Hodgson B, Lein D (1980). Reflex LH release in estrous cats 
following single and multiple copulations. Biology of Reproduction. 23(1):111-117. 
Davidson AP and Baker TW (2009). Reproductive ultrasound of the bitch and 
queen. Topics in Companion Animal Medicine. 24(2):55-63.  
Feldman EC and Nelson RW (2004). Feline reproduction. In: Feldman EC and 
Nelson RW (Eds.) Canine and Feline Endocrinology and Reproduction, 3rd Ed., 
Saunders, Elsevier, St. Louis, Missouri, pp. 1016-1043. 
Fontbonne A and Garnier F (1998). Données récentes en physiologie et 
endocrinologie sexuelles dans l’espèce feline. Le Point Veterinaire. 29(195):1107-
1112. 
Fontinha F, Saraiva AL, Payan-Carreira R, Pires MA (2015). Immunolocalization of 
activated caspase 3 and TNF alpha on normal endometrium and in feline 
endometrial adenocarcinoma. XXIII Porto Cancer Meeting. Porto. Portugal. pp. 44. 
Fontinha F (2014). Localização de TNF alfa e Caspase 3 em Endométrio de Gata 
no ciclo e no Adenocarcinoma do Endométrio. Master in Laboratorial Clinical 
Biology Thesis. University of Trás-os-Montes e Alto Douro, Vila Real, Portugal. 
Foster RA (2007). Female reproductive system. In: McGavin MD and Zachary JF 
(Eds.), Pathologic Basis of Veterinary Disease, 4th Ed., Mosby / Elsevier, St. Louis, 
Missouri, pp. 1263-1317. 
Contribution to the Study of Feline Endometrial Adenocarcinomas | 25 
 
Gatel L, Gory G, Chalvet-Monfray K, Saunders JH, Rault DN (2015). Intra- and inter-
observer variability in ultrasonographical measurements of the uterus and ovaries 
in healthy, non-pregnant queens. Journal of Feline Medicine and Surgery. Mar 18. 
pii: 1098612X15574317. [Epub ahead of print]. 
Gimenez F, Stornelli MC, Tittarelli CM, Savignone CA, Dorna IV, de la Sota RL, 
Stornelli MA (2009). Supression of estrus in cats with melatonin implants. 
Theriogenology. 72(4):493-499. 
Glover TE, Watson PF, Bonney RC (1985). Observations on variability in LH release 
and fertility during oestrus in the domestic cat (Felis catus). Journal of Reproduction 
and Fertility. 75(1):145-52. 
Goericke-Pesch S (2010). Reproduction control in cats: new developments in non-
surgical methods. Journal of Feline Medicine and Surgery. 12(7):539-546. 
Gudermuth DF, Newton L, Daels P, Concannon P (1997). Incidence of spontaneous 
ovulation in young, group-housed cats based on serum and fecal concentrations of 
progesterone. Journal of Reproduction and Fertility. Supplement. 51:177-184. 
Hagman R, Ström Holst B, Möller L, Egenvall A (2014). Incidence of pyometra in 
Swedish insured cats. Theriogenology. 82(1):114-120. 
Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague 
M, Ström A, Treuter E, Warner M, Gustafsson JA (2007). Estrogen receptors: how 
do they signal and what are their targets. Physiological Reviews. 87(3):905-931. 
Inomata T, Ariga M, Sakita N, Ito J, Yokoh K, Ninomiya H, Inoue S (2009). 
Development of external genitalia in fetal and neonatal domestic cats. The Journal 
of Veterinary Medical Science / The Japanese Society of Veterinary Science. 
71(2):139-145. 
Junqueira LC and Carneiro L (2004). Aparelho reprodutor feminino. In: Junqueira 
LC and Carneiro L (Eds.), Histologia Básica, Texto e Atlas, 10th Ed., Guanabara / 
Koogan, Rio de Janeiro, pp. 432-452. 
Jursza E, Szóstek AZ, Kowalewski MP, Boos A, Okuda K, Siemieniuch MJ (2014). 
LPS-challenged TNFα production, prostaglandin secretion, and TNFα/TNFRs 
expression in the endometrium of domestic cats in estrus or diestrus, and in cats 
26 | Contribution to the Study of Feline Endometrial Adenocarcinoma  
 
with pyometra or receiving medroxyprogesterone acetate. Mediators of 
Inflammation. 2014:689280. doi: 10.1155/2014/689280. Epub 2014 Jun 15. 
Karja NWK, Otoi T, Murakami M, Fahrudin M, Suzuki T (2002). In vitro maturation, 
fertilization and development of domestic cat oocytes recovered from ovaries 
collected at three stages of the reproductive cycle. Theriogenology. 57(9): 2289-
2298. 
Katzenellenbogen BS (1996). Estrogen receptors: bioactivities and interactions with 
cell signaling pathways. Biology of Reproduction. 54(2):287-293. 
Kempisty B, Bukowska D, Wozna M, Piotrowska H, Jackowska M, Zuraw A, 
Ciesiolka S, Antosik P, Maryniak H, Ociepa E, Porowski S, Brussow KP, Jaskowski 
JM, Nowicki M (2013). Endometritis and pyometra in bitches: a review. Veterinarni 
Medicina. 58(6):289–297. 
König HE and Liebich H-G (2007). Female genital organs. In: König HE and Liebich 
H-G (Eds.), Veterinary Anatomy of Domestic Mammals. Textbook and Colour Atlas, 
3rd Ed., Schattauer, Stuttgard, pp. 423-440. 
Kraus WL, Weis KE, Katzenellenbogen BS (1995). Inhibitory cross-talk between 
steroid hormone receptors: differential targeting of estrogen receptor in the 
repression of its transcriptional activity by agonist- and antagonist-occupied 
progestin receptors. Molecular and Cellular Biology. 15(4):1847-1857. 
Kutzler MA (2007). Estrus induction and synchronization in canids and felids. 
Theriogenology. 68(3):354-374. 
Lamm CG and Makloski CL (2012). Current Advances in Gestation and Parturition 
in Cats and Dogs. Veterinary Clinics: Small Animal Practice. 42(3):445–456. 
Leyva H, Madley T, Stabenfeldt GH (1989). Effect of light manipulation on ovarian 
activity and melatonin and prolactin secretion in the domestic cat. Journal of 
Reproduction and Fertility. Supplement. 39:125-133. 
Li W, Boomsma RA, Verhage HG (1992). Immunocytochemical analysis of estrogen 
and progestin receptors in uteri of steroid-treated and pregnant cats. Biology of 
Reproduction. 47(6):1073-1081. 
Contribution to the Study of Feline Endometrial Adenocarcinomas | 27 
 
Liman N, Alan E, Bayram GK, Gürbulak K (2013). Expression of survivin, Bcl-2 and 
Bax proteins in the domestic cat (Felis catus) endometrium during the oestrus cycle. 
Reproduction in Domestic Animals. 48(1):33-45. 
Malandain E, Rault D, Froment E, Baudon S, Desquilbet L, Begon D, Chastant-
Maillard S (2011). Follicular growth monitoring in the female cat during estrus. 
Theriogenology. 76(7):1337-1346. 
McIntyre RL, Levy JK, Roberts JF, Reep RL (2010). Developmental uterine 
anomalies in cats and dogs undergoing elective ovariohysterectomy. Journal of the 
American Veterinary Medical Association. 237(5):542-546. 
Mills JN, Valli VE, Lumsden JH (1979). Cyclical changes of vaginal cytology in the 
cat. Canadian Veterinary Journal. 20(4):95-101. 
Murray MK, Verhage HG, Jaffe RC (1986). Quantification of an estrogen-dependent 
cat uterine protein (CUPED) in uterine flushings of estrogen- and progesterone-
treated ovariectomized cats by radioimmunoassay. Biology of Reproduction. 
35(3):531-536. 
Murray MK, Verhage HG, Buhi WC, Jaffe RC (1985). The detection and purification 
of a cat uterine secretory protein that is estrogen dependent (CUPED). Biology of 
Reproduction. 32(5):1219-1227. 
Murray MK and Verhage HG (1985). The immunocytochemical localization of a cat 
uterine protein that is estrogen dependent (CUPED). Biology of Reproduction. 
32(5):1229-1235. 
Payan-Carreira R, Santos C, Miranda S, Pereira RM, Santos D, Pires MA (2014). 
Temporal changes in neutral endopeptidase/CD10 immunoexpression in the cyclic 
and early pregnant canine endometrium. Theriogenology. 82(6):815-826.  
Ponnampalam AP, Weston GC, Trajstman AC, Susil B, Rogers PA (2004). 
Molecular classification of human endometrial cycle stages by transcriptional 
profiling. Molecular Human Reproduction. 10(12):879-893. 
Rastogi SC (2007). Reproduction. In: Rastogi SC (Ed.), Essentials of Animal 
Physiology, 4th Ed., New Age International, New Delhi, pp. 435-460. 
28 | Contribution to the Study of Feline Endometrial Adenocarcinoma  
 
Reynaud K, Gicquel C, Thoumire S, Chebrout M, Ficheux C, Bestandji M, Chastant-
Maillard S (2009). Folliculogenesis and morphometry of oocyte and follicle growth 
in the feline ovary. Reproduction in Domestic Animals. 44(2):174-179. 
Schlafer DH and Gifford AT (2008). Cystic endometrial hyperplasia, pseudo-
placentational endometrial hyperplasia, and other cystic conditions of the canine 
and feline uterus. Theriogenology 70(3):349–358. 
Schmidt PM (1986). Feline breeding management. Veterinary Clinics of North 
America: Small Animal Practice. 16(3):435-451. 
Schmidt PM, Chakraborty PK, Wildt DE (1983). Ovarian activity, circulating 
hormones and sexual behavior in the cat. II. Relationships during pregnancy, 
parturition, lactation and the postpartum estrus. Biology of Reproduction. 28(3):657-
71. 
Shille VM, Munro C, Farmer SW, Papkoff H, Stabenfeldt GH (1983). Ovarian and 
endocrine responses in the cat after coitus. Journal of Reproduction and Fertility. 
69(1):29-39. 
Shille VM, Lundström KE, Stabenfeldt GH (1979). Follicular function in the domestic 
cat as determined by estradiol - 17β concentrations in the plasma: relation to estrous 
behavior and cornification of exfoliated vaginal epithelium. Biology of Reproduction. 
21(4):953-963. 
Siemieniuch MJ, Jursza E, Kowalewski MP, Majewska M, Skarzynski DJ (2013). 
Prostaglandin endoperoxide synthase 2 (PTGS2) and prostaglandins F2α and E2 
synthases (PGFS and PGES) expression and prostaglandin F2α and E2 secretion 
following oestrogen and/or progesterone stimulation of the feline endometrium. 
Reproduction in Domestic Animals. 48(1):72-78. 
Siemieniuch MJ, Mlynarczuk JJ, Skarzynski DJ, Okuda K (2011). Possible 
involvement of oxytocin and its receptor in the local regulation of prostaglandin 
secretion in the cat endometrium. Animal Reproduction Science. 123(1-2):89-97. 
Siemieniuch MJ, Bowolaksono A, Skarzynski DJ, Okuda K (2010). Ovarian steroids 
regulate prostaglandin secretion in the feline endometrium. Animal Reproduction 
Science.120(1-4):142-150. 
Contribution to the Study of Feline Endometrial Adenocarcinomas | 29 
 
da Silva TFP, da Silva LDM, Uchoa DC, Monteiro CLB, Thomaz LA (2006). Sexual 
characteristics of domestic queens kept in a natural equatorial photoperiod. 
Theriogenology. 66(6-7):1476-1481. 
Sisson S (1910). The female genital organs. In: Sisson S (Ed.), A Text-book of 
Veterinary Anatomy, Saunders Company, Philadelphia, pp. 508-523. 
Strowitzki T, Germeyer A, Popovici R, von Wolff M (2006). The human endometrium 
as a fertility-determining factor. Human reproduction update. 12(5):617-630. 
Tavares Pereira M (2012). Comparison of macrophages and lymphocytes in non-
diseased endometrium and feline endometrial adenocarcinomas. Integrated Master 
in Veterinary Medicine Thesis. University of Trás-os-Montes e Alto Douro, Vila Real, 
Portugal. 
Tsutsui T, Stabenfeldt GH (1993). Biology of ovarian cycles, pregnancy and 
pseudopregnancy in the domestic cat. Journal of Reproduction and Fertility. 
Supplement. 47:29-35. 
Uchikura K, Nagano M, Hishinuma M (2010). Evaluation of follicular development 
and oocyte quality in pre-pubertal cats. Reproduction in Domestic Animals. 
45(6):e405-411. 
Van Dijk JE, Gruys E, Mouwen JMVM (2007).The genital system. In: Van Dijk JE, 
Gruys E, Mouwen JMVM (Eds.), Color Atlas of Veterinary Pathology, 2nd Ed., 
Saunders, Elsevier, Philadelphia, PA, pp. 107-108. 
Verhage HG, Boomsma RA, Mavrogianis PA, Li W, Fazleabas AT, Jaffe RC (1989). 
Immunological characterization and immunocytochemical localization of a 
progesterone-dependent cat endometrial secretory protein. Biology of 
Reproduction. 41(2):347-54. 
Verhage HG, Murray MK, Boomsma RA, Rehfeldt PA, Jaffe RC (1984). The 
postovulatory cat oviduct and uterus: correlation of morphological features with 
progesterone receptor levels. The Anatomical Record. 208(4):521-531. 
Verhage HG, Beamer NB, Brenner RM (1976). Plasma levels of estradiol and 
progesterone in the cat during polyestrus, pregnancy and pseudopregnancy. 
Biology of Reproduction. 14(5):579-585. 
30 | Contribution to the Study of Feline Endometrial Adenocarcinoma  
 
West NB, Verhage HG, Brenner RM (1977). Changes in nuclear estradiol receptor 
and cell structure during estrous cycles and pregnancy in the oviduct and uterus of 
cats. Biology of Reproduction. 17(1):138-143. 
West NB, Verhage HG, Brenner RM (1976). Suppression of the estradiol receptor 
system by progesterone in the oviduct and uterus of the cat. Endocrinology. 
99(4):1010-1016. 
Wildt DE, Chan SYW, Seager SWJ, Chakraborty PK (1981). Ovarian activity, 
circulating hormones, and sexual behavior in the cat. I. Relationships during coitus-
induced luteal phase and the estrous period without mating. Biology of 
Reproduction. 25(1):15-28. 
Williamson PE (1988). The reproductive system. In: Robinson WF and Huxtable 
CRR (Eds.), Clinicopathologic Principles for Veterinary Medicine, Cambridge 
University Press, Cambridge, pp. 399-418. 
Zambelli D, Bini C, Cunto M (2015). Endoscopic transcervical catheterization in the 
domestic cat. Reproduction in Domestic Animals. 50(1):13-16. 
Zambelli D and Cunto M (2005). Vaginal and cervical modifications during the estrus 
cycle in the domestic cat. Theriogenology. 64(3): 679-684. 
Zambelli D, Buccioli M, Castagnetti C, Belluzi S (2004). Vaginal and cervical 
anatomic modifications during the oestrus cycle in relation to transcervical 
catheterization in the domestic cat. Reproduction in Domestic Animals. 39(2):76-80. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2 
 
 
FELINE ENDOMETRIAL ADENOCARCINOMAS 
 
 
 
 
 
 
 
 
THE CONTENT OF THIS CHAPTER WAS PUBLISHED IN: 
Saraiva AL, Payan-Carreira R, Gärtner F, Pires MA (2012). Feline Endometrial Adenocarcinomas. 
In: MA Longoria and JI Alcalá (Eds.) Adenocarcinoma: Pathogenesis, Treatment and Prognosis. 
Series Cancer Etiology, Diagnosis and Treatments. Nova Science Publishers, Hauppauge, NY, pp. 
175–189. 

Contribution to the Study of Feline Endometrial Adenocarcinomas | 33 
 
FELINE ENDOMETRIAL ADENOCARCINOMAS 
 
ABSTRACT 
 
Endometrial adenocarcinomas are considered to be rare in domestic 
animals, in particular comparing to non-epithelial tumours of the uterus, such as 
leiomyoma, in part because they are likely underdiagnosed. In cats, though uterus 
was the most common site for genital tract tumours, endometrial adenocarcinomas 
were found to be rare in all available references.  
In the study presented herein, forty feline primary endometrial 
adenocarcinomas, identified by a minimum of three pathologists on conventional 
haematoxylin and eosin-stained sections, obtained from the archives of four 
different laboratories, for a period of 13 years were used in a retrospective study on 
the subject.  
In previous studies on feline endometrial adenocarcinomas (FEA) it has been 
found an increase incidence in purebred animals, which has been associated with 
a longer reproductive activity in those animals in comparison with domestic cats. 
However, this should be read with caution, as population ratios between purebred 
and domestic mongrel animals may change with the geographic location. Also the 
cultural adoption of gonadectomy as a contraceptive measure may interfere with the 
regional prevalence of the disease. In fact, in Portugal the number of intact domestic 
cats is higher than the purebreds, due to the tendency for late spaying age (most of 
them due to uterine or mammary diseases), which could influence the incidence of 
FEA in our country. Some of the specimens used in this study were obtained at 
ovariohysterectomy following a clinical diagnosis of pyometra. Unless metastasic 
disease exists, to which illness is often associated, most frequent signs for FEA are 
vague and unspecific, making difficult the early diagnosis of endometrial carcinoma. 
The histological evaluation shows the existence of different tumour 
phenotypes, where clear cell are often found. The presence of nuclear atypia and 
the Ki67 expression seem not to be related to the malignancy of the tumour. 
Furthermore, one report refers the presence of oestrogen receptors, which could 
explain the low levels of metastization or invasiveness proposed for FEA, or the 
clinical outcome for the tumour. For most situations of primary FEA, in particular in 
early stages of the disease, myometrial invasion is limited and often absent. Also 
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vascular invasion is seldom observed even in tumours with moderate nuclear atypia. 
However, limited information exists on specimens from early FEA stages, which 
impair the presentation of a reliable prognosis for that animal. The major challenge 
seems to be the identification of valuable prognostic markers to achieve a definitive 
prognosis for animal life. 
Feline endometrial adenocarcinomas are possibly more common than we 
might presume and the clinical impact of such tumours may be increasing with the 
increase in the ability to establish an early diagnosis allied to an extended duration 
of life in cats. A recent report defends that FEA are more common than smooth 
muscle tumours of the uterus. Furthermore, as it frequently co-exists with pyometra 
or mucometra, it is also possible that a large number of cases fail to reach the 
pathological evaluation and hence remain undiagnosed. 
In this chapter we propose to discuss the clinical and morphological data of 
all the forty feline primary endometrial adenocarcinomas, supported by an extended 
review of the literature. 
 
INTRODUCTION 
 
 Although the uterus is considered the most common site of feline 
reproductive tract tumours in one study, uterine tumours comprised only 0,29% of 
all feline neoplasms diagnosed during the study period (Miller et al., 2003). 
Adenocarcinomas of the endometrium are considered to be rare in all domestic 
species, with exception of cattle and rabbits (Cotchin, 1964; Kennedy et al., 1998; 
McEntee and Nielsen, 1976), with the common practice of ovariohysterectomy 
(OVH) in cats being referred as protective from uterine neoplasia (Miller et al., 2003; 
Taylor, 2010). Spaying of young queens for contraception is neither a worldwide 
procedure nor a common practice in purebred cats, and hence is may not always 
be the reason for the small percentage of uterine adenocarcinomas. Furthermore, 
there are also reports of adenocarcinoma in the uterine stump of neutered cats 
(Anderson and Pratschke, 2011; Miller et al., 2003). On the other hand, the rarity of 
these tumours in cats might be related to inadequate post-mortem examination of 
the genital tract, but also to lack of interest in anatomopathological evaluation of 
ovariohysterectomy surgical specimens. In fact, in the study by Miller et al. (2003), 
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from all the uterine tumours the endometrial adenocarcinoma was the most 
commonly found in cats. 
According to clinical reports and our own experience, uterine carcinoma does 
not present specific signs. It rather shares some clinical signs with other uterine 
diseases and abortion, such as fluid accumulation with distension of the organ and 
increased thickness of the uterine walls, combined with emaciation or vaginal 
haemorrhagic discharge (Anderson and Pratschke, 2011; Belter et al., 1968; 
Preiser, 1964). These features further strength the possibility that the situations may 
be underdiagnosed, as the excised genital segments at OVH are seldom sent to 
histopathological analysis. Endometrial adenocarcinoma occurs most frequently in 
middle age to old animals, and its putative association with progestagens-based 
contraception is controversial. Nevertheless, very young animals can develop the 
disease. 
In other species, endometrial adenocarcinoma evolves as a malignant 
epithelial neoplasm. Also in felids, some reports exist on the presence of metastasis 
at the moment of diagnosis (Anderson and Pratschke, 2011; Belter et al., 1968; 
Preiser, 1964); however, its occurrence seems sporadic, and predictive markers 
have not yet been established. 
The major challenge seems to be the identification of diagnostic markers of 
feline endometrial adenocarcinomas, since there are few reports about these 
features, all of them in small case series. Because of the same reason, the 
achievement of prognosis of these lesions is difficult and requires further studies. 
Different morphologies of feline endometrial adenocarcinomas can be 
defined, which included papillary serous carcinoma (with or without clear cells), clear 
cell carcinoma and in situ carcinoma according to cytological criteria of malignancy, 
cell morphology and invasion of adjacent tissues (Saraiva et al., 2011). 
It is the intent of this paper to summarize what is known about the feline 
endometrial adenocarcinoma, supported by the findings of 40 histopathological 
situations. We will discuss the incidence of the disease, the main clinical signs as 
well as its diagnosis and the need for reliable prognostic markers. Further we will 
characterize the main morphological features of the three main types of feline 
endometrial adenocarcinoma (FEA) found in our casuistic. 
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INCIDENCE / EPIDEMIOLOGY OF FEA 
 
 Endometrial carcinoma/adenocarcinoma is more common in the cat than the 
dog (Morris and Dobson, 2001). Uterine adenocarcinoma is believed to be locally 
invasive, and the occurrence of metastasis are commonly reported. Severe illness 
is mainly associated with metastatic disease and is often at the origin of the 
presentation at the clinic. 
Although no breed predisposition has been reported (Klein, 2007), in previous 
studies on feline endometrial adenocarcinomas (FEA) it has been found an increase 
incidence in purebred animals, which has been associated with a longer 
reproductive activity in those animals in comparison with domestic cats (Johnston 
et al., 2001). However, this should be read with caution, as population ratios 
between purebred and domestic crossbread animals may change with the 
geographic location. Uterine samples with FEA were more frequently found, within 
the cases used herein, in domestic crossbread animals than in purebred (with the 
registry of only two Siamese and one Persian queen). This might be explained by 
the fact that in Portugal the number of intact domestic cats is higher than the 
purebreds, due to the tendency for late spaying age (most of them due to uterine or 
mammary diseases), which could influence the incidence of FEA in our country. 
From our database, in the last thirteen years 197 female genital tracts have 
been sent for analysis (almost 12% of all female feline analysis), from which 41.16% 
(81:197) did not show signs of uterine disease, 6.6% (13:197) were pregnant or with 
signs of abortion, 33.5% (66:197) showed inflammatory diseases of the uterus and 
20.30% (37:197) were diagnosed with FEA. The relative frequency of FEA is quite 
high in our database, which could be associated to the fact that in the last three 
years, we performed the systematic evaluation of excised genitalia for a PhD 
project. The analysis of the frequencies for the other clinical situations also 
highlights the fact that most frequently the clinicians send to commercial laboratories 
for analysis the organs with macroscopic signs of disease. Consequently, it is 
possible that small lesions may be undetected during their first trial, hence not being 
submitted for diagnosis, or incorrectly assumed as having pyometra. FEA most 
frequently develops in older animals, with more than 9 years (Belter et al., 1968; 
Klein, 2007; McEntee, 1990; Morris and Dobson, 2001; Preiser, 1964), although 
sporadic reports on younger animals around 5 years old have been published. 
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Although clinical information was only possible for half the animals used in our 
studies, in our cases the age of the females diagnosed with FEA ranged from 2 to 
15 years old. The age mean was 7 years and median for age was 6 years old. 
 
CLINICAL SIGNS 
 
Albeit several studies on feline endometrial carcinoma have been published, 
few reports detail the clinical aspects of the pathology. Furthermore, most 
descriptions refers to late stages of the disease (Anderson and Pratschke, 2011; 
Belter et al., 1968; Preiser, 1964), as often FEA evolves as a silent disease, not 
detected clinically unless large lesions or metastases are present. Illness is usually 
related to metastatic disease, and the major presenting complaint. 
The clinical signs of FEA vary with the size of the neoplasic lesions, but also 
with the age of the process and the existence and pattern of metastasis. It is possible 
that the morphological type of the tumour may also interfere with the most prevalent 
clinical sign. The size of the tumour may vary from less than one centimetre to 
greater than 10 cm (Johnston et al., 2001). Small-sized tumours are most frequently 
found incidentally at ovariohysterectomy or postmortem, whilst the large one usually 
gives more or less notorious clinical signs. 
If metastases are not present, vague and unspecific signs of uterine disease 
may be found, since the presence of a mass within the uterus may induce in chronic 
inflammation causing a mucous, purulent or haemorrhagic vaginal discharge, or 
pyometra (Taylor, 2010). Vulvar discharge may be intermittent (Meier, 1956, cited 
by McEntee, 1990). As consequence of this inflammatory reaction signs such as 
vomiting, irregular appetite and polyuria/polydipsia are present, and together with 
the vaginal discharge are usually the main complaints at consultation. Rarely, 
abnormal oestrous cycles have been described in association with FEA. 
Enlargement of the uterus, abdominal distress and distension of the abdomen are 
also frequently found during transabdominal palpation or when larger tumours exist 
(Johnston et al., 2001; Taylor, 2010). Also, when the lesions grow large enough to 
compress adjacente viscera, other signs may develop (Klein, 2007), like 
constipation or dysuria. They are frequently found in published reports on metastatic 
FEA situations, but are not always associated with the metastasis itself. Whenever 
metastasis exists, ascites, anorexia and weight loss are commonly found clinical 
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signs, which may co-exist with anaemia, fever and cachexia (Meier, 1956, cited by 
McEntee, 1990; Johnston et al., 2001). FEA may metastasize regionally or at the 
distance, to lungs, brain, or eyes (Klein, 2007; McEntee, 1990; Taylor, 2010). 
Depending on the location of the metastasis, secondary symptoms may be found: 
cough and respiratory distress, if metastases are thoracic, blindness or motor 
incoordination if in the central nervous system, ascites if in the abdominal organs. 
According to Taylor (2010) most cats develop metastatic disease within 6 months 
of diagnosis, if uterine excision is not performed or lymphatic invasion already exist 
at diagnosis. However, this period should be considered as indicative, as for most 
published reports, the tumour was diagnosed in later stages of the disease. 
 
MORPHOLOGICAL FEATURES OF PRIMARY EPITHELIAL TUMOURS OF THE UTERUS  
 
Several studies had been published in small series of feline endometrial 
adenocarcinomas, mainly related with their immunoprofile (Espinosa de los 
Monteros et al., 1999; Gil da Costa et al., 2009; Martin de las Mulas et al., 1995; 
Miller et al., 2003), but there is lack of literature explaining the different 
morphological aspects of these tumours, even when case reports are described 
(Anderson and Pratschke, 2011; Belter et al., 1968; Sapierzynski et al., 2009). 
Based in our experience, there are three different morphologies of primary 
endometrial adenocarcinomas in cats, which can be compared with women 
endometrial carcinoma (Horn et al., 2007): papillary serous carcinoma, clear cell 
carcinoma and a lesion restricted to the superficial endometrium that we might 
classified as “in situ” carcinoma. 
Macroscopically, these three different morphologies appear to be 
indistinguishable, presenting as a diffuse thickening of the endometrium along both 
uterine horns and corpus or as multiple white nodules, projecting to the lumen 
(FIGURE 1). The uterine wall can be also thinner if an abundant purulent content is 
present within the organ. In invasive tumours, it is possible to detect tumoral 
infiltration through the myometrium, sometimes with umbilication in the serosa that 
could rupture, promoting in this cases peritonitis. 
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FIGURE 1: Feline endometrial adenocarcinoma. A. Gross evaluation shows the uterus enlarged in all 
the extension. B. Longitudinal section shows the endometrium diffusely thicker through the uterine 
horn, appearing as a proliferative white tissue. 
 
PAPILLARY SEROUS CARCINOMA 
The majority of feline endometrial carcinomas, as described in the references 
cited above, have a papillary growth pattern projected into the lumen (FIGURE 2 A). 
The papillae are supported by a thin fibrovascular stroma (that may be edematous 
or hyalinized) and lined by more than one layer of neoplastic cells. The cells are 
pleomorphic columnar shaped, with moderate amount of eosinophilic cytoplasm, 
sometimes with focal clearing. The nuclei are round to oval, vesicular or 
hyperchromatic, and the cells loose the normal polarity; large nucleoli are evident 
and sometimes are found intranuclear clear inclusions. Mitotic figures are frequent 
and often bizarre. There is a moderate degree of anisokaryosis and anisocytosis. 
Numerous multinucleated cells can be found within the tumour. In some tumours, is 
possible to see squamous metaplasia. Randomly distributed areas of necrosis are 
found within the neoplasm and occasionally psammoma bodies are present. The 
invasion of the myometrium, vessels and lymphatics is not a constant feature. Some 
tumours have a clear inflammatory component, with macrophages, plasma cells, 
lymphocytes, neutrophils and occasionally eosinophils. Although these tumours 
show a predominant papillary serous morphology, areas of solid growth and a 
glomerular pattern may be present, as well as various numbers of clear cells, which 
are described in the next section. 
 
CLEAR CELL CARCINOMA 
Clear cell carcinomas of the feline endometrium are almost entirely 
composed by large, round to polygonal cells, with foamy cytoplasm and eccentric 
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crenate or ovoid nucleus, with a prominent eosinoplilic nucleolus. The cells are 
arranged in papillae, sheets or solid nests surrounded by a fibrovascular stroma 
(Figure 2 B). As in papillary serous carcinoma, there is a moderate degree of 
anisokaryosis and anisocytosis but multinucleated cells are absent. It can also be 
found necrosis and inflammatory cells are rare. The invasion of the myometrium is 
not a constant feature. Vessel or lymphatic tumoral emboli were not found in the 
available cases. 
 
“IN SITU” CARCINOMA 
Morphologic aspects of “in situ” carcinoma are very similar to those described 
for the papillary serous carcinoma. The differences are related to the location of this 
tumour that is very superficial in the apical endometrium and to the lack of invasion 
of the stroma (FIGURE 2 C). As the name implies, these tumours are non invasive. 
 
FIGURE 2: Morphological aspects of feline endometrial adenocarcinomas (HE). A. Papillary serous 
carcinoma (Obj. 10x). The papillae are surrounded by more than one layer of neoplastic cells and 
supported by scant fibrovascular stroma. It is possible to observe several multinucleated cells. B. 
Clear cell carcinoma (Obj. 10x). Nests of foamy cells, sometimes with central necrosis, surrounded 
by fibrovascular stroma. C. “In situ” carcinoma (Obj. 4x). Non invasive, superficial malignant 
proliferation of the endometrium. 
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DIAGNOSTIC MARKERS 
 
Major available reports do not distinguish between the three abovementioned 
FEA phenotypes when studying the expression of molecular markers in uterine 
epithelial tumours. However, it is possible that their grow, invading behaviour and 
metastatic potential may differ between the tumour´ types. Only by searching for the 
differences we may be able to develop markers that can be use for treatment and 
prognosis. 
Adenocarcinomas of the endometrium, like other epithelial tumours, tend to 
express broad-spectrum cytokeratins (CK), clones AE1/AE3 and MNF 116, but 
reactivity with AE1/AE3 is generally more intense and more frequent than with MNF 
116 (Gil da Costa et al., 2009; Miller et al., 2003; Sapierzynski et al., 2009). Espinosa 
de los Monteros et al. (1999) described the coordinate expression of cytokeratins 7 
and 20 in 67% of the feline endometrial carcinomas under study, in accordance with 
the results observed in the normal feline endometrium. Therefore, they proposed 
that coordinate expression of these two cytokeratins provides important information 
that can help in the diagnosis of these tumours (Espinosa de los Monteros et al., 
1999). The tumours do not express CK14 (Gil da Costa et al., 2009), as well as 
intermediate filament cytokeratins RDK-102 and NCL-5D3 (Martín de las Mulas et 
al., 1995). 
The great majority of feline endometrial carcinomas are negative for vimentin, 
but there are reports of tumours with expression of this molecule (Gil da Costa et 
al., 2009; Martín de las Mulas et al., 1995; Miller et al., 2003). 
According to the literature, feline endometrial adenocarcinomas are generally 
negative for the estrogen receptor-α (ERα), but in some tumours, up to 50% of the 
neoplastic cells have nuclear staining for ERα (Gil da Costa et al., 2009; Miller et 
al., 2003; Sapierzynski et al., 2009). Miller et al. (2003) found a tendency for 
metastization by the tumours that are negative for Erα and they defend that the loss 
of expression of estrogen receptors in such tumours suggests estrogen 
independence and may indicate a worse prognosis. 
The score of expression of progesterone receptor is very variable in 
endometrial adenocarcinomas, as well as the intensity of expression of this marker, 
but there is a tendency to a markedly reduced expression in these neoplasms (Gil 
da Costa et al., 2009; Sapierzynski et al., 2009). However, usually no information is 
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available on progesterone blood levels thus impairing the correct interpretaiton of 
the results. 
There is a moderate to strong expression of cyclooxygenade-2 (COX-2) by 
up to 50% of the neoplastic cells and a loss of polarity compared with the normal 
endometrium (Gil da Costa et al., 2009). 
Disperse information on other molecular markers, not explored from the 
biological point of view on respect to the tumour behaviour, are available in the 
literature. Endometrial adenocarcinomas of cats express E-cadherin and β- catenin, 
as the normal endometrium (Gil da Costa et al., 2009; Sapierzynski et al., 2009). In 
one case report, about 40% of tumoral cells of adenocarcinoma epithelium stained 
with Ki67 (Sapierzynski et al., 2009). The tumours are negative for smooth muscle 
actin, desmin, glial fibrillary acid protein and caveolin-1 (Gil da Costa et al., 2009; 
Martín de las Mulas et al., 1995; Miller et al., 2003; Sapierzynski et al., 2009). 
 
CLINICAL DIAGNOSIS 
 
History, presenting complaint, and physical examination findings usually 
provide the basis for diagnostic. Vaginal bleeding or vaginal discharge may direct 
the differential diagnosis into abortion, uterine tumour or cystic endometrial 
hyperplasia/pyometra. 
On early stages of the disease, FEA progress silently or giving discrete 
clinical signs. Most frequently, when signs of uterine disease are present, the animal 
is submitted to OVH under the suspicion of cystic endometrial disease or pyometra. 
Thus, the diagnosis is normally made at OVH or at necropsy. No consistent 
laboratory abnormalities have been noted, unless pyometra exist, and abdominal 
radiographs only confirm the presence of an abdominal or uterine mass. 
Hematological abnormalities might include regenerative anemia or neutrophilia 
(Klein, 2007; Morris and Dobson, 2001). 
Whenever clinical signs for uterine disease are present, the diagnosis is 
based on the clinical signs, abdominal palpation and ultrasound or radiological 
exploration of the abdominal and thoracic cavities. A soft tissue mass in the mid or 
caudal abdomen may be detected on the palpation of abdomen, and its echogenicity 
may be study by plain abdominal radiography or ultrasonography (US). US findings 
may include hypoechoic masses in one or both uterine horns or lesions miming CEH 
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lesions. As frequently accompanying mucometra or pyometra are found, enlarged 
coils of uterus may be distinguishable, along with the presence of small amount of 
fluid in the uterus. Ultrasonography may further be useful to define the origin of the 
mass or to evaluate regional metastasis (Klein, 2007; Morris and Dobson, 2001). 
Sporadically, surgical exploration may be needed to achieve the diagnosis (Klein, 
2007; Taylor, 2010). Radiographic findings can include soft tissue density masses 
that may displace the surrounding viscera. A definitive diagnosis is only obtained 
through histological examination of surgically excised specimens (Klein, 2007). 
In FEA more advanced stages, clinical signs may occur as a result of 
metastatic disease even before any clinical indication of the primary tumour is 
detected. In such cases, the overall clinical signs may delude the origin of the 
carcinoma. If ascitis is detected, peritoneal fluid can be collected via 
abdominocentesis and sent for analysis. 
Survival and outcome data are sparse for metastatic disease due to FEA 
(Klein, 2007; Taylor, 2010). The poor animal condition at diagnosis frequently limits 
the chances for successful treatment and often euthanasia is the human outcome 
for it. The differential diagnoses should contemplate other metastatic diseases 
associated to other carcinoma, as those at the mammary glands, liver, etc. In the 
absence of neurological signs, the presence of metastases on the lungs, eye, 
abdominal lymph nodes, liver and diaphragm should be ascertain, as it can influence 
both the treatment and the prognosis. 
 
TREATMENT 
 
In case of co-existing pyometra, supportive care should be provided. The use 
of antibiotics has to be pondered individually. 
If metastatic disease is still not apparent, a complete OVH is recommended, 
and the uterus should be sent (the entire surgical piece) for histopathological 
analysis. Whenever the uterus shows abnormal macroscopic features, even if gross 
evidence of a tumour is not present, the histopathological analysis ought to be 
requested. During the surgical procedure, the abdominal cavity should be explored 
and any suspected mass biopsied for histopathology. Attempts should be made to 
remove all tumours and metastatic foci. 
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Chemotherapy and radiation therapy for treating uterine tumours are largely 
untested in veterinary cases. However, adjunctive chemotherapy may be 
considered if malignancy is detected upon histopathology (Morris and Dobson, 
2001). Its use may be of survival benefit for patients, as it may prevent or delay the 
development of metastasis. However, the owner must be advertised that the 
benefits are yet unclear. For cats, the use of doxorubicin or carboplatin has been 
suggested. As limited information on the chemotherapy outcome for uterine 
tumours, health parameters should be closely monitored for undesirable side 
effects. Follow-up appointments should be schedule every three months to check 
for cancer spread and adjust the therapy as needed. 
 
PROGNOSIS 
 
In general, because clinical signs rarely are evident until late in the course of 
the disease, the prognosis should always be considered guarded, in particular 
because FEA have a documented metastatic potential. Metastatic disease warrants 
a severe prognosis. 
Nevertheless, the quality of the studies made so far about this theme doesn’t 
allow the accurate determination of prognosis of endometrial adenocarcinomas in 
cats, and its metastatic potential has been based on the number of clinical reports, 
but not on trustful clinical surveys. Only one study reveals that there might be a 
tendency to metastases by the tumours that are negative for ERα, which can 
indicate a worse prognosis (Miller et al., 2003). In case reports available in the 
literature, the tumours were presented in an advanced stage, resulting in a reserved 
prognosis and euthanasia (Anderson and Pratschke, 2011; Belter et al., 1968; 
Preiser, 1964; Sapierzynski et al., 2009). According to our experience, if the tumour 
is detected precociously and the ovariohysterectomy is performed, the prognosis is 
favourable. Furthermore, “in situ” carcinomas, non invasive papillary serous 
carcinomas and non invasive clear cell carcinomas tend to have a better prognosis 
in the immediate future, but a longer period of time should be evaluated for definitive 
conclusions. 
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CONCLUSION 
 
Feline endometrial adenocarcinomas are possibly more common than the 
literature describes and distinct morphologies are here proposed: papillary serous 
carcinoma, clear cell carcinoma and “in situ” carcinoma. Few studies are available 
and all on small case series of these tumours, which difficult the determination of 
several aspects of these neoplasms. Nevertheless, all of them describe the loss of 
expression of estrogen receptor by neoplastic cells, as being a consensual feature 
of feline endometrial adenocarcinomas, and possibly related to a worse prognosis. 
So far, from other authors’ studies, this seems to be the best diagnostic marker 
associated with prognosis for feline endometrial adenocarcinomas. Another feature 
of feline endometrial adenocarcinomas is the coordinate expression of cytokeratins 
7 and 20, which helps the diagnosis of these tumours. COX-2 may play an important 
role in the carcinogenesis of the endometrium, but more studies in larger case series 
are expected to extend the existent knowledge. New studies including the clinical 
data on the patients diagnosed with FEA in early stages of the disease are desired 
in order to establish incidence, common clinical profiles and survival rates for the 
disease. 
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ABSTRACT  
 
BACKGROUND 
Endometrial adenocarcinomas are a rare type of tumour in cats. Though 
different morphologies have been reported, the most frequent histological type of 
feline endometrial adenocarcinoma (FEA) is the papillary serous. Characterization 
of molecular markers expression in FEA may contribute to clarify the pathogenesis 
of these tumours and to assess the differences between normal endometrium and 
FEA regarding the expression pattern of several proteins. Therefore, this study 
aimed to evaluate the immunohistochemical profile of a wide panel of antibodies 
(specific for ER-α, PR, Ki-67, CK7 and CK20) in twenty-four cases of FEA. 
Comparisons were made between FEA and feline normal cyclic endometrium in 
follicular (n= 13) and luteal (n= 10) stages. Except for Ki-67, all other molecular 
markers were assessed independently for the intensity of immunolabeling and for 
the percentage of cells expressing the protein. 
 
RESULTS 
This study showed that in FEA a loss of expression occurs, both in the 
proportion of labelled cells and in the intensity determined, both for ER (P≤ 0.0001) 
and less marked for PR (P= 0.002 and P= 0.024 for the percentage of positive cells 
and intensity of labelling, respectively). Proliferative activity, estimated via Ki-67 
immunoreaction, significantly increased in FEA as compared to normal 
endometrium (P≤ 0.0001). Feline endometrial adenocarcinomas maintained the 
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CK7+/CK20+ status of normal endometrium. However, FEA showed decreased 
CK7 intensity of labelling compared to normal endometria (P≤ 0.0001) and lost 
CK20 expression, both in intensity (P≤ 0.0001) and in percentage of positive cells 
(P= 0.01), compared to normal tissues. 
 
CONCLUSIONS 
Data gathered in this study suggest that proliferation in FEA accompanies 
ER-α down-regulation, possibly following activation of pathways mediated by local 
growth factors. Moreover, FEA retains combined expression of CK7 and CK20, as 
evidenced in normal endometrial epithelia, although a decrease in CK7 expression 
was observed. 
 
KEY-WORDS 
Cat diseases; endometrium; adenocarcinoma; immunohistochemistry  
 
BACKGROUND  
 
Endometrial adenocarcinomas are a rare type of tumour in cats (Cotchin, 
1964; Kennedy et al., 1998; McEntee and Nielsen, 1976). Uterine neoplasms 
account to 1 to 2% of the tumours affecting the queen’s reproductive organs, 
representing 0.2 to 0.4% of all feline tumours (Johnston et al., 2001). Nevertheless, 
in recent years an increasing number of reports on feline endometrial 
adenocarcinomas (FEA) have been published (Anderson and Pratschke, 2011; Cho 
et al., 2011; Payan-Carreira et al., 2013; Saraiva et al., 2015; Sontas et al., 2013) 
suggesting that FEA may be more common than once believed.  
Clinically, FEA are not distinguishable from other non-neoplastic diseases of 
the cat uterus, like pyometra, though they may have a completely different outcome, 
particularly in older females (Payan-Carreira et al., 2013; Pires et al., 2013). 
Knowledge on FEA is very restricted and mostly originated from case 
descriptions, complemented with a few studies developed in a limited case series, 
supporting the need for additional studies in larger case series (Gil da Costa et al., 
2009; Payan-Carreira et. al., 2013). Immunohistochemistry is an acknowledged 
well-established routine technique in anatomical pathology, very useful on account 
of its easiness, safety and inexpensiveness compared to other molecular techniques 
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(Millanta et al., 2005). Moreover, locating a protein in tissue sections may be helpful 
to study morphological characterization and potential behaviour of tumours. 
The cyclic interchange of estrogens and progesterone secreted by the 
ovaries determines cyclic patterned changes in the mammalian endometrium – the 
endometrial cycle - with the ultimate goal of achieving a pregnancy. In the 
endometrium, major functions of circulating sex steroids are dependent on the 
estrogen and progesterone receptors (ER and PR). Particularly, these receptors 
mediate the continuous synchronized epithelial-stromal crosstalk that ultimately 
regulates the endometrial proliferation, differentiation and secretion and thereby 
promote embryo receptivity (Franco et al., 2012; Weihua et al., 2000). In general 
terms, estrogen stimulates the proliferation of both glandular and stromal cells, 
whereas progesterone inhibits the growth of glandular cells and stimulates the 
secretory activity in the endometrial glands. A disruption in the equilibrium of ER/PR 
(Olson et al., 2007), or mutations in the genes coding these molecules (Bender et 
al., 2011), may interfere with the normal proliferative or secretory patterns, and 
predispose to endometrial disease. Estrogen and progesterone receptors have 
been described in human endometrial carcinomas as independent prognostic 
factors (Trovik et al., 2013). Information on sex steroid receptors in feline 
endometrium is scarce. Furthermore, in FEA, available data concerning sex steroid 
receptors expression is limited and frequently opposed. In general, loss of ER-α has 
been reported, ranging from 50% (4/8 cases) (Miller et al., 2003) to 83.3% (5/6 
cases) (Gil da Costa et al., 2009); one study also refers that PR are generally 
expressed in FEA (Gil da Costa et al., 2009). This may raise an important concern 
when sub-clinical FEA females are under progestagen contraceptive treatment, 
which could interfere with FEA progression and outcome. Moreover, the hormone 
receptors status of FEA may adjoin important information for medical management 
after ovariohysterectomy (OVH) (Gil da Costa et al., 2009), deserving additional 
studies. 
In general, cancer development and progression is associated with 
deregulation of cell proliferation and of programmed cell death. The increased 
proliferative activity in a tumour is related to its growth rate, and may account for its 
malignancy and the clinical course of the disease. Thus, its assessment yields 
useful prognostic information related to survival of patients in various types of 
tumours (Kushi et al., 2002). Evaluation of the tumour proliferative activity is 
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frequently assessed by immunohistochemistry, using the expression of Ki-67 
nuclear antigen (Dias Pereira et al., 2004), a nuclear non-histone protein present 
exclusively in proliferating cells, irrespectively of whether they are normal or 
neoplastic (Scholzen and Gerdes, 2000). Assessment of Ki-67 index has been 
applied to the normal endometrium, to characterize the cyclic changes in cell 
proliferation in mares (Aupperle et al., 2000), cows (Arai et al., 2013) and bitches 
(Van Cruchten et al., 2004). Furthermore, the immunohistochemical profile of Ki-67 
has also been sporadically determined in feline endometrial lesions, including in two 
FEA case reports (Sontas et al., 2013) - in which Ki-67 varied from moderate to high 
- and in the description of multiple uterine lesions, which included an area of 
endometrial adenocarcinoma, that exhibited 40% of positive cells for Ki-67 
(Sapierzynski et al., 2009). 
Cytokeratins (CK) are the largest group of intermediary filaments proteins; 
they are essential in the development and differentiation of epithelial cells. They are 
also crucial for the normal structure and function of the epithelium, as CK are 
involved in signal transduction, cell polarity and gene regulation (Jasik, 2012); in 
addition, particular CK may also contribute to the epithelial innate defence 
mechanisms, through their antimicrobial properties (Tam et al., 2012). Cytokeratins 
are divided into two groups. Cytokeratin 20 is included in the type I CK, which are 
acidic, low molecular weight (40-56.5 kDa) proteins; whilst CK7 belongs to type II 
CK, that consist of basic, high molecular weight (52-67 kDa) proteins (Iwatsuki and 
Suda, 2010). Different types of epithelia show specific patterns of CK expression. In 
the uterus, CK are commonly found in the luminal and glandular epithelia (Jasik, 
2012) and in the invading trophoblast (Maldonado-Estrada et al., 2004; Mühlhauser 
et al., 1995). Antibodies raised against CK are used as specific markers for epithelial 
cell differentiation and are largely used for tumour identification and classification 
(Thuróczy et al., 2009). The human uterine carcinoma presents a CK7+/CK20- 
phenotype (Jasik, 2012). Espinosa de los Monteros et al. (1999) strengthen the 
usefulness of the coordinate expression of CK7 and CK20 to distinguish different 
primary feline carcinomas and to ascertain its origin, in case of metastatic disease; 
they also described the normal pattern of these CK in feline normal endometrium. 
Cytokeratin 7+ / cytokeratin 20+ profiles were described in 2/3 (66.7%) FEA 
(Espinosa de los Monteros et al., 1999). In another study, 3/6 (50.0%) FEA 
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expressed CK7, whereas 4/6 (66.7%) FEA showed positive reaction for CK20 (Miller 
et al., 2003). 
Most published case series studies on FEA used a small number of cases, 
ranging from three (Espinosa de los Monteros et al., 1999) to six (Gil da Costa et 
al., 2009) or eight (Miller et al., 2003), which might have contributed to the reported 
contrasting results. 
Therefore, the objectives of this study were: 1) to evaluate the 
immunohistochemical expression of ER-α, PR, Ki-67, CK7 and CK20 in the papillary 
serous form of FEA using the largest case series reported so far; 2) to monitor the 
changes in the immunoexpression of these molecules as compared to the 
immunohistochemical profile of feline normal endometrium in two different stages of 
the estrous cycle; 3) to estimate putative associations between the molecular 
markers and the histopathological predictors of dedifferentiation; 4) to study the 
relationship between these markers. 
 
METHODS 
 
SAMPLES AND ANIMALS 
The study was conducted in twenty-four samples of FEA retrieved from the 
archives of four different laboratories, during a period of 8 years. As controls, twenty-
three archived samples of histologically normal feline uteri were selected (13 
samples for the follicular stage – FS – and 10 samples for the luteal stage – LS). All 
samples were previously fixed in 4% neutral-buffered formalin and routinely 
processed for paraffin embedding.  
Control uterine samples were obtained after elective ovariohysterectomy 
(OVH), from post-pubertal queens aged seven months to eight years of age (mean 
1.5 years). Breed was unavailable in 65.3% of the records; on the other 34.7% 
records, represented breeds included Domestic Shorthaired cats (n= 7; 30.4%) and 
Persian (n= 1; 4.3%). For controls (normal endometria), only queens not submitted 
to contraceptive treatment were selected. 
Feline endometrial adenocarcinomas were diagnosed in queens aged one 
year to 15 years of age (mean 7.9 years); breeds included Domestic Shorthaired 
cats (n= 17; 70.8%), Siamese (n= 2; 8.3%) and Persian (n= 1; 4.2%). Contraception 
was given in five (20.8%) animals and was denied in three (12.5%) FEA cases, 
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though the length of treatment was not mentioned in the form; no information existed 
in the request form for the remainder 16 cases (66.7%). 
Regarding the clinical history of the animals diagnosed for FEA, data was 
collected from the histopathological request forms. The existence of clinical signs of 
uterine disease was mentioned in 11 (45.8%) cases, whilst in six (25.0%) other 
cases, the coexistence of pyometra and a concurrent mammary tumour were 
referred. FEA was diagnosed in two (8.3%) animals without acknowledge clinical 
symptoms, the lesions in the uterus being detected only during elective OVH as an 
enlarged organ with increased consistency. For all the other cases (n= 5; 20.8%), 
the reasons for OVH were not declared. 
 
MORPHOLOGICAL EVALUATION 
Feline endometrial adenocarcinomas diagnosis and the staging of the cycle 
stage in normal samples of healthy endometria (controls) were performed by light 
microscopy, on three-micrometres sections routinely stained with haematoxylin and 
eosin. The tumours were evaluated according to several criteria of malignancy 
described in the literature (Al Kushi et al., 2002; Goldschmidt et al., 2011; Horn et 
al., 2007), enabling the diagnosis of FEA of the papillary serous type (Saraiva et al., 
2012). The histopathological features included: nuclear atypia, classified as low to 
moderate or high; mean number of mitoses per high power field (HPF), scored as 
lower than one, one to five and more than five; and the existence of myometrium, 
serosa or vascular / lymphatic invasion, evaluated as present or absent.  
Normal uterine samples were staged as FS or LS based on the summative 
information gathered by the ovarian morphology (presence of follicles vs. corpora 
lutea), and the histological endometrial features (the epithelial cell height and the 
degree of development and coiling of endometrial glands). For patients diagnosed 
with FEA, determination of the stage of the estrous cycle was evaluated according 
to the presence of follicles in different stages of development – FS – or the presence 
of corpora lutea – LS – in the ovary. 
For FEA cases, 11 cats (45.8%) were in FS and seven animals (25.0%) were 
in the LS of the estrous cycle; on the remaining cases (n = 7; 29.2%), the surgical 
specimen did not include the ovaries thus impairing the staging of the estrous cycle. 
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IMMUNOHISTOCHEMISTRY 
Immunohistochemistry was performed in three-micrometre sections by the 
indirect avidin-biotin peroxidase complex technique. TABLE 1 summarizes the 
references of the antibodies used in this study, their dilution and incubating time. 
Antigen retrieval was performed in a steamer with slides immersed in boiling citrate 
buffer (pH 6.0; about 94 ºC) for 3 minutes. After cooling in phosphate buffered saline 
(PBS), the sections were immersed in 3% hydrogen peroxide during 20 minutes to 
block endogenous peroxidase activity. After the incubation with the normal serum 
for 5 minutes, the slides were incubated with the primary antibodies (TABLE 1) for an 
overnight period, in a humid chamber. Immunohistochemical labelling was achieved 
by using the products specified in TABLE 1, following the manufacturer’s instructions. 
Colour was developed with 3,3-diaminobenzidine tetrahydrochloride and sections 
were counterstained with Gill’s haematoxylin, dehydrated and mounted for 
evaluation on light microscopy. 
 
TABLE 1: Primary antibodies used for immunohistochemistry. 
ANTIBODY CLONE SOURCE DILUTION STAINING 
PATTERN LABELLING 
Monoclonal 
mouse anti-
human 
estrogen 
receptor (ER) 
ER-12 Cell Marque
®, 
USA 1:40 
Nuclear 
Novolink® Polymer 
Detection System, 
(RE7280-K) Leica 
Biosystems®, UK 
 
Monoclonal 
mouse anti-
human 
progesterone 
receptor (PR) 
1A6 Novocastra®, UK 1:30 
Monoclonal 
Mouse 
Anti-Human 
Ki-67 Antigen 
MIB-1 Dako®, Denmark 1:50 
Clonal rabbit 
anti-human 
Cytokeratin 7 
(CK7) 
R17-S DB Biotech
®, 
Slovak Republic 1:100 
Cytoplasm 
Lab Vision® 
UltraVision® Large 
Volume Detection 
System, Thermo 
Fisher Scientific®, 
USA 
Monoclonal 
mouse anti-
human Keratin 
20 (CK20) 
Ks 20.8 Thermo Fisher Scientific®, USA 1:100 
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QUANTIFICATION OF IMMUNOLABELLING 
In normal endometrium, the immunolabelling for ER-α, PR, Ki-67, CK7 and 
CK20 was evaluated independently in the surface epithelium (SE), superficial and 
deep glandular epithelium (SGE and DGE, respectively). In FEA the immunostaining 
was assessed in epithelial tumour cells. Stromal and myometrial labelling were 
evaluated independently for ER-α and PR in both normal and neoplastic epithelium.  
The intensity of ER-α and PR immunolabelling was graded as 0 = no staining, 1 = 
weak, 2 = moderate and 3 = strong. Regarding the percentage of cells expressing 
ER-α and PR, the negative cut-off was established at 5% (Ferrandina et al., 2005; 
Martín de las Mulas et al., 2000; Millanta et al., 2005; Mingzhu et al., 2014). Since 
the majority of the controls (n = 20/23) had more than 80% of positive cells, this was 
settled as the maximum cut-off. Therefore, the samples were further classified 
semiquantitatively according to the marks: 0 = negative (≤ 5 % positive nuclei); 1 = 
loss of expression (5 to 80% positive nuclei) and 2 = positive (≥ 80% positive nuclei).  
The evaluation of Ki-67 immunostaining was performed in 1000 cells in 10 HPF (x 
400) and expressed as a percentage – proliferative index (Dias Pereira et al., 2004). 
The immunoexpression for CK7 and 20 was semiquantitatively scored for 
both the percentage of labelled cells (1 to 33% = low; 34 to 66% = moderate; 67 to 
100% = high) and the labelling intensity (1 = weak; 2 = moderate; 3 = strong) 
(Espinosa de los Monteros et al., 1999). This evaluation was performed for the entire 
endometrium section in controls and in representative microscopic fields for FEA. 
The labelling intensity was evaluated on the basis of the most frequently observed. 
 
STATISTICAL ANALYSIS 
Statistical comparisons were performed by using chi-square and Fisher exact 
tests in the IBM SPSS Statistics Base 20.0 software®. Ki-67 data were analysed 
using the ANOVA test, the post hoc paired comparisons were carried out using the 
Bonferroni correction. P values < 0.05 were regarded as statistically significant. 
 
RESULTS  
 
HISTOPATHOLOGICAL EVALUATION 
In the present study, FEA were primarily characterized by the multi-layered 
proliferation of neoplastic endometrial epithelial cells on papillae into the lumen 
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supported by a thin fibrovascular stroma. Tubular and solid proliferation was scantly 
present. Therefore, tumours were histologically classified as FEA of the papillary 
serous type (FIGURE 1). Neoplastic cells were pleomorphic columnar shaped, with a 
moderate amount of eosinophilic cytoplasm and round-to-oval, vesicular or 
hyperchromatic nuclei that lost the normal polarity. Numerous multinucleated cells 
with darkened nuclei were present within and at the surface of the lesions. A variable 
number of clear cells - large, round to polygonal cells, with foamy cytoplasm and 
eccentric, crenated or ovoid nucleus – comprised less than 50% of the tumours’ 
area. Nucleoli were evident; occasional intranuclear clear inclusions were also 
found. Randomly distributed areas of necrosis within the tumours were frequently 
present. A variable degree of atypia was found in FEA lesions (TABLE 2), with 54.2% 
(13/24) of the cases evidencing high atypia. 
 
FIGURE 1: FEA. Papillary growth of epithelial tumour cells supported by thin fibrovascular stroma. 
Necrosis is observed at the lumen of neoplastic glands. At the right bottom, the tumour invades 
uterine myometrium. Haematoxylin and eosin. BAR = 500 μm. 
 
The mean number of mitoses per HPF in FEA was higher, compared to 
normal epithelia (P≤ 0.0001). In the majority of FEA (n= 19; 79.2%), the mean 
number of mitoses per HPF was established between one and five, with very few 
cases (n= 2; 8.3%) presenting more than five mitoses per HPF (TABLE 2), in contrast 
with the recorded in the normal endometrium. The SE always presented less than 
one mitosis per HPF, both whether the FS and LS was considered (TABLE 2). The 
mean number of mitoses per HPF in the glandular epithelia was more variable, but 
the prevailing value was less than one for the SGE in 92.3% (12/13) to 100% (10/10) 
of the samples in FS and LS, respectively. The mean number of mitoses was similar 
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in the DGE in the FS (92.3%; 12/13), but slightly lower in the LS (70.0%; 7/10) (TABLE 
2). 
Myometrial invasion was observed in a large proportion of cases (66.7%; 
16/24), while vascular invasion was observed in only 12.5% (3/24) of the cases; 
serosa impairment was only detected in 4.2% (1/24) FEA; though vascular and 
serosa invasion occurred independently in either situation myometrial invasion. In 
normal uterine samples, as expected, the anatomical integrity of myometrium and 
serosa layer was maintained. 
 
IMMUNOHISTOCHEMISTRY 
In the samples of normal endometrium, immunoreaction against ER-α and 
PR was consistently detected in all epithelial types, as well as in the stroma and 
myometrium (TABLE 3; FIGURE 2 A-B).  
The intensity of labelling against ER-α was, in general, weaker in the SE than 
in the GE and the intensity scores were higher in the DGE than in SGE. However, 
the differences in the represented epithelia were significant for LS, but not for FS 
(P= 0.011 and P= 0.593, respectively; TABLE 3). The intensity of immunostaining for 
ER-α was slightly lower in the SE and SGE during LS in comparison to FS, but 
changes were more discrete regarding the DGE intensity of immunostaining. A 
moderate to strong intensity (scores 2 or 3) was evidenced in both the stroma and 
the epithelial elements in the normal endometrium for most samples (TABLE 3). A 
slight reduction was observed in the ER-α intensity for the endometrial stroma 
(TABLE 3). However, the stage of the cycle did not significantly affect the intensity of 
ER-α expression in stroma (P= 0.507). In the myometrium, the moderate intensity 
of ER-α staining prevailed in both stages, with no differences detected between the 
FS and LS (P= 0.363). 
Regarding the percentage of positive cells for ER-α, all the represented 
endometrial epithelia expressed this marker during FS (score 2 for all the samples; 
TABLE 3). A slight reduction was observed in the percentage of labelled cells in the 
SE of LS, but not in the other endometrial epithelia (TABLE 3); still, the majority of 
samples retained a score 2 in the SE of LS, and the differences were non-significant. 
In FS, the number of cells ER-α positive in the endometrial stroma was more 
heterogeneous than in the endometrial epithelia, the scores ranging between 1 (5 
to 80% of positive nuclei) and 2 (score 2 ≥ 80% of positive nuclei). The stromal 
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compartment in LS showed a reduction in the number of ER-α positive cells as 
compared to the FS, but these changes were not significant (P= 0.669). The 
myometrium was consistently positive to ER-α expression, independently of the 
stage of the cycle (TABLE 3). 
In what regards the ER-α immunoreaction in FEA, a marked decrease in the 
intensity and the percentage of labelled cells was recorded for both the epithelium 
and the stromal compartments (FIGURE 2 C). In FEA, around 70% of the samples 
presented a score ≤ 1 for epithelial ER-α intensity, considerably lower than any 
epithelia in either the FS or LS normal endometrium (P≤ 0.0001; TABLE 3). 
Simultaneously, a marked decrease in the percentage of positive cells to ER-α in 
the neoplastic epithelium was observed as compared to normal endometrium 
epithelia (P≤ 0.0001): in FEA, half the samples showed positive nuclei in less than 
5% of the cells, with 45.8% of the cases displaying ER-α positive nuclei in less than 
80% of the cells (TABLE 3). Similarly, a loss in the overall expression of ER-α, both 
in intensity of the immunoreaction and the number of cells with positive nuclei, was 
observed in FEA stromal compartment compared to the normal endometrial stroma 
(P≤ 0.0001; TABLE 3). Tumours characterized by myometrial invasion were more 
likely to be negative for ER-α in the stromal compartment (P= 0.033). The 
percentage of ER-α positive smooth muscle cells in the FEA myometrium was 
considerably lower than in the normal endometrium (P≤ 0.0001); notwithstanding, 
the intensity of the ER-α immunoreaction did not change between normal 
endometrium and FEA (P= 0.153). 
In general, the intensity of PR immunoreaction was similar between all the 
represented endometrial epithelia (TABLE 3). In the FS a moderate intensity 
prevailed over the strong intensity of immunolabeling, particularly in the SE and SGE 
(Table 3). The intensity of immunostaining showed a slight increase during the LS 
in all the represented epithelia, in particular in the DGE, but these changes were 
devoid of significance. The immunoreaction in the stromal compartment was more 
heterogeneous than the observed for ER-α. Higher scores were recorded in the FS; 
in LS it was observed a marked loss in the intensity of immunostaining (P= 0.010; 
Table 3). Contrasting, lower scores for PR intensity of immunostaining were 
observed in myometrium in FS compared to LS, but in the latter a wider variation of 
intensity scores was obtained. However, the differences among FS and LS were 
non-significant for this layer (P= 0.141). 
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Progesterone receptors were consistently positive in all evaluated epithelia 
during the FS; in comparison, a slight non-significant decrease in the percentage of 
PR positive cells was observed in LS (P= 0.435; TABLE 3). The percentage of PR 
positive cells in the stromal compartment was higher in the FS than in the LS (P= 
0.027; Table 3). However, score 1 (5 to 80% of positive nuclei) was the most 
prevalent in both stages. A small non-significant reduction in the percentage of PR 
positive cells was observed also in myometrium during the LS, compared to FS (P= 
0.070; TABLE 3). 
Compared to the normal endometrium, FEA displayed more discrete 
differences in what concerns PR expression than those presented for ER-α, both at 
the epithelial and the stroma compartment (TABLE 3; FIGURE 2 D). Feline endometrial 
adenocarcinomas epithelium showed a significant reduction in either the percentage 
of PR positive of cells (P= 0.002) and the intensity of immunolabeling (P= 0.024). 
Albeit a small decrease in the intensity and the percentage of cells with positive 
nuclei in both FEA stroma and myometrium compared to normal endometrium, the 
differences in PR expression in these compartments were devoid of significance 
(TABLE 3). 
No association between ER-α and PR expression was found in the epithelial 
or stromal compartments of normal or neoplastic endometria. Also, we did not find 
a significant association between hormone receptor status and the stage of the 
estrous cycle in FEA. 
The proliferative indexes, as estimated by Ki-67 counting, were similar 
between FS and LS (P > 0.05). In FS, the proliferative indexes were higher for SGE 
(16.7±5.4) as compared to SE and DGE (9.0±2.6 and 7.3±2.8, respectively). In LS, 
the proliferative indexes were higher for the glandular epithelia, particularly for the 
DGE (21.5±10.0 vs. 13.0±5.2 in SGE), than for the SE (7.1± 2.1). Considering the 
epithelia as a whole, the mean proliferative indexes were 11.0±2.3 and 13.9±3.8 in 
FS and LS, respectively. The proliferative index was considerably higher in the 
neoplastic epithelium (42.9±3.8) than in normal endometrial epithelia in FS (95% 
CI= 20.9 – 42.9) or LS (95% CI= 17.3 – 40.8) (FIGURE 3). Ki-67 expression was 
independent of the tested clinicopathological features analysed as an indication of 
tumour aggressiveness and of the hormonal receptor status. 
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FIGURE 2: ER-α and PR immunohistochemical expression in feline normal and neoplastic 
endometrium. A. ER-α and B. PR in the LS of cyclic endometrium are expressed in all uterine layers. 
BAR = 250 μm C. ER-α expression is decreased in FEA. Transition between positive normal glands 
and negative neoplastic cells are notorious. BAR =100 μm. D. PR expression is maintained in FEA. 
BAR =100 μm. Counterstained with Gill´s haematoxylin. 
 
 
FIGURE 3: Ki-67 immunohistochemical expression in feline endometrium. A. Normal endometrium at 
the LS shows scarcely positive c ells. A positive cell in metaphase is positive to Ki-67 antigen at the 
lower bottom. B. FEA are largely positive to Ki-67 antigen. BAR = 50 μm. Counterstained with Gill´s 
haematoxylin. 
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Normal feline endometrium presented a CK7+/CK20+ immunoprofile (FIGURE 
4 A-B). The SE presented a strong intensity of immunoreaction against CK7, which 
did not change with the stage of the estrous cycle (TABLE 4). The intensity of CK7 
immunolabeling differed between the SGE and the DGE, according to the stage of 
the cycle. A strong intensity of immunolabelling prevailed in the SGE and in the DGE 
in FS, but a decrease in the labelling intensity for this molecule was observed in 
both epithelia during the LS (P= 0.04 and P= 0.039, respectively for SGE and DGE; 
TABLE 4), whereby the most prevalent intensity of labelling was the moderate. 
Cytokeratin 7 was consistently detected by all the epithelia represented in the 
endometrium, independently of the stage of estrous cycle (TABLE 4). 
 
FIGURE 4: CK7 and CK20 immunohistochemical expression in feline endometrium. A. CK7 is strongly 
expressed in all epithelia of normal endometrium in FS. Contrasting, B. CK20 is expressed with a 
low intensity of labelling. BAR = 250 μm. C. FEA displays a maintenance of CK7+ expression 
although with a heterogeneous positivity D. CK20+ immunophenotype in FEA shows a decreased 
expression and a scarcely, heterogeneous positivity. BAR = 100 μm. Counterstained with Gill´s 
haematoxylin. 
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The stage of the cycle affected the intensity of immunoexpression for CK20. The 
intensity of immunostaining most often recorded in FS was the moderate, the DGE 
presenting a slightly increased immunostaining as compared with the SE and the 
SGE (TABLE 4). In LS, a shift towards stronger intensities was observed in the SE 
(P= 0.002) and in the SGE (P= 0.045), but not in the DGE (TABLE 4). As for the 
percentage of positive CK20 cells, similar scores were observed in FS and LS, 
despite the small non-significant decrease observed in the surface epithelium in the 
LS (P= 0.178; TABLE 4). 
In FEA the CK7+/CK20+ epithelial immunoprofile was maintained (FIGURE 4 
C-D). However, a heterogeneous, patchy immunolabelling was observed for both 
CK in the neoplastic epithelium. A loss in CK7 expression intensity was observed in 
FEA as compared to the normal endometrial epithelium (P≤ 0.0001), whilst the 
percentage of CK7 positive cells remained practically unchanged (P= 0.065; TABLE 
4). Similarly, CK20 was also lost in FEA as compared to the normal endometrium, 
both in terms of the percentage of positive cells and the intensity of labelling (P≤ 
0.0001 and P= 0.01, respectively; TABLE 4). No relation was established between 
CK7 and CK20 status in epithelial cells. 
The comparison between the immunohistochemical results and the available 
clinicopathological data suggested that the myometrial invasion observed in FEA 
was associated with negative stromal ER-α status (P= 0.033 and P= 0.006, 
respectively for percentage of positive cells and intensity of immunolabelling) and 
with a higher percentage of CK20-positive cells (P= 0.033). In tumours, nuclear 
atypia was related to a lower intensity of CK7 labelling (P= 0.026). The loss of PR 
positive cells in the myometrium in FEA was related to a higher nuclear atypia in 
carcinoma cells (P= 0.016). 
 
DISCUSSION  
 
Despite the rarity of FEA described in the literature (Cotchin, 1964; Kennedy et al., 
1998; McEntee and Nielsen, 1976), a recent increasing number of reports suggest 
that the prevalence of these tumours may be underestimated (Anderson and 
Pratschke, 2011; Cho et al., 2011; Payan-Carreira et al., 2013; Sontas et al., 2013). 
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Moreover, in one study on uterine tumours in domestic cats, FEA was the most 
commonly diagnosed neoplasm (Miller et al., 2003). The selection of cases 
diagnosed as FEA from the archives of four different laboratories allowed the use of 
a larger series than usual. Its architecture and the histological features of neoplasic 
epithelial cells classified the cases under papillary serous type, the most frequent 
type of FEA (Saraiva et al., 2012). Herein, we describe an immunohistochemical 
panel performed on FEA to gather helpful information regarding its diagnosis and 
management, as well as to drive upcoming areas for study on FEA. 
Estrogen receptor alpha and PR expression was found in epithelial and 
stromal endometrial compartments and in myometrium of normal feline uteri. 
Information on ER-α and PR expression in normal healthy endometrium of this 
species is very limited, and mostly based on the work of Li et al. (1992) that 
mimicked the ovarian steroids effects on the feline uterus through the scheduled 
administration of exogenous estrogens and progesterone (Li et al., 1992). However, 
changes in the intensity of immunostaining of ER-α from FS to LS followed the 
expected physiological modifications, evidencing a small decrease in the LS 
suggestive of the suppressive effect of progesterone receptor activation. Changes 
were more notorious in the surface epithelium and the superficial glandular epithelia 
than in deep glandular epithelium; this may be related with to the increased 
branching of upper endometrial glands in FS and to the persistency of proliferation 
of basal glands during the LS, that is reflected in the increased coiling reported in 
this stage (Chatdarong et al., 2005), which was supported by data gathered by Ki-
67 immunolabeling.  
Progesterone receptor expression in epithelial cells from normal 
endometrium showed a small decrease from the FS to LS, following an expectable 
physiological pattern. The high heterogeneity of the intensity scores presented by 
the different samples might relate to individual differences in the moment of the LS 
or the blood levels of progesterone, which were not assessed in the present study. 
The unavailability of information concerning the normal PR expression in cat 
endometrium limits the interpretation of the decrease in the PR stromal expression 
during LS. However, it is possible that, in line with other species, stromal and 
epithelial compartments of the endometrium may respond differently to steroid 
hormones (Aupperle et al., 2000). In addition, since endometrial stroma and 
epithelium influence each other proliferation and differentiation (Pierro et al., 2001), 
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differences in either compartment responses to sex steroids may be necessary to 
the normal interplay through the uterine cycle. 
Recently, a consensus was proposed on the standard guidelines for hormone 
receptor assessment using immunohistochemistry for canine mammary tumours 
(Peña et al., 2014). However, no guidelines exist for feline mammary or uterine 
neoplasms. Consequently, the cases used in the present study were evaluated on 
the basis of the results obtained in controls, using the negative cut-off established 
before for feline mammary tumours and human endometrial carcinomas (Ferrandina 
et al., 2005; Martín de las Mulas et al., 2000; Millanta et al., 2005; Mingzhu et al., 
2014).  
All FEA analysed herein lost ER-α immunoexpression in comparison to the 
normal endometrium. Moreover, the tumours were negative for epithelial and for 
stromal expression of ER-α (respectively in 50.0% and 45.8% of the samples). 
The role of estrogen receptors in the regulation of mammalian endometrium, 
particularly the endometrial proliferation, remains unclear. Uterine proliferation 
seems to depend on ER mediated transcription, which may result from either the 
ligand ER-α activation (associated to estrogen stimulation) or a ligand-independent 
pathway (Hewitt and Korach, 2002). Activation of the ER-α drives the transactivation 
of numerous growth factors, which in turn activate their cognate receptors, leading 
to multiple signalling cascades controlling cellular proliferation. Estrogen receptor 
alpha may be induced in estrogen-driven tumours, and tumour growth is often 
limited by progesterone, once ER expression is down-regulated by activated PR 
(Leslie et al., 2013). However, proliferation in a tumour may occur driven by the 
constitutive activation of a parallel growth factor pathway. In that case, proliferation 
would not depend on the presence of estrogen and progesterone.  
Down-regulation of ER-α expression in a variety of tissues has been 
associated to methylation and to loss of transcriptional activators (Hayashi et al., 
2003; Pinzone et al., 2004) or to transdominance by ER-β which has an anti-
proliferative role (Martinkovich et al., 2014; Weihua et al., 2000). These would 
explain the loss of ER expression and the acquisition of a hormone resistance status 
(Pinzone et al., 2004), often associated with high-grade adenocarcinoma 
developing in the uterus. Such independence from the sex steroid control is 
considered a negative indicator for the clinical outcome (Leslie et al., 2013).  
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It was shown that in the endometrium, the loss of ER-α compromises E2-
induced vascular endothelial growth factor (VEGF) expression in epithelial cells, 
shifting VEGF production to stromal cells thereby inducing stroma-mediated 
epithelial cell proliferation (Koos, 2011). Data from the present study suggest that 
FEA may enter the category of tumours evolving in the absence or reduced 
expression of activated ER-α, thus highlighting the need to address in future studies 
the presence of local growth factors associated to proliferation, including insulin-like 
growth factor 1 (IGF-I) and VEGF. The proliferative index observed in neoplastic 
epithelium is considerably increased compared to normal, healthy endometrial 
epithelia, supporting the hypothesis that additional molecules other than the ER- β 
are involved in the regulation of the proliferative pathways in FEA. In the uterus ER- 
β has been described as a proliferation controller, while in other organs, such the 
mammary gland and the prostate, ER- β plays a pro-differentiating role (Morani et 
al., 2008).  
As referred before, a different situation was found concerning PR. Although 
the tumours also lost PR expression, this was non-significant in both intensity and 
percentage of labelled cells for the stroma, contrary to the epithelium. Therefore, 
endometrial cells in FEA retain the ability to respond to progesterone stimulation, 
but show a reduced ability to respond to estrogens. 
The expression of hormone receptors in FEA is still poorly understood, 
contrasting to the well-studied hormone status in human endometrial carcinomas. It 
has been recently proposed that the expression of PR changes during tumour 
progression in endometrial adenocarcinoma (Tangen et al., 2014). Several 
mechanisms for progesterone inhibition of endometrial proliferation have been 
proposed, including inhibition of proliferation through opposing the proliferative 
effects of estrogen in normal endometrium, which is generally associated with down-
regulation of ER-α actions (Tangen et al., 2014) and up-regulation of ER-β, in a 
manner that is progesterone dose-related (Tessier et al., 2000).  
Data on sex steroid receptors obtained in the present study share some 
resemblance to results from earlier studies in rabbit endometrial adenocarcinomas. 
Likewise cats, rabbits are an induced ovulation species, but, in contrast to cats, 
rabbits frequently develop endometrial adenocarcinomas, which present two main 
histological types: papillary adenocarcinoma and tubular/solid adenocarcinomas. In 
that species, papillary adenocarcinomas are negative for ER-α and PR (Asakawa et 
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al., 2008) and Vinci and collaborators (2010) concluded that PR expression was not 
directly involved in endometrial epithelial carcinogenesis and that such expression 
was not of prognostic value (Vinci et al., 2010). On the other hand, in women ER 
and PR have been established as prognostic markers for endometrial neoplasms 
(Tangen et al., 2014; Trovik et al., 2013). Also, loss of ER-α and PR is associated 
with markers of aggressiveness such as age, myometrial infiltration and lymph node 
status (Ferrandina et al., 2005; Tangen et al., 2014). Interestingly, in FEA, the 
negative status for ER-α expression in the stromal cells was associated with 
myometrial invasion. Our results suggest that loss of ER-α in FEA may be related 
to invasive characteristics of the tumour, and further strengthen the need for 
additional studies on the putative influence of growth factors acting over the 
proliferation pathways. In women, it was recently proposed that reduced expression 
of ER-α and PR-A, particularly in neoplastic stromal cells, may be of utmost 
importance in predicting invasiveness (Kreizman-Shefer et al., 2014). Additional 
studies are needed to ascertain this hypothesis in FEA.  
Although in endometrial carcinomas of women, ER and PR show significant 
correlation (Ferrandina et al., 2005; Mingzhu et al., 2014), we did not fund such 
association in cats. Interestingly, we found that loss of positive cells for PR in the 
myometrium of FEA was related to a higher nuclear atypia in carcinoma cells. 
Recently, Tomica et al. (2014) observed lower levels of PR than ER in the 
myometrium of high-risk human endometrial carcinomas (Tomica et al., 2014). Also, 
a relation between cancer cells and the surrounding tissues has been proposed as 
a necessary event for endometrial normal functioning and carcinogenesis (Yang et 
al., 2011). Our results suggest that myometrial expression of PR may be related to 
tumour dedifferentiation and that myometrium may crosstalk with epithelial and 
stromal compartments during tumour progression.  
The expression of hormonal receptors is usually used in humans to provide 
important information for adjuvant hormonal therapy in steroid-responsive tumours. 
In women, potential effectiveness of hormonal therapy is dependent upon the 
patient selection based on positive receptor status (Carlson et al., 2014). Thus, our 
study sheds light into whether or not the medical treatment would be of choice for 
most animals with endometrial carcinomas. Nevertheless, it would be of interest to 
rely on the expression of sex steroids receptors to predict metastasis development. 
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We strongly recommend that the hormonal receptor status of FEA should be 
determined by the time of histopathological diagnosis. 
To the best of our knowledge, this is the first study on Ki-67 (clone MIB-1) 
expression in feline cyclic and neoplastic endometrium. In normal endometrium, 
proliferative indexes were higher in the SGE during the FS, while in the LS the higher 
proliferative indices were found in the DGE. These findings are in agreement with 
the morphological features that characterize the cycle of glandular development in 
the species (respectively the branching of the upper area of the glands in the FS 
and the coiling of the basal glandular area during LS) (Chatdarong et al., 2005).  In 
FEA, the proliferative index was remarkably higher than in normal endometrial 
epithelia, alike the reported in humans (Kreizman-Shefer et al., 2014). Ki-67 is 
widely used to assess proliferative activity. In human endometrial carcinomas its 
expression correlates with the histological grade, depth of myometrium invasion and 
risk of carcinoma recurrence (Prat, 2004). Also in women, Ki-67 status is inversely 
related to hormonal receptor status, particularly in higher grade, ER-α negative, 
endometrial carcinomas (Ferrandina et al., 2005; Mingzhu et al., 2014; Tangen et 
al., 2014). In this particular feature, FEA may be included in the group of endometrial 
neoplasias with high proliferation indexes, but with reduced or null expression of 
ER-α. As discussed before, this is suggestive of the existence of alternative 
pathways controlling the proliferation in FEA, which needs to be explored in future 
studies.  
Cytokeratins, the largest group of intermediary filament proteins, are an 
important partner in the renewal and repair of epithelia, to whom they provide rigidity 
and strength to cell cytoskeleton, by providing flexibility (Windoffer et al., 2011). 
Further, CK represent important differentiation markers for different types of 
epithelia and epithelial tumours (Thuróczy et al., 2009). Particularly, the coordinate 
expression of CK7 and CK20 defines unique subsets of carcinomas (Jasik, 2012). 
Different types of epithelia show specific patterns of CK expression; CK7 and CK20 
are often named as “ductal-type” keratins (Moll et al., 2008). Limited knowledge 
exists on the normal pattern of CK7 and CK20 expression in domestic mammal 
endometrium. The present study showed that normal endometrial epithelia in cats 
present a profile CK7+/CK20+ that shows cyclic variation. For CK7, the intensity of 
immunolabeling remained unchanged for the surface epithelium, despite the 
decrease observed in the intensity of the glandular epithelia immunolabeling. As for 
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CK20, an increase in the intensity of immunostaining was observed in the LS. 
Moreover, the overall expression of CK7 was higher compared to that of CK20.  
Immunohistochemical expression of CK7 and CK20 has been used in the 
differentiation of human primary and metastatic tumours of unknown origin (Chu et 
al., 2000; Moll et al., 2008; Shin et al., 2010). Cytokeratin 7 and CK20 are generally 
confined to epithelia and cell profile for those CK is largely conserved during 
malignant transformation (reviewed by Campbell and Herrington, 2001; Moll et al., 
2008). Cytokeratin 7 and 20 are potentially potent epithelial differentiation and 
tumour markers (Moll et al., 2008) in human and domestic animals. The association 
CK7+/CK20- is used in humans to prove the endometrial origin of tumours (Chu et 
al., 2000; Moll et al., 2008).  
Results from the present study also show that FEA retain a CK7+/CK20+ 
phenotype, despite the decrease observed in CK7 expression and a more 
heterogeneous intensity of labelling on regards to CK20. These findings corroborate 
previous reports in smaller case series (Espinosa de los Monteros et al., 1999). 
Notably, conflicting reports exist on the expression of CK7 and CK20 in FEA: Miller 
et al. 2003, described 3/6 and 4/6 positive FEA respectively for CK7 and CK20 
(Miller et al., 2003). It has been suggested that CK20 may play a role in facilitating 
cytoskeleton breakdown and related keratin filament reorganization (Zhou et al., 
2006). Furthermore, the loss of expression of CK20 has been associated to cell 
dedifferentiation (Moll et al., 2008). Myometrial invasion and atypia – histological 
features commonly associated to invasiveness - were related to a higher percentage 
of positive cells for CK20 and a lower intensity in CK7 labelling, respectively. 
Cytokeratins are also involved in multiple signalling pathways beyond their 
mechanical functions, among epithelial cells or between the epithelial and 
mesenchymal compartments (Moll et al., 2008). These widely complex mechanisms 
may be related to our findings, but currently we cannot conclude on the putative role 
of CK in FEA dedifferentiation and invasiveness. Our sample comprised six (25.0%) 
animals with clinical history of mammary gland tumour. One should be aware of the 
possibility of uterine metastasis of mammary gland adenocarcinomas. Moreover, 
morphological features of both tumours may be indistinguishable. Unlike primary 
FEA, feline mammary gland carcinomas are generally negative for CK20, 
maintaining the immunophenotype of the normal mammary gland in this species 
(Espinosa de los Monteros et al., 1999). Therefore, CK20 may be helpful to 
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distinguish between endometrial primary adenocarcinoma and a metastatic 
carcinoma in the uterus, as the pattern of expression of CK20 in different 
carcinomas is preserved in metastasis (Moll et al., 1992). Altogether, CK20 might 
be an important marker for FEA diagnosis in cases of concomitant mammary 
carcinomas, since CK7 was previously demonstrated in 50% of feline mammary 
gland (Espinosa de los Monteros et al., 1999). The results presented herein confirm 
the positivity of FEA for CK7 reported by Espinosa de los Monteros and co-workers 
(1999). Thus, CK7 profile does not seem valuable in differential diagnosis of FEA 
and a uterine metastasis of a mammary gland tumour. 
 
CONCLUSIONS   
 
Our results show that FEA have a self-hormonal status, different from that 
observed in normal endometrium. Their loss of expression of ER-α in all endometrial 
compartments (epithelium and stroma) as well as in myometrium, while retaining 
PR expression in stroma and myometrium suggests that epithelial proliferation may 
be determined by alternative pathways possibly involving local growth factors. As 
expected, proliferative index assessed by Ki-67 immunoreaction is higher in FEA 
than in normal endometrium.  
Importantly, CK20 is regarded herein as a potentially powerful marker for the 
diagnosis of primary FEA, enabling to differentiate FEA from metastatic disease 
from mammary gland. Although other molecular studies are indicated to support our 
findings, determination of the immunohistochemical CK20 profile of uterine tumours 
in cats may be of utmost importance in the diagnostic routine. 
In the present study, we highlight the importance of evaluation both epithelial, 
stromal and myometrial cells in neoplastic endometrium, comparing such results 
with normal controls. These compartments are likely to respond in a different way 
to overall hormonal environment and probably interact with each other. These 
mechanisms remain unclear and further studies must be performed to clarify these 
hypotheses.  
With this study, we have unveiled some of the molecular events likely 
involved in feline endometrium carcinogenesis. This will certainly ascertain tumour 
morphological characterization. Future studies are needed in order to establish 
clinical outcome of FEA.  
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CONTENTS 
 
Cyclooxygenase-2 (COX-2) is overexpressed in several human and animal 
neoplasms, including the human endometrial carcinoma. It has been suggested as 
a prognostic marker and a potential therapeutic target. This study aimed to (1) clarify 
histological aspects of feline endometrial adenocarcinomas (FEA) of the papillary 
serous type and (2) characterize COX-2 immunohistochemical expression in 
normal, hyperplastic and neoplastic endometrium in this species. Archived paraffin 
embedded tissue samples of thirty-three FEA, eight cystic endometrial hyperplasia 
(CEH) and twenty-one samples of normal, healthy endometrium in the follicular (FS; 
n= 10) and luteal (LS; n= 11) stages were evaluated. Histological evaluation of 
haematoxylin and eosin stained sections of the FEA revealed a papillary 
proliferation of neoplastic cells of serous type, accompanied by clear and 
multinucleated cells. Other architectural arrangements mainly included solid and 
tubular growth. Randomly distributed areas of necrosis within the tumours were 
commonly observed. Invasion of the myometrium, of the serosa and of vascular 
and/or lymphatic vessels were not constant features. The mean number of mitoses 
was higher in FEA compared to non-neoplastic endometrium. COX-2 scores were 
lower in FEA (P= 0.003) and CEH (P= 0.05) when compared to normal epithelium 
(NE). The loss of the membrane apical reinforcement in epithelial cells was 
observed in FEA samples, which was accompanied by the dislocation of COX-2 
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labelling into the cytoplasm and the perinuclear area; contrasting, in epithelial cells 
in the healthy and hyperplastic endometria the immunoreaction showed the 
characteristic pattern of apical membrane reinforcement, suggestive of the 
membrane polarization. COX-2 epithelial scores were higher in FS than in LS. No 
differences were found in stromal COX-2 expression between normal, CEH and 
FEA groups but it was higher in LS than in FS. In summary, loss of COX-2 
compartmentalization in neoplastic epithelial cells might be one of the molecular 
events underlying endometrial carcinogenesis. 
 
INTRODUCTION 
 
In contrast to the situation in women, endometrial adenocarcinomas are 
considered to be rare in cats (Cotchin, 1964; Kennedy et al., 1998; McEntee and 
Nielsen, 1976). The common practice of ovariohysterectomy (OVH) has been 
referred to as protective from uterine neoplasia (Miller et al. 2003; Taylor 2010). Still, 
there are reports of adenocarcinoma in the uterine stump of neutered cats 
(Anderson and Pratschke, 2011; Miller et al., 2003). The rarity of these tumours in 
cats has also been related to an inadequate post mortem examination of the genital 
tract (Schlafer and Miller, 2007), and to the infrequent routine histopathological 
analysis of OVH surgical specimens (Sontas et al., 2013). Therefore, feline 
endometrial adenocarcinomas (FEA) might be more common than described in the 
literature. The clinical impact of such tumours may increase with the ability to 
establish an early diagnosis and identify the molecular events that lead to 
endometrial carcinogenesis (Saraiva et al., 2012). Few studies are available on FEA 
(Gil da Costa et al., 2009; Martín de las Mulas et al., 1995; Miller et al., 2003). 
Previously, the authors have briefly described three different morphologies of FEA, 
named papillary serous adenocarcinomas, in situ adenocarcinomas and clear cell 
adenocarcinomas (Saraiva et al., 2012). One aim of this study was to clarify some 
histological features of FEA of papillary serous type. 
Cystic endometrial hyperplasia is a phase of the CEH/pyometra complex 
(CEH-P), which culminates with bacterial colonization of the uterus and 
accumulation of exudates in the uterine cavity (Agudelo, 2005; Kempisty et al., 
2013; Schlafer and Gifford, 2008). CEH-P occurrence has been proposed to be 
dependant of progesterone stimuli, although this is not the only hormonal factor 
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involved in the process (Agudelo, 2005). Along with specific characteristics of 
invading bacteria, changes within the endometrium are presumed to be involved in 
the pathogenesis of CEH-P syndrome (Schlafer and Gifford, 2008). Despite the high 
frequency of this lesion, little is known regarding the molecular events underlying 
CEH-P (Kempisty et al. 2013; Schlafer and Gifford, 2008).  
Cyclooxygenase enzyme plays a key role in the conversion of arachidonic 
acid to prostaglandins (PG) and has two main isoforms: COX-1 and COX-2. COX-2 
expression is induced by several agents such as cytokines, growth factors and 
mitogens, and is often associated with inflammation and cancer (Williams et al., 
1999). Several animal and human neoplasms overexpress COX-2, including human 
endometrial carcinomas (Erkanli et al., 2007; Tong et al., 2000). A selective COX-2 
inhibitor has been demonstrated as potentially beneficial for the treatment of COX-
2 positive human endometrial carcinomas (Hasegawa et al., 2011). According to 
Doré (2011) COX-2 has also been demonstrated in several feline tumours, mainly 
in feline mammary invasive carcinomas. Considering that inhibition of COX-2 has 
been proposed as a potential strategy for prevention and treatment of some feline 
cancers (DiBernardi et al., 2007; Sayasith et al., 2009), studies on the expression 
of this molecule in feline reproductive disorders are needed. A second aim was to 
characterize the immunohistochemical expression of COX-2 in feline NE, CEH and 
in primary FEA of papillary serous type.  
 
MATERIALS AND METHODS 
 
SOURCE OF SAMPLES 
Thirty-three samples of FEA were obtained from the archives of four different 
laboratories, during a period of sixteen years along with eight CEH and twenty-one 
archived samples of histologically normal feline uterus, which were selected as 
controls (10 samples for the follicular stage – FS - and 11 samples for the luteal 
stage - LS).  
All samples were previously fixed in 4% neutral-buffered formalin and 
paraffin-embedded. FEA and CEH were submitted after OVH, which was performed 
routinely, or after clinical diagnosis of reproductive disease or mammary gland 
tumour. One case of FEA was diagnosed post mortem. Normal uterine samples 
were obtained after routine OVH, from post-pubertal animals. They were selected 
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from animals not treated with progestins; for the other samples, the use of progestin 
contraception was recorded where possible. Three of the eight animals diagnosed 
with CEH and 7 of the 33 cats diagnosed with FEA were under progestin based 
contraception. Patient signalment also included breed, age and the motive for 
surgery. 
 
HISTOPATHOLOGICAL EXAMINATION 
Sections with 3µm were routinely stained with haematoxylin and eosin for 
diagnosis of FEA and CEH and staging of normal samples by light microscopy. 
Normal uterine samples were classified as: (1) FS if presenting large antral 
follicles bulging at the ovarian surface and cuboidal epithelial cells in the 
endometrial epithelia, with glands scarcely distributed in the endometrium; (2) LS if 
presenting ovarian corpora lutea and columnar epithelial elements in the 
endometrial surface and glandular epithelia, together with glands highly coiled and 
developed. 
Cystic endometrial hyperplasia was diagnosed according to the World Health 
Organization criteria (Kennedy et al., 1998). These included endometrial thickening 
by focal and diffuse cystic dilatation of the endometrial glands; cysts often lined by 
flattened epithelial cells; surface and glandular epithelia lined by cuboidal to low 
columnar cells; signals of stromal edema and inflammation were reported (Kennedy 
et al., 1998). 
The tumours were evaluated according to several criteria of malignancy, 
described in the literature (Goldschmidt et al., 2011; Horn et al., 2007; Miller et al., 
2003). The criteria included: significant nuclear and cellular pleomorphism, 
anisokaryosis, anisocytosis and nuclear atypia (considered as high or low to 
moderate); mean number of mitoses per high power field (categorized as lower than 
1, 1 to 5 and more than 5); presence of randomly distributed areas of necrosis within 
the neoplasm and invasion of the myometrium, of the serosa or of 
lymphatic/vascular vessels. Neoplastic cells were evaluated according the following 
features: architectural arrangement; morphology; loss of polarity; presence of clear 
cells (considered present if more than 5% of neoplastic cells had abundant and 
foamy cytoplasm); and presence of multinucleated cells.  
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In CEH and FEA samples the co-existence of pyometra (presence of a 
purulent exudate within the uterine lumen) or endometritis (inflammatory cells in the 
supporting stroma) were recorded.  
 
IMMUNOHISTOCHEMISTRY 
Immunohistochemistry was performed using a monoclonal antibody against 
COX-2 (SP21; Neomarkers & LabVision Corporation®), previously tested in feline 
tissues, at 1:75 dilution (Gil da Costa et al., 2009). Immunohistochemical labelling 
was achieved by using the Novolink® Polymer Detection System (ref. RE7280-K, 
Novocastra®). Sections of human colonic carcinoma (as stated in the datasheet of 
antibody), feline corpora lutea and endometrial macrophages were used as positive 
controls. The primary antibody was omitted for negative controls. 
 
QUANTIFICATION OF IMMUNOLABELLING 
Epithelial and stromal immunolabelling for COX-2 were evaluated 
independently. The percentage of positive epithelial cells was assessed 
semiquantitatively, according to the marks: 0= < 5%, 1= 5-25%, 2= 26-50%, 3= 51-
75%, and 4= >75%. When immunoreaction against COX-2 existed, its intensity was 
graded as 1= weak, 2= moderate and 3= strong. Overall scores were assessed by 
the product of percentage of positive cells and intensity of expression, being 
evaluated as follows: 1-4= low, 5-7= intermediate and 8-12= high (Sayasith et al., 
2009). The intracellular staining patterns were evaluated as membrane (with or 
without polarity, i.e. in a diffuse membrane labelling or concentrated as apical 
reinforcement, respectively), cytoplasmic and perinuclear. Evaluation of the 
intracellular pattern did not contribute to the overall score.  COX-2 expression in the 
stromal compartment was also evaluated. Since endometrial stromal compartment 
was not equally stained within the samples, it was graded according to the scale: 0= 
absent; 1= low; 2= intermediate and 3= high. 
 
STATISTICAL ANALYSIS 
Statistical comparisons were performed by using the IBM SPSS Statistics 
Base 20.0 software®. All statistical analyses were performed using the chi-square 
and Fisher exact tests. P values < 0.05 were regarded as statistically significant. 
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RESULTS 
 
ANIMALS 
Normal uterine samples were from post-pubertal animals aged 7 months to 
8 years of age (mean 1.5 years); breeds included Domestic Shorthaired cats and 
Persian.  
Cystic endometrial hyperplasia was diagnosed in queens 2 to 10 years of age 
(mean 6.1 years); the age of females diagnosed with FEA ranged from 1 to 15 years 
old (mean 7.3 years). For these two groups, breeds included Domestic Shorthaired 
cats, Persian and Siamese.  
 
HISTOPATHOLOGICAL FEATURES 
Feline endometrial adenocarcinomas of papillary serous type (FIGURE 1 A-B) 
were primarily characterized by the proliferation of endometrial epithelial cells on 
papillae into the lumen supported by a thin fibrovascular stroma and lined by 
multilayered neoplastic cells. Areas of tubular, solid and glomeruloid intracystic 
growth were also present. Neoplastic cells were pleomorphic columnar shaped, with 
moderate amount of eosinophilic cytoplasm and round to oval, vesicular or 
hyperchromatic nuclei that lost the normal polarity. Nucleoli were evident and 
occasionally intranuclear clear inclusions were found. There was a moderate to high 
degree of anisokaryosis and anisocytosis. Numerous multinucleated cells were 
present within and at the surface of the lesions. A moderate number of clear cells - 
large, round to polygonal cells, with foamy cytoplasm and eccentric crenate or ovoid 
nucleus - was identified. Randomly distributed areas of necrosis were frequently 
present. The mean number of mitoses per high power field was generally lower than 
1 in non-neoplastic epithelia and lower than 5 in FEA. It was higher in tumour 
epithelium when compared to normal and hyperplastic endometrium (P ≤ 0.0001). 
The invasion of the myometrium was not a constant feature, although FEA 
consistently invaded the deeper stromal layer and submucosa. Histopathological 
features of FEA are summarized in TABLE 1. 
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FIGURE 1: Feline endometrial adenocarcinomas of papillary serous type. A: Neoplastic cells 
projecting into the lumen and invading the myometrium. Focal areas of necrosis are seen within the 
tumour; bar = 500 µm. B: Multilayered papillary and solid growth of neoplastic cells. Images of 
myometrium invasion; bar = 250 µm. Haematoxylin and eosin stain. 
 
TABLE 1: Histological features of feline endometrial adenocarcinomas. 
 
 NUMBER OF 
CASES 
(N= 33) 
 SOLID 11 
ARCHITECTURAL REARRANGEMENT TUBULAR 27 
 GLOMERULOID 3 
CLEAR CELLS (> 5%)  12 
NUCLEAR ATYPIA 
LOW TO 
MODERATE 14 
HIGH 19 
PYOMETRA  10 
ENDOMETRITIS  27 
NECROSIS  27 
MYOMETRIUM INVASION 
ABSENT 12 
SUPERFICIAL 12 
DEEP 9 
SEROSA INVASION  2 
VASCULAR/LYMPHATIC INVASION  4 
MEAN NUMBER OF MITOSES PER HIGH POWER 
FIELD 
≤ 1 16 
1-5 14 
≥ 5 3 
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COX-2 IMMUNOHISTOCHEMISTRY 
COX-2 expression was found in the surface and glandular epithelium of 
normal endometrium (FIGURE 2 A); in the surface, glandular and cystic lining 
epithelium of CEH (FIGURE 2 B); and also in neoplastic cells (FIGURE 2 C). 
Expressions of COX-2 score are shown in TABLE 2. COX-2 scores in NE did not 
differ amongst the epithelial type (surface vs. glandular; P= 0.741), but the overall 
scores were higher in the FS than in LS (P= 0.035). In CEH samples, no differences 
were found between the surface, glandular or cystic epithelia (P= 0.442). COX-2 
expression was decreased in CEH and FEA epithelia compared to NE; however, no 
differences were found on what concerns the score between CEH and FEA (TABLE 
2). COX-2 immunolabelling in CEH revealed a loss of homogeneity, particularly in 
cystic epithelium, and this was even more pronounced in FEA. 
 
FIGURE 2: COX-2 immunoexpression in feline endometrium (bar = 50 µm). A: Normal endometrium 
(luteal stage). Membrane labelling with apical reinforcement is noticed in epithelial cells; stroma also 
exhibits COX-2 expression. B: Cystic endometrial hyperplasia. The cystic epithelium shows 
cytoplasmic staining while the glandular epithelium shows membrane labelling with apical 
reinforcement. C: Feline endometrial adenocarcinoma. Epithelial tumour cells show heterogeneous 
intensity in membrane and cytoplasm as well as perinuclear labelling. Avidin-biotin peroxidase 
technique counterstained with Gill’s haematoxylin. 
 
In NE, the dominant intracellular pattern for COX-2 expression was the 
membrane with apical reinforcement, with sporadic labelling in the cytoplasm and 
the perinuclear area (FIGURE 2 A). No difference was found regarding the 
intracellular pattern of immunostaining between surface and glandular epithelium of 
normal endometrium. However, when the two phases of oestrous cycle were 
compared, the perinuclear staining was only found in FS samples (P= 0.043). In 
CEH, an increase of cytoplasmic staining was observed in the surface and cystic 
epithelia, but not in glandular epithelium compared to NE; still, the COX-2 
intracellular patterns were similar between NE and CEH (FIGURE 2 B). The 
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neoplastic epithelium had less membrane expression than NE; this was 
accompanied by a loss of the apical reinforcement along with the dislocation of the 
immunoreaction into the cytoplasm and the perinuclear area (FIGURE 2 C). The 
intracellular patterns of COX-2 staining in normal, hyperplastic and neoplastic 
epithelial cells are shown in FIGURE 3 and TABLE 3. COX-2 expression in the stromal 
compartment was higher in LS than in FS (P= 0.026), but the immunostaining 
expressed in NE stroma was not different from that observed in CEH and FEA. 
TABLE 4 summarizes COX-2 expression in the stromal compartment of normal, 
hyperplastic and neoplastic endometrium. 
 
TABLE 2: COX-2 scores in the epithelial cells from normal and hyperplastic endometria and in FEA. 
The scores, assessed by the product of percentage of positive cells (using the marks: 0= < 5%, 1= 
5-25%, 2= 26-50%, 3= 51-75%, and 4= >75%) and intensity of expression (1= weak, 2= moderate 
and 3= strong), were evaluated as absent (=0), low (1-4), intermediate (5-7) and high (8-12). 
 GROUP  
COX-2 SCOREa NE CEH FEA 
P VALUE  
(BETWEEN 3 
GROUPS) 
ABSENT 0.0 % 0.0 % 9.1 % 
0.007 
LOW 14.3 % 33.3 % 21.2 % 
INTERMEDIATE 7.1 % 16.7 % 27.3 % 
HIGH 78.6 % 50.0 % 42.4 % 
a NE vs. CEH, P= 0.050; NE vs. FEA, P= 0.003; CEH vs. FEA, P= 0.330. 
 
 
FIGURE 3: COX-2 intracellular staining patterns in the epithelial cells from normal and hyperplastic 
endometria and in FEA. 
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TABLE 3: COX-2 intracellular staining patterns in the epithelial cells from normal and hyperplastic 
endometria and in FEA.  
 GROUP  
COX-2 STAINING 
PATTERN NE CEH FEA 
P VALUE 
(BETWEEN 3 
GROUPS) 
MEMBRANE 100.0 % a 95.8 % 87.9 % a 0.041 
APICAL 
REINFORCEMENT 
83.3 % b 87.5 % c 0.0 % b, c ≤ 0.0001 
PERINUCLEAR 9.5 % d 16.7 % e 84.8 % d, e ≤ 0.0001 
CYTOPLASM 23.8 % f, g 54.2 % g, h 90.0 % f, h ≤ 0.0001 
Different superscripts following percentages within a row indicate statistical significance at P< 0.05.  
a P= 0.034; b-f P≤ 0.0001; g P= 0.013; h P= 0.001. 
 
TABLE 4: COX-2 expression in the stroma of normal and hyperplastic endometrium and FEA, graded 
according to the scale: 0= absent; 1= low; 2= intermediate and 3= high. 
 STROMA GROUP  
COX-2a 
NE P VALUE 
(FS VS 
LS) 
CEH FEA 
P VALUE  
(BETWEEN 3 
GROUPS) 
FS LS 
ABSENT 0.0% 18.2%
0.026 
0.0 % 9.1 % 
0.472 
LOW 80.0% 18.2% 75.0 % 39.4 % 
INTERMEDIATE 10.0% 18.2% 25.0 % 30.3 % 
HIGH 10.0% 45.5% 0.0 % 22.2 % 
a NE vs. CEH, P= 0.275; NE vs. FEA, P= 0.605; CEH vs. FEA, P= 0.337. 
 
DISCUSSION 
 
The increasing number of reports on FEA (Anderson and Pratschke, 2011; 
Cho et al., 2011; Payan-Carreira et al., 2013; Sontas et al., 2013) alerts to the need 
of raising veterinarians awareness for endometrial tumours in cats. Early recognition 
of FEA along with the understanding of molecular events underlying carcinogenesis 
in feline endometrium is important for improving diagnosis, treatment and prognosis. 
Definitive diagnosis of endometrial adenocarcinomas may only be 
accomplished by histopathological exam (Klein, 2007), which may be challenging 
because the described histological features are inconstant (Anderson and 
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Pratschke, 2011; Belter et al., 1968; Gil da Costa et al., 2009; Martín de las Mulas 
et al., 1995; McEntee and Nielsen, 1976; Miller et al., 2003; Preiser, 1964; Saraiva 
et al., 2012). In this study, 33 tumours were classified as primary FEA of papillary 
serous type, as proposed by Saraiva et al. (2012) and described by Payan-Carreira 
et al. (2013). In the present study, the mean number of mitoses supported previous 
findings reporting mitotic indexes below 5 mitoses per high power field (Anderson 
and Pratschke, 2011; Gil da Costa et al., 2009). This parameter does not seem to 
be correlated with tumour invasiveness or the outcome of the patient (Miller et al., 
2003). However, in the present study, the mean number of mitosis per high power 
field was significantly higher in FEA than in non-neoplastic endometrium, confirming 
this morphological parameter as a tumour feature. Myometrial or vascular/lymphatic 
invasion were inconstant, as previously reported (Miller et al., 2003; Payan-Carreira 
et al., 2013; Saraiva et al., 2012). Miller et al. (2003) failed to correlate histologic 
appearance of FEA to the biological behaviour. Vascular invasion accompanied 
deep myometrial invasion and peritoneal carcinomatosis; however, metastases 
were also found in the absence of vascular permeation or invasion evidences and 
in a case of superficial myometrial invasion (Miller et al., 2003). Similar findings can 
be found in other FEA descriptions (Belter et al., 1968; Cho et al., 2011; Preiser, 
1964). Inadequate vascularization during tumour growth, leads to ischaemia and 
hypoxia, which are the most common conditions for activation of necrosis 
(Proskuryakov and Gabai, 2010). In FEA, there were scattered areas of necrosis 
within 81.8% of the tumours, suggesting a rapid neoplastic growth that is not 
supported by adequate vascularization. This issue deserves to be addressed in 
future studies. 
Constitutive expression of COX-2 was recognized in women reproductive 
tract (reviewed by Rouzer and Marnett, 2009). COX-2 expression has been 
described in the surface and glandular epithelium of cyclic feline endometrial 
samples (Gil da Costa et al., 2009), although that study did not conclude on 
recognised differences between COX-2 immunoreaction in the stages of oestrous 
cycle and did not assess COX-2 expression in endometrial stroma. However, 
reports on porcine and rat endometrium describe the existence of positive 
immunoreaction for COX-2 in the endometrial stroma (Blitek et al., 2006; St-Louis 
et al., 2010), as confirmed by the results presented in the present study. Higher 
COX-2 scores were found in epithelia in the FS than in LS, though no differences 
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were found between the surface and the glandular epithelia. In contrast, stromal 
expression of COX-2 was higher in LS than in FS. It is generally accepted that major 
uterine cell-types respond differently to progesterone and/or estrogen (Paria et al., 
2000). The results suggest a progesterone influence on COX-2 expression, which 
might be associated with physiological tissue remodelling accompanying the 
glandular development. In sheep and pigs, COX-2 epithelial expression varies 
according to the stage of oestrous cycle, being higher during LS (Blitek et al., 2006; 
Kim et al., 2003). COX-2 was proposed as mediator of epithelial-stromal cell 
interactions (Kim et al., 2010), particularly important for the endometrial functioning. 
Proposed roles for COX-2 in normal tissues and in tumours include proliferation, 
angiogenesis, protection against apoptosis and cell adhesion (Kim et al., 2010; 
Sobolewski et al., 2010). COX-2 overexpression in tumours was associated with 
activation of membrane metalloproteinases, a system that has been also involved 
in the endometrial remodelling during the endometrial cycle (Kim et al., 2010; 
Plaisier et al., 2006). 
Despite being a frequent condition in the dog and cat, CEH-P is still not much 
studied in cats (Kempisty et al., 2013). To the best of the authors’ knowledge, this 
is the first study on COX-2 expression in feline hyperplastic endometrium.  
An increase in TNFα production followed by elevated PG secretion by 
epithelial cells has been pointed out as an important pathway in innate resistance 
of the endometrium to infection. Recently, COX-2 was recognized as being involved 
in TNFα-induced PG secretion in cat endometrial cells, since a selective COX-2 
inhibitor, nimesulide, abolished TNFα-induced PG synthesis, as well as basal PG 
synthesis (Jursza et al., 2014). In the present study, COX-2 expression was 
decreased in CEH, suggesting that disruption of this inflammatory pathway may 
contribute to the progression of the disease, enhancing bacterial infection. COX-2 
inhibitors may thus not be indicated in the medical treatment of feline CEH. 
In FEA, there was a clear change in COX-2 expression supporting previous 
findings (Gil da Costa et al., 2009), with loss of the cell polarity and a dislocation of 
the binding into the cytoplasm and the perinuclear area. Predominance of the 
cytoplasmic pattern has also been described in human bladder carcinomas and in 
chronic inflammatory conditions of the biliary epithelia, in organs that also express 
COX-2 in a constitutive way, and is envisaged as a poor prognostic marker 
associated with invasiveness (Kim et al., 2010). 
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Limited information on COX-2 expression in FEA exists, contrasting with the 
large number of studies existing for human endometrial carcinoma, in which COX-2 
overexpression has been reported (Nasir et al., 2007; Tong et al., 2000), 
accompanying an intracellular cytoplasmic pattern of labelling in tumour cells 
(Ferrandina et al., 2005; Ferrandina et al., 2002; Lambropoulou et al., 2010; Nasir 
et al., 2007). The overall expression described for human endometrial carcinoma 
was not found in FEA in the current study. On the contrary, there was a decrease in 
COX-2 score of FEA, which may be explained by differences in the types of human 
and feline tumours, the uterine hormonal environment, the scoring systems or the 
antibodies used. To support these results, molecular quantification of COX-2 in 
tumour tissues is required. 
COX-2 localization in the perinuclear area in FEA epithelial cells resembles 
the described in feline transitional cell carcinomas of the urinary bladder and 
mammary carcinomas (Beam et al., 2003; Sayasith et al., 2009), which has been 
proposed to be associated with PG pathways involved on cell growth, apoptosis or 
cell differentiation, including malignant transformation (Sobolewski et al., 2010; 
Vane et al., 1998). 
Banu et al. (2008) showed that COX-2 inhibition decreases growth, migration, 
and invasion of immortalized human endometriotic epithelial and stromal cells. Their 
findings support the hypothesis that absence of an increased expression of COX-2 
in FEA stroma and epithelia scores might be related to the apparently low 
aggressiveness of such tumours.  
Interestingly, COX-2 scores and staining intracellular pattern were similar 
between normal, hyperplastic and neoplastic endometrium. Unlike the situation in 
the endometrium of women, where COX-2 was proposed to be overexpressed 
between endometrial hyperplasia and adenocarcinoma (Nasir et al., 2007), the 
results presented herein suggest that CEH might not be a precursor lesion of FEA. 
However, in one report of multiple uterine pathologies in a cat, the authors proposed 
that adenocarcinoma lesions might have been a consequence of long lasting 
inflammation or hyperplastic reaction of endometrial glands (Sapierzynski et al., 
2009). 
In conclusion, though COX-2 scores were decreased in FEA, evidence of 
loss of compartmentalization of COX-2 expression in neoplastic epithelium in FEA 
most likely reflects the involvement of this enzyme in feline endometrial 
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carcinogenesis. Additional studies are needed to fully understand the molecular 
background to these conditions. 
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ABSTRACT 
 
Human epidermal growth factor receptor type 2 (c-erbB-2) is overexpressed 
in several human and animal tumours. The expression of this oncoprotein in 
tumours was referred for potential prognostic marker and therapeutic target, but 
information regarding this molecule in feline tumours is scarce. This study aimed to 
assess the changes in the immunohistochemical expression of c-erbB-2 in feline 
endometrial adenocarcinomas (FEA) compared to normal endometrium. An 
immunohistochemistry assay using the antibody against c-erbB-2 was performed in 
FEA samples (n= 34) and in normal endometrium in the follicular (FS; n= 12) and 
luteal (LS; n= 11) stages. In FEA, the immunoexpression of c-erbB-2 was assessed 
in neoplastic epithelial cells, whilst in the normal endometrium, it was evaluated 
independently in the surface epithelium and the superficial and deep glandular 
epithelia (SE, SGE and DGE, respectively). In FS, all epithelia were consistently 
positive for c-erbB-2, with the exception of one sample (8.3%), negative for this 
molecule in the SE. In LS, the SE was positive for c-erbB-2 in 10 samples (90.9%) 
and negative in only one sample (9.1%); SGE was positive in all evaluated samples 
(100.0%), whereas DGE was positive in only 45.4% (n= 5). Twenty FEA (58.8%) 
were positive for c-erbB-2 immunolabelling. The c-erbB-2 expression was 
significantly higher in all the epithelia in the FS compared to FEA (P≤ 0.0001) or the 
LS (P= 0.016). In the LS, its expression was significantly higher in the SGE, 
compared to DGE (P= 0.024). Results suggest that c-erbB-2 expression in the 
endometrium reflects changes occurring during the estrous cycle and may also be 
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involved in feline endometrial carcinogenesis, though an open question remains on 
the importance of additional pathways of epithelial proliferation in the neoplastic 
changes in feline endometrium.  
 
KEY-WORDS 
Uterine diseases; endometrium; adenocarcinoma; c-erbB-2; cats 
 
INTRODUCTION 
 
Human epidermal growth factor receptor type 2 (HER2), also known as c-
erbB-2 or HER2/neu, is a 185 kD membrane tyrosine kinase receptor, which has 
been associated to tumour cell proliferation, survival, differentiation, angiogenesis, 
invasion and metastasis (Yarden and Sliwkowski, 2001; Selvarajan et al., 2004; 
Gutierrez and Schiff, 2011). Since c-erbB-2 does not have a ligand, when expressed 
at elevated levels to be activated it depends on heterodimerization with other HER-
family receptors, among other molecules, or homodimerization (Yarden and 
Sliwkowski, 2001; Gutierrez and Schiff, 2011). Human epidermal growth factor 
receptor type 2 activates second messenger pathways and crosstalk with other 
membrane signaling pathways, including the sex steroid hormone. A negative 
correlation between c-erbB-2 and estrogen receptor (ER) and progesterone 
receptor (in a lesser extend) is described in human mammary carcinomas. 
Importantly, ER negative / c-erbB-2 positive neoplasms usually have a worst 
diagnosis. That immunophenotype concerning c-erbB-2 diminishes the response to 
anti-estrogenic therapy (Harari and Yarden, 2000; Yarden and Sliwkowski, 2001). 
In women, c-erbB-2 is expressed in the female genital tract and thus seems 
to be a normal membrane constituent of uterine glandular epithelial cells (Wang et 
al., 1992). In the mouse uterus, c-erbB-2 is mainly expressed in epithelial cells, 
showing cyclic variations. Exogenous steroid hormone administration to 
ovariectomized mice resulted in up- or down-regulation of c-erbB-2 mRNA, 
respectively for estradiol and progesterone administrations, suggesting that ovarian 
hormones influence c-erbB-2 expression. c-erbB-2 is also expressed in the peri-
implantation uterus, where it may be involved in epithelial cell proliferation and 
differentiation, since it expression is limited to the luminal and glandular epithelium 
(Lim et al., 1997). The studies of Mühlhauser and colleagues (1993) localized c-
Contribution to the Study of Feline Endometrial Adenocarcinomas | 111 
 
erbB-2 protein along the apical membrane of the syncytiotrophoblast, in cells 
negative to Ki-67. In that work, the authors associate the c-erbB-2 protein to 
trophoblast differentiation, but not to the proliferative events occurring in the first-
trimester human placenta (Mühlhauser et al., 1993). 
Concerning the feline endometrium, the studies published so far are scarce. 
Misirlioglu and collaborators (2006) described for the first time, c-erbB-2 expression 
in normal and hyperplastic endometrium in 10 and 20 queens, respectively. They 
found that c-erbB-2 expression increased in surface and glandular epithelium in 
hyperplasia compared with the normal endometrium, concluding on the importance 
of c-erbB-2 activation in the pathogenesis of feline endometrial hyperplasia. This 
was supported by a second report on c-erbB-2 expression in two hyperplastic 
endometrial polyps (Misirlioglu et al., 2009). 
Human epidermal growth factor receptor type 2 is overexpressed in several 
human cancers, including endometrial adenocarcinomas (Yarden and Sliwkowski, 
2001), and its amplification is often associated with tumour invasiveness, particularly 
in breast cancer (Brix et al., 2014). In women, the reported rates of c-erbB-2 
overexpression in endometrial carcinomas vary from 1% to 80% depending on the 
histological type of the tumours (reviewed by Buza et al., 2014). This very wide 
range of results is pointed as related to small sample sizes, different 
clinicopathological features considered and/or differences in the staining and the 
scoring systems used in immunohistochemistry evaluation of the tumours. For those 
reasons it is possible that c-erbB-2 overexpression and tumour prognosis and 
outcome may not always be correlated, in human endometrial carcinomas (Buza et 
al., 2014). On the other hand, an increased expression of c-erbB-2 is particularly 
well studied in women mammary carcinomas (Yarden and Sliwkowski, 2001). In c-
erbB-2-overexpressing human breast carcinomas, targeted therapy against c-erbB-
2 is proven to be effective. Therefore, standardization of c-erbB-2 assessment is 
well established in these tumours (Wolff et al., 2013), unlike in the endometrial 
cancer (Buza et al., 2014). 
Scoring guidelines for c-erbB-2 evaluation by immunohistochemistry have 
been recently established for the canine mammary tumours (Peña et al., 2014), 
similar to those existing in humans. The evaluation of c-erbB-2 in feline mammary 
tumours has also been studied, though without similar guidelines (Millanta et al., 
2005; Winston et al., 2005; Ordás et al., 2007; Rasotto et al., 2011). Several studies 
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suggest c-erbB-2 overexpression in feline mammary carcinomas as a marker of 
malignancy and a prognostic indicator (Millanta et al., 2005; Winston et al., 2005; 
Ordás et al., 2007), but this is controversial and Rasotto and collaborators (2011) 
defend that c-erbB-2 may not play a major role in mammary carcinogenesis and 
prognosis. Technical factors and subjective interpretation of  
c-erbB-2 immunolabelling may explain the disagreements in the incidence of c-
erbB-2 expression between studies (Rasotto et al., 2011).  
Increasing reports in feline endometrial adenocarcinomas (FEA) (Anderson 
and Pratschke, 2011; Cho et al., 2011; Gil da Costa et al., 2009; Payan-Carreira et 
al., 2013; Sontas et al., 2013; Saraiva et al., 2015a) suggest that the disease may 
be more common than previously described. The definitive diagnosis is usually 
accomplished by histopathological exam. Histopathological features of FEA, 
although not constant, include recognised criteria of malignancy such as nuclear 
atypia, bizarre mitosis, necrosis, and vascular, myometrium and/or serosa invasion 
(Anderson and Pratschke, 2011; Miller et al., 2003; Papparella et al., 1984; Saraiva 
et al., 2012). Despite the growing number of studies in FEA, little is known about the 
molecular events related to the carcinogenesis of the endometrium in queens. 
Moreover, immunohistochemical characterization of FEA is limited and performed 
in small case series (Gil da Costa et al., 2009; Miller et al., 2003; Espinosa de los 
Monteros et al., 1999). Nevertheless, the pathogenesis of FEA remains elusive.  
Speculating that c-erbB-2 may play a role in feline endometrial 
carcinogenesis, the present study aimed to characterize the c-erbB-2 
immunohistochemical pattern of expression in FEA compared to normal 
endometrium, and to explore putative roles of c-erbB-2 in feline cyclic and neoplastic 
endometrium 
 
MATERIAL AND METHODS 
 
ANIMALS AND TISSUE PREPARATION 
The samples of FEA (n= 34) and of normal postpubertal feline uterus (n= 23, 
12 in the follicular stage and 11 in the luteal stage) used in the present work were 
collected from the archives of four different laboratories in Portugal, during a period 
of eight years (from 2003 to 2011). Animals’ age, breed, and past or present 
progestin based contraception were assessed by the request forms that 
Contribution to the Study of Feline Endometrial Adenocarcinomas | 113 
 
accompanied surgical specimens for histopathological evaluation. For FEA, the 
clinical history that led to the submission of specimens to the laboratories was also 
recorded. 
Tissues were fixed in 10% buffered formalin and paraffin embedded. Three-
micrometer thick sections were cut, one slide routinely stained with haematoxylin 
and eosin for histopathological diagnosis. The tumours were evaluated according to 
several criteria of malignancy as described in Saraiva et al. (2015a). Briefly, the 
histopathological criteria used included potential indicators of tumours 
dedifferentiation, namely: nuclear atypia, considered as low to moderate or high; 
mean number of mitosis per high power field (HPF; 400x), valued as lower than 1 
(<1), 1-5 and more than 5 (>5); and the myometrium, serosa and/or vascular 
invasion, evaluated as present or absent. Twenty-three normal uterine samples 
were staged as follicular (FS; n= 12) or luteal (LS; n= 11) based on the presence of 
follicles or corpora lutea in the ovaries and the epithelial cell height and the degree 
of development and coiling of endometrial glands (Saraiva et al., 2015a). 
 
IMMUNOHISTOCHEMISTRY 
Immunohistochemistry was performed using a polymer-based system 
(Novolink® Polymer Detection System, Product No: RE7280-K Leica Biosystems, 
Newcastke, UK), according to the manufacturer’s instructions. The sections were 
deparaffinised with xylene and rehydrated through graded alcohols; antigen retrieval 
was performed in a pressure cooker (~ 96 ºC) in 10 mmol/L sodium citrate buffer 
(pH 6.0) for 3 minutes. The slides were cooled for 10 min at room temperature and 
rinsed twice in triphosphate buffered saline (TBS) for 5 min. Endogenous peroxidase 
activity was blocked by treating the sections with the Peroxidase Block provided in 
the kit. Sections were incubated overnight at 4°C in a humid chamber with 1:40 
Polyclonal Rabbit Anti-Human c-erbB-2 Oncoprotein (Code A0485 Dako, Denmark) 
that labels an intracellular domain of c-erbB2 oncoprotein. Colour was developed 
with 3,3’- diaminobenzidine (DAB), incubated at room temperature, and sections 
were then counterstained with Mayer’s haematoxylin, dehydrated and mounted. 
Sections of human colonic adenocarcinoma were used as positive control. For 
negative controls, the primary antibody was omitted. 
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EVALUATION OF IMMUNOLABELING 
The immunoreactivity of c-erbB-2 was assessed semiquantitatively, in 
morphologically representative areas of the tumour at low power fields, based in the 
Hercep-Test scoring criteria, described in the American Society of Clinical Oncology 
(ASCO) guidelines (Wolff et al. 2013). Briefly, samples were classified according to 
the score: IHC 3+, when the circumferential membrane staining is complete, intense 
and within > 10% of tumour cells (“chicken-wire pattern”); IHC 2+, if the 
circumferential membrane staining is incomplete and or weak/moderate and within 
> 10 % of tumour cells or complete and circumferential membrane staining that is 
intense and within ≤ 10% of tumour cells; IHC 1+, if incomplete membrane staining 
is faint/barely perceptible and within > 10% of tumour cells; IHC 0, no staining is 
observed or membrane staining that is incomplete and is faint/barely perceptible 
and within ≤ 10% of tumour cells (Wolff et al. 2013). Scores of IHC 0 and 1+ were 
considered negative, whereas scores of IHC 2+ and 3+ were considered positive 
(Grushko et al., 2008; Rasotto et al. 2011; Togami et al., 2012). In the normal uterus, 
the analysis of immunoreaction against c-erbB-2 was assessed independently in the 
surface epithelium (SE), the superficial and deep glandular epithelia (SGE and DGE, 
respectively) and stromal compartment, using the same scoring system. 
 
STATISTICS 
Statistical analysis was performed using chi-square and Fisher exact tests in the 
IBM SPSS Statistics Base 20.0 software®. P values < 0.05 were regarded as 
statistically significant. 
 
RESULTS 
 
The thirty-four FEA used in this study were diagnosed in queens with an aged 
range between one to 15 years (mean 7.8 years); this result respects to 26 queens, 
since this information was not declared for the remaining eight animals. Breeds 
included Domestic Shorthaired cats (n= 24; 70.6%), Siamese (n= 2; 5.9%) and 
Persian (n= 1; 42.9%); in 7 cases, breed was omitted. Contraception was confirmed 
in 9 (26.5%) animals, whilst it was denied in 3 (8.8%) cases. In the remaining 32 
cases, data concerning contraception was not mentioned in the form. When such 
information existed, the length of the treatment was not declared. The reasons 
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leading to the request of histopathological analyses included clinical signs of uterine 
disease (n= 14; 41.2%), concurrent mammary tumour (n= 10; 29.4%) and uterine 
lesions detected during routine ovariohysterectomy (n= 4; 11.8%). 
Normal uterine samples (n= 23) used as controls were obtained from post-
pubertal animals submitted to routine ovariohysterectomy. Queens’ age was 
declared for 16 controls and ranged between 7 months to 8 years of age (mean 1.4 
years). Breeds included Domestic Shorthaired cats (n= 7; 30.4%) and Persian (n= 
1; 4.3 %); this information was not specified for the remaining animals. In controls, 
none of the queens were submitted to contraceptive treatment. 
The morphology of FEA was characterized by papillary proliferation, lined by 
multiple layers of neoplastic cells supported by a fibrovascular stroma. Other 
architectural patterns scarcely present within the tumours included solid, tubular and 
glomeruloid. These features supported the classification of the tumours as a 
papillary serous type. Neoplastic cells were pleomorphic columnar shaped, with a 
moderate amount of eosinophilic cytoplasm and round-to-oval, vesicular or 
hyperchromatic nuclei that lost the normal polarity. Numerous multinucleated cells 
were present within and at the surface of the lesions. A variable number of clear 
cells was also observed. Nucleoli were evident and occasionally intranuclear clear 
inclusions were also found. Randomly distributed areas of necrosis within the 
tumours were frequently present. Histopathological features presumably related to 
tumour dedifferentiation are summarized in TABLE 1. Seventeen tumours (50.0%) 
had a low to moderate degree of atypia, whereas the other half of the sample  
(n= 17; 50.0%) was characterized by high atypia. The majority of tumours (n= 24; 
70.6%) showed a mean number of mitosis per HPF between 1 and 5, while in seven 
tumours (20.6%) it was <1 whilst in a minority of cases (n= 3; 8.8%) it was >5 mitosis. 
In normal samples, the SE in either FS or LS consistently presented <1 mitosis per 
HPF (n= 12 and n= 11, respectively; 100.0%). The mean number of mitosis per HPF 
in tumours was higher, compared to the normal epithelia  
(P≤ 0.0001) (TABLE 1). In the FS, the glandular epithelia (both the SGE and DGE) 
showed <1 mitoses per HPF. In the LS, the mean number of mitosis differed 
between the superficial and the deep glandular epithelia, though without statistical 
meaning: the SGE regularly presented a mean number of mitosis <1 (90.9%;  
n= 10) with only one sample showing a mean number of mitosis between 1 and 5 
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(9.1%), whilst the DGE showed a mean number of mitosis either <1 (n= 7; 63.6%) 
or between 1 to 5 mitosis (n= 4; 36.4%). 
 
TABLE 1: Major Histopathological Features Assessed in FEA Cases. 
HISTOPATHOLOGICAL FEATURES NUMBER OF FEA 
IN 34 (%) 
NUCLEAR ATYPIA 
LOW TO 
MODERATE 
17 (50.0) 
HIGH 17 (50.0) 
MEAN NUMBER OF MITOSIS 
 PER HPF 
< 1 7 (20.6) 
1 - 5 24 (70.6) 
> 5 3 (8.8) 
MYOMETRIUM INVASION YES 22 (54.7) NO 12 (35.3) 
SEROSA INVASION YES 1 (2.9) NO 33 (97.1) 
VASCULAR INVASION YES 3 (8.8) 
NO 31 (91.2) 
 
Myometrial invasion was observed in 22 tumours (64.7%). Vascular and 
serosa impairment were present in three (8.8%) and one (2.9%) tumours, 
respectively. These cases occurred independently but always co-existing with 
myometrial invasion. 
FIGURE 1: Immunohistochemical expression of c-erbB-2 in FEA, counterstained with Mayer’s 
haematoxylin. Bar = 50 μm. (A) A negative scoring, with cells showing incomplete membrane staining 
that is faint/barely perceptible and within > 10% of tumour cells; (B) Positive FEA with cells displaying 
strong and complete membrane staining (referred as chicken-wire pattern) scored as 3+.  
 
The immunoreaction against c-erbB-2 oncoprotein in FEA is summarized in 
TABLE 2. Of the 34 FEA cases, 14 (41.2%) were considered negative to c-erbB-2: 
four cases (11.8%) were classified as IHC0 and 10 cases (29.4%) as IHC1+.  
BA 
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The remainder 20 FEA samples (58.8%) were positive for c-erbB-2 (FIGURE 1), being 
18 (52.9%) scored as IHC2+ and two (5.9%) as IHC3+. The immunoreaction of c-
erbB-2 in both normal and FEA stroma was consistently negative. 
 
TABLE 2: Immunohistochemical expression of c-erbB-2 oncoprotein in FEA and normal endometrium. 
Samples were classified according to the score: IHC 3+, circumferential membrane staining that is 
complete, intense and within > 10% of tumour cells (“chicken-wire pattern”); IHC 2+, circumferential 
membrane staining that is incomplete and or weak/moderate and within > 10 % of tumour cells or 
complete and circumferential membrane staining that is intense and within ≤ 10% of tumour cells; 
IHC 1+, incomplete membrane staining that is faint/barely perceptible and within > 10% of tumour 
cells; ICH 0, no staining is observed or membrane staining that is incomplete and is faint/barely 
perceptible and within ≤ 10% of tumour cells. Scores of 0 and 1+ were considered negative, whereas 
scores of 2+ and 3+ were considered positive and indicative of c-erbB-2 oncoprotein overexpression. 
 C-ERBB-2 IHC SCORE 
 n (%) 
 NEGATIVE POSITIVE 
IHC 0 IHC 1+ TOTAL IHC 2+ IHC 3+ TOTAL 
FOLLICULAR STAGE (N=12) a, b 
SE 1 (8.3) 0 1 (8.3) 9 (75.0) 2 (16.7) 11 (91.7) 
SGE 0 0 0 4 (33.3) 8 (66.7) 12 (100.0) 
DGE c 0 0 0 7 (58.3) 5 (41.7) 12 (100.0) 
LUTEAL STAGE (N=11) a 
SE 0 1 (9.1) 1 (9.1%) 6 (54.5) 4 (36.4) 10 (90.9) 
SGE d 0 0 0 9 (81.8) 2 (18.2) 11 (100.0) 
DGE c, d 2 (18.2) 4 (36.4) 6 (54.6) 5 (45.4) 0 5 (45.4) 
FEA (N=34) b 4 (11.8) 10 (29.4) 14 (41.2) 18 (52.9) 2 (5.9) 20 (58.8) 
IHC = immunohistochemical; FEA = feline endometrial adenocarcinomas; SE = surface epithelium; SGE = superficial 
glandular epithelium; DGE = deep glandular epithelium.  
Different superscripts indicate a statistical significance: a P= 0.016; b P< 0.0001; c P= 0.004; d P= 0.024. 
 
The immunoreaction against c-erbB-2 in the normal uterus differed according 
to the stage of the cycle.  Concerning the overall epithelial expression of c-erbB-2 
in FS and LS, controls of the FS were most commonly positive  
for c-erbB-2 (P= 0.016). In FS, the endometrial epithelia were generally positive for 
c-erbB-2 (TABLE 2; FIGURE 2), with only one case (8.3%) with negative scores for 
this oncoprotein in the SE. Scores varied between IHC2+ and IHC3+, accounting 
75.0% (n= 9) and 16.7% (n= 2) in the SE, 33.3% (n= 4) and 66.7% (n= 8) in the 
SGE, and 58.3% (n= 7) and 41.7% (n= 5) in the DGE, respectively. In the LS, the 
SE was negative in only one sample (9.1%), being positive in 10 specimens 
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(90.9%), represented by six samples (54.5%) with a score IHC2+ and four (36.4%) 
with IHC3+. While the SGE of LS was considered positive in all the cases, being 
nine (81.8%) scored as IHC2+ and two (18.2%) scored as IHC3+, the DGE was 
mainly negative (n=6; %); two cases (18.2%) were scored as IHC0 and four (36.4%) 
samples had a score of IHC1+. Only four samples (36.4%) were found positive for 
c-erbB-2 with a score of IHC2+. In the LS, the SGE was more frequently positive for 
c-erbB-2 than the DGE (P= 0.024). Positivity for c-erbB-2 was more frequent in DGE 
of the FS than in the homologous counterpart of the LS (P= 0.004). Feline 
endometrial adenocarcinomas were more likely negative for c-erbB-2 expression 
than controls of FS (P≤ 0.0001). No significant differences were detected between 
FEA and LS.  
FIGURE 2: Immunohistochemical expression of c-erbB-2 in the normal feline endometrium, 
counterstained with Mayer’s haematoxylin. Bar = 50 μm. (A) In the follicular stage, the superficial 
epithelium show positivity for c-erbB-2. (B) In the luteal stage, cells in the deep glandular epithelium 
are negative for c-erbB-2 immunostaining. 
 
In tumours, c-erbB-2 expression was compared with nuclear atypia, number 
of mitosis per HPF and myometrium, serosa and vascular invasion, all features 
presumably indicative of tumour dedifferentiation. However, no statistically 
significant differences were recorded. 
 
DISCUSSION 
 
The present study proposed to establish the pattern of immunohistochemical 
expression for c-erbB-2 oncoprotein in feline endometrial adenocarcinomas (FEA), 
compared to the normal feline endometrium and to explore putative associations 
A B
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between c-erbB-2 and the histopathological features of FEA that might be related to 
poor prognosis and worse outcome. To the best of our knowledge this is the first 
description of c-erbB-2 immunohistochemical expression in feline neoplastic 
endometrium. 
Endometrial adenocarcinomas were usually considered to be rare tumours in 
all domestic species, with exception of cows and the rabbits (Cotchin, 1964; 
Kennedy et al., 1998; McEntee and Nielsen, 1976). The increasing number of 
reports on feline endometrial adenocarcinomas (FEA), however, questions the 
possibility that these tumors may be more common than the literature refers 
(Anderson and Pratschke, 2011; Cho et al., 2011; Gil da Costa et al., 2009; Payan-
Carreira et al., 2013: Sontas et al., 2013). Therefore, additional studies addressing 
FEA characterization are required.  
The 34 cases used herein were classified as FEA of the papillary serous type, 
using previously reported criteria (Preiser 1964; Belter et al. 1968; McEntee and 
Nielsen 1976; Martin de las Mulas et al., 1995; Miller et al., 2003; Gil da Costa et 
al., 2009; Anderson and Pratschke 2011; Saraiva et al., 2012; Saraiva et al., 2015a). 
Moreover, there were also evaluated specific histologic features of malignancy 
(Miller et al. 2003; Horn et al. 2007; Goldschmidt et al. 2011), namely nuclear atypia, 
mitotic activity and myometrial, vascular and/or serosa invasion. 
Human epidermal growth factor receptor type 2 (c-erbB-2) was expressed in 
58.8% of the cases under study. In women, the c-erbB-2 positive phenotype has 
been associated to high-grade tumours (Ferrandina et al., 2005; Mariani et al., 2005) 
and to early stages of the disease (Sugimoto et al., 2007). Data gathered in the 
present study failed to evidence an association between c-erbB-2 scoring and 
histopathological malignant features mentioned above, as it has been also referred 
regarding the women endometrial carcinomas (Ferrandina et al., 2005; Togami et 
al., 2012). Therefore, we can speculate that c-erbB-2 expression does not have a 
great impact in the progression or the prognosis of FEA. 
In women endometrial carcinomas, myometrial invasion is correlated with 
proliferation, risk of recurrence and poor outcome (Prat, 2004). Mitotic indexes are 
used in routine histopathological diagnosis to assess proliferation and it is often a 
predictor of malignancy. Neoplastic cells are often compared to trophoblastic cells 
on respect to invasiveness. However, studies in humans showed that the cells of 
the cyto- and the syncytiotrophoblast seldom express c-erbB-2 protein (Mühlhauser 
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et al., 1993; Wang et al., 1992), suggesting that this molecule may not be directly 
associated with proliferation events, but mainly with differentiation phenomena. 
Thus, a positive expression of c-erbB-2 oncoprotein seems unrelated to poor clinical 
outcome of FEA. However, to assure this hypothesis, additional studies in follow-up 
of FEA and feline placenta are needed to further investigate the potential prognostic 
value of FEA histological features of malignancy. 
The present study also localized the c-erbB-2 protein in the normal feline 
uterus in the follicular and luteal stages of the cat estrous cycle. Differences in the 
expression of c-erbB-2 between the normal feline endometrium and in endometrial 
hyperplasia had been determined (Misirlioglu et al., 2006). In that study, it was 
referred that the c-erbB-2 content in SE of normal feline uterus was lower than that 
of the glandular epithelium, contrasting to the findings in the present study. The 
differences may be explained by the fact that different antibody and scoring systems 
were used, as well as that the oestrous cycle was not staged, therefore impairing 
any inference on eventual cyclic changes in this molecule expression. Still, the 
results reported herein showed that expression for this protein was confined to 
epithelial compartment, as it has been reported regarding the human endometrium 
(Wang et al., 1992). Interestingly, in the present study, the expression of c-erbB-2 
was significantly higher in the FS of feline cyclic endometrium than in LS. Van Dam 
and collaborators (1991) detected non-significantly higher levels of c-erbB-2 
oncoprotein in the proliferative phase of premenopausal endometrium (grossly 
equivalent to the FS described herein), compared with the secretory phase (which 
would correspond to the LS in our work), alike to the results presented herein.  
Estrogens increase the levels of epidermal growth receptor (EGFR) in the 
endometrium (Mukku and Stancel, 1985), and the cyclic interchange between 
estrogens and progesterone has been proved to have a greater effect on EGF 
synthesis (Imai et al., 1995). Steroids also determine the interplay between the 
epithelial and stromal elements of the endometrium, which seems to have a major 
role in the endometrial proliferation and differentiation (Pierro et al., 2001). Once  
c-erbB-2 shares functional and morphologic homologies with EGFRs, it could 
mediate estrogen-induced proliferation (Maia et al., 2002). However, our previous 
work showed that ER-α is underexpressed in FEA compared to normal 
endometrium, suggesting that the proliferation of FEA might be controlled by a 
different pathway, involving local growth factors, rather than by ER-α expression 
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(Saraiva et al., 2015b, submitted). In that work it was also reported that the 
proliferative indexes, estimated on the basis of Ki-67 (MIB-1) immunolabelling, were 
higher in FEA than in the normal endometrium, irrespectively of the oestrous stage 
considered (Saraiva et al., 2015b, submitted). A positive correlation between c-
erbB-2 and MIB-1 is described in human endometrial carcinomas (Ioachim et al., 
2001), which seems to contrast with results reported herein. In fact, c-erbB-2 
expression in LS was higher in the SGE compared to DGE. However, the 
persistency of proliferation of the basal glands during LS, which is reflected by the 
increased coiling reported in this stage (Chatdarong et al., 2005), should 
accompanied an increase in c-erbB-2 expression if this pathway was involved in 
epithelial proliferation of feline endometrium. Watson and collaborators (1996) 
proposed that differentiation and decidualization in the LS is a progesterone-
mediated event, regulated by EGF (Watson et al., 1996). Payan-Carreira et al. 
(2014) also suggested that progesterone is an important driver for differentiation 
events occurring in the canine endometrium during the LS. All the above agreed 
with the involvement of c-erbB-2 with differentiation phenomena occurring during 
trophoblast invasion, as suggested by Mühlhauser et al. (1993). 
These could explain the absence of association between the c-erbB-2 protein 
expression and the histopathological malignant features expressed in FEA, such as 
mitotic index or the invasiveness. Therefore, data gathered in the current study 
regarding c-erbB-2 molecule sustain the hypothesis previously raised (Saraiva et 
al., 2015b, submitted) that other pathways controlling epithelial proliferation in the 
feline endometrium may be involved in FEA carcinogenesis. Therefore, further 
studies ought to address the importance of the loop between oncogenes, growth 
factors and steroid hormones in the determination of proliferative and differentiation 
phenomena in feline cyclic and diseased endometrium. 
 
CONCLUSION 
 
The immunohistochemical location and pattern of distribution of c-erbB-2 in 
FEA and the normal endometrium in FS and LS was described for the first time, to 
the best of our knowledge. The majority of the FEA cases under study were positive 
to c-erbB-2 immunolabeling; however, a decrease in the expression of this protein 
in FEA was observed when compared to the FS of normal endometrium. No 
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associations were established between c-erbB-2 expression and the 
histopathological features potentially related to FEA dedifferentiation and poor 
outcome. The expression of c-erbB-2 was significantly higher in the epithelia of the 
FS compared to LS, which suggests that this protein is influenced by functional 
changes, whether hormonal or non-hormonal, occurring during the feline estrous 
cycle. Additional studies are required to further investigate the role of c-erbB-2 in 
feline endometrial physiology and carcinogenesis. 
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GENERAL DISCUSSION 
 
 Feline endometrial adenocarcinomas are considered rare neoplasms 
(Cotchin, 1964; McEntee and Nielsen, 1976; Kennedy et al., 1998). The common 
practice of spaying in early stages (Miller et al., 2003; Taylor, 2010), the inadequate 
post mortem examination of the genital tract (Schlafer and Miller, 2007) or the lack 
of interest in the anatomopathological evaluation of ovariohysterectomy surgical 
specimens (Sontas et al., 2013) were pointed as the major factors contribution to 
the limited number of diagnosed FEA. Therefore, FEA might be more common than 
described in the literature. 
 While a pathologist, that perception originated the interest in the study of FEA 
and the localization of FEA cases within the archives of four different laboratories in 
Portugal, allowing the identification of a total of thirty cases diagnosed as FEA during 
a period of fifteen years (1995-2010). The cases were revised and the diagnostic 
was confirmed on haematoxylin and eosin (H-E) stained sections. 
In order to increase the series in this study, several private clinics and 
veterinary hospitals were contacted to collect as many surgical specimens of feline 
ovariohysterectomy as possible. These specimens would represent normal feline 
uterus at different stages of the estrous cycle, to be used as controls, as well as 
uterus displaying signs of disease. At the end of the first year of our work, we had 
collected additional nineteen samples of FEA. Staging of the estrous cycle and the 
diagnosis of uterine disease were performed in H-E, the later allowing to distinguish 
between primary FEA, delayed uterine involution and other inflammatory conditions 
of the uterus. 
All the FEA were diagnosed taking in account several criteria of malignancy 
described in the literature (Miller et al., 2003; Horn et al., 2007; Goldschmidt et al., 
2011), which included: significant nuclear and cellular pleomorphism, anisokaryosis, 
anisocytosis and nuclear atypia; mean number of mitoses per high-power field; the 
presence of randomly distributed areas of necrosis within the neoplasm; and 
invasion of the myometrium, of the serosa or of lymphatic/vascular vessels. 
Neoplastic cells were evaluated accordingly to the architectural arrangement, 
morphology, loss of polarity, presence of clear cells (considered present if more than 
5% of neoplastic cells had abundant and foamy cytoplasm), and the presence of 
multinucleated cells. 
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 The histological evaluation of those tumours revealed the existence of three 
different morphologies, as reported in CHAPTER 2: 1) FEA of the papillary serous 
type; 2) FEA in situ and 3) clear cell carcinomas/FEA (Saraiva et al., 2012).  
 In the course of the present study, an increasing number of FEA reports 
(Anderson and Pratschke, 2011; Cho et al., 2011; Sontas et al., 2013; Payan-
Carreira et al., 2013), along with our aforementioned observations support the 
supposition that these tumours are seemly more common than previously 
established. However, limited knowledge on FEA still existed, in particular 
concerning their molecular characterization. These concerns triggered the present 
investigation. 
 Previous reports on FEA described several histological features (Preiser, 
1964; Belter et al., 1968; McEntee and Nielsen, 1976; Martín de las Mulas et al., 
1995; Miller et al. 2003; Gil da Costa et al., 2009; Anderson and Pratschke, 2011; 
Payan-Carreira et al., 2013). Earlier studies on FEA mainly refer to the papillary 
serous type, supporting the findings presented herein, in CHAPTER 2; the most 
prevalent tumour type found in that study was the papillary serous (71.4%), 
compared to FEA in situ (22.5%) and clear cell carcinomas (6.1%). In CHAPTER 2, 
the histopathological features related to FEA were also clarified. For the papillary 
serous type, these included a papillary growth pattern of neoplastic cells, with 
eosinophilic cytoplasm and atypical nucleus, projected into the lumen, with frequent 
and often bizarre mitosis. Other possible but less common arrangements included 
tubular, glomeruloid and solid. Interestingly, FEA were characterized by numerous 
multinucleated cells within or at the surface of the tumour. Randomly distributed 
areas of necrosis were found within the neoplasms. The invasion of the 
myometrium, vessels and lymphatics was not a constant feature. 
 Feline in situ adenocarcinomas were morphologically identical to the papillary 
serous FEA, however they were localized superficially in the endometrium, without 
invasion of surrounding tissues. Feline clear cell carcinomas were almost entirely 
composed by large, round to polygonal cells, with foamy cytoplasm and eccentric 
crenate or ovoid nucleus, with a prominent eosinoplilic nucleolus. There was a 
moderate degree of anisokaryosis and anisocytosis. The cells were arranged in 
papillae, sheets or solid nests surrounded by a fibrovascular stroma. Multinucleated 
cells were absent. Necrosis within the tumours was observed, but inflammatory cells 
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were rare. The invasion of the myometrium was not a constant feature. Vessel or 
lymphatic tumoural emboli were not found in available cases. 
Moreover, the present study also characterized the morphology and 
immunoprofile of FEA of the papillary serous type, regarding a broad panel of 
antibodies, frequently used in routine diagnostic procedures. In fact, results 
presented herein will contribute to improve the histopathological diagnosis of FEA. 
Immunohistochemistry is a current tool to determine antigens in formalin-fixed, 
paraffin-embedded tissues, which principles and procedures apply across mammals 
(Ward and Regh, 2014). Furthermore, it is routinely performed in most laboratories 
of veterinary anatomical pathology to increase the diagnostic accuracy, because of 
its easiness, safeness and relative low cost (Millanta et al., 2005). The 
immunolocalization of cell structures and organelles is a fundamental attribute to 
morphology-based investigation (Leong et al., 2010). Another important trait of 
immunohistochemistry is the evaluation of over- or underexpression of several 
proteins (i.e. c-erbB-2, ER and PR) targeting cancer therapies (Leong et al., 2010). 
These features motivated the use of immunohistochemistry in the present work, 
aiming to provide additional markers for FEA histological diagnosis and for a better 
understanding of the feline endometrial cancer biology. 
 The use of controls and a critical detailed interpretation of the 
immunohistochemistry results are of the utmost importance to take full advantage 
of this technique (Leong et al., 2010; Ward and Regh, 2014). In the present work, 
all the used antibodies were also tested in positive controls, both external and 
internal. Moreover, normal uterine samples were also tested as controls (since for 
most markers the information on the normal pattern in the cat uterus was scarce) 
for comparison with the expression pattern of those markers in FEA tissues. This 
allowed to describe the immunohistochemical expression of a broad panel of 
antibodies in the normal cycling feline uterus and to determine the differences 
observed in diseased uteri. 
 As previously mentioned, the knowledge on FEA is rather limited. Some 
reports described the immunohistochemical expression of ER-α, PR, CK7, CK20 
and COX-2 in small case series (Espinosa de los Monteros et al., 1999; Gil da Costa 
et al., 2009), often without a differential evaluation of the two endometrial 
compartments (epithelium and stroma) or of the myometrium. On the contrary, these 
molecules are largely studied in women endometrial carcinoma, with proved 
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importance as diagnostic and prognostic markers, together with Ki-67 and c-erbB-2 
(Chu et al., 2000; Ferrandina et al., 2002; Prat, 2004). These evidences motivated 
the choice of antibodies used in the present study.  To our knowledge herein the 
expression of Ki-67 and c-erbB-2 in FEA and in cyclic endometrium are described 
for the first time (CHAPTERS 3 TO 5). 
  CHAPTER 3 reports the expression of ER- α and PR in normal endometrium 
(epithelial and stromal compartments) and myometrium. It was shown a small 
decrease in the intensity of immunostaining of ER-α in the luteal stage compared to 
follicular stage, suggestive of the suppressive effect of progesterone receptor 
activation. Similarly, there was a small decrease in the percentage of positive 
epithelial and stromal cells to PR, from the follicular stage to the luteal stage. Our 
results indicate that stromal and epithelial compartments of the endometrium 
respond differently to steroid hormones, as it was suggested before in the mare 
(Aupperle et al., 2000); further, it is also currently accepted that a crosstalk exists 
between both compartments, influencing each other proliferation and differentiation 
(Pierro et al., 2001).  
In FEA, a loss of immunoexpression of ER-α was observed, indicating that 
endometrial cells in FEA possess reduced ability to respond to estrogens. A slightly 
non-significant decrease was observed in the PR immunoexpression, suggestive 
that those cells retain the ability to respond to progesterone stimulation (CHAPTER 
3); therefore, it can be speculated that, in animals with clinically undiagnosed FEA, 
putative progestagen contraception may interfere in the evolution of FEA. This issue 
deserves further investigation. 
The reduced expression of ER-α and PR-A, particularly in neoplastic stromal 
cells, may be important in predicting invasiveness of women endometrial 
carcinomas (Kreizman-Shefer et al., 2014). Similarly, in the present study (CHAPTER 
3) the negative status for ER-α expression in the stromal cells was associated with 
myometrial invasion, a feature usually related to malignancy. Also, lower myometrial 
PR levels compared to ER were found in high-risk human endometrial carcinomas 
(Tomica et al., 2014). Herein, a loss of positive cells for PR in the myometrium of 
FEA was also reported, in relation to higher nuclear atypia in carcinoma cells, 
suggesting that PR may be related to tumour dedifferentiation. Results presented in 
CHAPTER 3 also suggest an intimate interaction between the components of the 
endometrium - epithelium and stroma - as well as between these and the 
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myometrium, likewise the relation between cancer cells and the surrounding tissues 
described in human uterus as a required event for endometrial normal functioning 
and carcinogenesis (Yang et al., 2011).  
 In the normal endometrium, Ki-67 immunoexpression recapitulated the 
morphological features that characterize each stage in the cycling endometrium. In 
the follicular stage, the branching of the upper area of the glands was observed, 
whereas in the luteal stage, the basal glandular area is coiled (Chatdarong et al., 
2005). Therefore, proliferative indexes were expectably higher in the superficial 
glandular epithelium during the follicular stage while in the luteal stage the higher 
proliferative indices were found in the deep glandular epithelium. However, no 
differences were established between the overall Ki-67 expression in the two 
evaluated phases of the estrous cycle (CHAPTER 3). 
 The proliferative index determined by Ki-67 immunoexpression was 
remarkably higher in FEA than in normal endometrial epithelia (CHAPTER 3). In 
women endometrial carcinomas, Ki-67 positively correlates with the histological 
grade, depth of myometrium invasion and risk of carcinoma recurrence (Prat, 2004),  
and is inversely related to hormonal receptor status, particularly in higher grade, ER-
α negative, endometrial carcinomas (Ferrandina et al., 2005; Mingzhu et al., 2014; 
Tangen et al., 2014). However, those association between Ki-67 expression and 
histopathological features were not found in FEA, during the present studies. 
Estrogen receptor alpha may be induced in estrogen-driven tumours, and 
tumour growth is often limited by progesterone, once ER expression is down-
regulated by activated PR (Leslie et al., 2013). Herein, it was demonstrated that Ki-
67 expression was higher in FEA than in normal endometrium similarly to the 
reported for women tumours (Kreizman-Shefer et al., 2014). Since epithelial cell 
proliferation may be stroma-mediated through VEGF production (Koos, 2011), 
future studies on the expression of this and other growth factors expression in FEA 
are needed. Vinci and collaborators (2010) speculated that PR expression is not 
directly involved in endometrial epithelial carcinogenesis (Vinci et al., 2010), a 
feature also hypothesised in the current study. Contrary to the described in women 
(Ferrandina et al., 2005; Mingzhu et al., 2014), no significant correlation was found 
between ER and PR in FEA. 
Feline normal endometrium showed a CK7+/CK20+ immunoprofile, with a 
higher overall expression of CK7 (CHAPTER 3). Very limited knowledge exists 
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concerning cytokeratins’ immunoprofile of feline normal endometrium. However, 
CK7 and CK20 expression is highly conserved during malignant transformation in 
human cancer (Moll et al., 2008), which could be important to the diagnostic 
procedure of primary epithelial neoplasms. 
Feline endometrial adenocarcinomas under study conserved the 
CK7+/CK20+ phenotype observed in normal endometrium (CHAPTER 3). Our results 
are in accordance to those of Espinosa de los Monteros and collaborators (1999). 
Despite the different immunohistochemical profile (CK7+/CK20-) present in women 
endometrial carcinomas, conservation of the normal endometrium phenotype is an 
important tool for diagnosis (Moll et al., 2008). Importantly, the immunophenotype 
of FEA determined in the present study can be an important marker for endometrial 
origin, since the uterus is a possible metastatic site for tumours located elsewhere, 
including mammary neoplasms (Travassos, 2006), which are morphologically 
similar to primary FEA. However, contrary to feline primary endometrial neoplasms, 
feline mammary gland carcinomas are generally negative for CK20, maintaining the 
immunophenotype of the normal mammary gland in this species (Espinosa de los 
Monteros et al., 1999). 
Cyclooxygenase-2 was constitutively expressed in feline normal uterus, as it 
was also reported for women (reviewed by Rouzer and Marnett, 2009). Our results 
support the descriptions by Gil da Costa and collaborators (2009), and further 
enhance that COX-2 is also expressed in feline endometrial stroma. In normal 
endometrial epithelial cells, we found an apical reinforcement of COX-2 
immunolabelling. Epithelial expression of COX-2 was higher in follicular stage than 
in luteal stage. Conversely, the immunoexpression of this molecule was higher in 
the stroma in the luteal stage than in the follicular stage. Data presented in CHAPTER 
4 suggest a progesterone influence on COX-2 expression, which might be 
associated with physiological tissue remodeling accompanying the glandular 
development (Saraiva et al., 2015). 
In FEA, we observed a loss of cell polarity with a dislocation of COX-2 
labelling to the cytoplasm and perinuclear area of epithelial cells (Saraiva et al., 
2015). Loss of COX-2 compartmentalization in FEA supports earlier findings (Gil da 
Costa et al., 2009). In women endometrial carcinomas, COX-2 is overexpressed 
reported (Nasir et al., 2007; Tong et al., 2000). On the contrary, we found a decrease 
in COX-2 expression in FEA. The reasons proposed for this difference included: 
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variances in the types of human and feline tumours, the uterine hormonal 
environment, the scoring systems or the antibodies used (Saraiva et al., 2015). 
Cytoplasmic pattern of expression of COX-2 is described in women 
endometrial carcinomas (Ferrandina et al., 2002, 2005; Lambropoulou et al., 2010; 
Nasir et al., 2007) and is often related with poor prognosis (Kim et al., 2010). 
However, COX-2 inhibition was proved to decrease growth, migration and invasion 
of immortalized human endometrioid epithelial and stromal cells (Banu et al., 2008). 
The results presented in the present study suggest that FEA are apparently low 
aggressive tumours, despite cytoplasmic expression of COX-2 (Saraiva et al., 
2015). The perinuclear pattern of COX-2 immunolabelling was previously described 
in feline transitional cell carcinomas of the urinary bladder and mammary 
carcinomas (Beam et al., 2003; Sayasith et al., 2009). This feature may be related 
with prostaglandins pathways involved in cell growth, apoptosis or cell 
differentiation, including malignant transformation (Sobolewski et al., 2010; Vane et 
al., 1998). 
The cyclic variations in the immunoexpression of the c-erbB-2 oncoprotein in 
feline normal uterus were demonstrated herein for the first time. As shown in 
CHAPTER 5, the expression of c-erbB-2 in the epithelial cells of the endometrium in 
the follicular stage was higher than in the luteal stage, especially concerning deep 
glandular epithelium. These results are not in accordance to the previously referred 
concerning Ki-67 status of normal feline endometrium, suggesting that in this tissue, 
proliferation might not be related to c-erbB-2 pathway. Van Dam and collaborators 
(1991) proposed that higher amounts of c-erbB-2 may increase proliferation for a 
given amount of released growth factor (Van Dam et al., 1991). Therefore, further 
studies on growth factors expression in feline endometrium may clarify this topic. 
 In FEA, c-erbB-2 was expressed in less extend than in the follicular stage of 
normal endometrium (CHAPTER 5). However, no differences were established 
between c-erbB-2 oncoprotein expression in FEA and the luteal stage. Currently it 
was not possible to clarify the role of c-erbB-2 in FEA, however, its decreased 
expression suggests some influence of this oncoprotein in feline endometrial 
carcinogenesis. Similarly to the results reported for women endometrial carcinomas 
(Ferrandina et al., 2005; Togami et al., 2012), no associations were found between 
histopathological data and c-erbB-2 status of FEA. Therefore, c-erbB-2 expression 
seems not to be related to poor clinical outcome of these tumours in queens, as it 
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has also being described for feline mammary neoplasia (Rasotto et al., 2011).  Alike 
in the study of Rasotto and collaborators (2011), the results of the current study did 
not support the existence of an association between c-erbB-2 status and Ki-67 
expression. In order to acknowledge the preliminary results on c-erbB-2 
immunohistochemical expression presented herein, additional studies are required, 
namely for determination of gene amplification. 
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
 In conclusion, FEA despite being uncommon in proportion to the total of 
tumours diagnosed in cats, are more frequent than we initially thought. Concerning 
the uterine neoplasms of the queens, FEA are even the tumours most commonly 
diagnosed, the papillary serous type being the most frequently seen. These tumours 
are characterized by the papillary proliferation of neoplastic cells of serous type, 
accompanied by clear and multinucleated cells. Other architectural arrangements 
mainly included glomeruloide, solid and tubular growth. Randomly distributed areas 
of necrosis within the tumours are commonly observed. Invasion of the myometrium, 
of the serosa and of the vascular and/or lymphatic vessels are not constant features. 
The mean number of mitoses is higher in FEA compared to non-neoplastic 
endometrium. Whether these histopathological findings are related to poor 
prognosis in FEA is a subject of interest in future studies. 
 The results presented herein support that immunohistochemistry can be a 
helpful tool to the routine diagnosis of FEA. These neoplasms markedly lose the 
expression of ER-α compared to normal endometrium, though the loss of PR is not 
so remarkable. Additional studies are required to understand the prognostic and 
therapeutic implication of hormonal receptors status in FEA.  
Proliferation indexes increase in FEA, compared to normal endometrium. The 
antibody against Ki-67 is routinely used to access proliferation status of tumours and 
can be related to a worse prognosis. Further investigation on FEA is important to 
additional information regarding this issue. Other markers of proliferation should be 
included (e.g. PCNA) and the follow-up of queens diagnosed with FEA is needed. 
As in normal tissues, FEA maintain the CK7+/CK20+ profile, however they 
lose some expression of these filaments. This feature can be used as an important 
marker of primary endometrial origin, excluding uterine metastases of epithelial 
neoplasm with any other origin.  
Interestingly, we assist to a different subcellular localization of COX-2 in FEA, 
compared to the apical membrane reinforcement in normal epithelium. Therefore, 
COX-2 is very likely involved in endometrial carcinogenesis. To determine at which 
level this occurs, additional studies are needed, namely in the quantification of the 
protein in normal and tumour tissues. 
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Finally, c-erbB-2 immunolabeling is seen in the majority of FEA, however a 
decrease in the expression of this protein is observed when compared to the 
follicular stage of normal endometrium and no differences are noticed between 
tumours and normal luteal stage. Although it is possible taht c-erbB-2 plays a role 
in feline endometrial carcinogenesis other than proliferation, however it remains 
unclear. Further studies using fluorescent in situ hybridization (FISH), chromogenic 
in situ hybridization (CISH) or silver-enhanced in situ hybridization (SISH) to 
determine HER2 status should be used in complement to immunohistochemistry. 
In the future, additional studies on molecular characterization of FEA can 
improve the knowledge of the mechanisms underlying the disease. Advanced 
molecular techniques are now available and we can benefit from its use to enhance 
our findings. Therefore, we hope that this work goes towards a profitable journey. 
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ABSTRACT 
 
Uterine neoplasms of epithelial origin are rare in cats and most often are 
described in older females. Yet, in less than two years, 4 ovariohysterectomy 
specimens were submitted from different practices to the Laboratory of Histology 
and Anatomical Pathology, at UTAD (Vila Real, Portugal), that emitted a diagnosis 
of feline endometrial adenocarcinoma. Untypically, all the females were aged under 
one year old at the surgery. Access to the clinical files was requested to document 
the clinical features of the four cases, including any complementary data available, 
to construct the present case reports. The clinical situation developed with discrete 
signs, but vulvar discharge was present in 3 cases, ranging from bloody to brownish 
or colourless, and from purulent to mucous. The females were in dioestrus, though 
the estrus remained unperceived in most cases. In this study, the four clinical 
situations are described and discussed on the basis of available literature, 
highlighting the aspects that may impair an early diagnosis and that may favour the 
progression of the disease and also that age should not be an excluding criteria 
when analysing the differential diagnosis list.  
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INTRODUCTION 
Inflammatory lesions in dog and cat endometrium are far more frequent than 
tumours. Among tumours, it is also believe that mesenchymal tumours are found 
more regularly than the epithelial ones (Kennedy et al., 1998; Papparella and 
Roperto 1984; Sapierzynski et al., 2009). 
Feline endometrial carcinoma (FEA) has been considered a rare malignant 
condition that more frequently develops in the uterus of old females (Klein 2007; 
McEntee, 1990; Morris and Dobson, 2001). Dubious information exists concerning 
its association to contraceptive progesterone-based treatments (Miller et al., 2003). 
Yet, recently one case of feline endometrial adenocarcinoma has been described in 
a young, 2 years old, FeLV positive female cat (Cho et al., 2011). The routine 
ovariohysterectomy practiced in cats has been described as protective from uterine 
neoplasia (Miller et al., 2003), although this may not be completely true since FEA 
may develop from the uterine stump (Anderson and Pratschke, 2011). In most 
frequently described situations, uterine adenocarcinomas developed silently, the 
clinical signs for FEA being vague and unspecific, hampering the early diagnosis of 
endometrial carcinoma. The clinical condition becoming visible when metastatic 
disease originates the first clinical symptoms in older female cats (Anderson and 
Pratschke, 2011; Belter et al., 1968; Preiser, 1964). Nevertheless, pyometra 
symptoms are often described in association to FEA. This feature raise the 
suspicion that FEA occurrence may be higher than the described (Sapierzynski et 
al., 2009; Saraiva et al. 2012a; Taylor, 2010), considering that insufficient 
histopathological evaluation of the surgical specimens may occurs whenever 
pyometra-like changes are observed in the excised genital tract. 
The present report describes the clinical signs, the ultrasonographic images 
and the histopathological findings of feline uterine adenocarcinoma in four young 
domestic shorthaired queens, aged under one year old, which were never submitted 
to exogenous progestagens. They are an example of untypical occurrence of an 
endometrial epithelial tumour in very young animals, which only recently started their 
cyclic activity. The major clinical sign was the existence of a discontinuous vulvar 
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discharge that in one case was assumed to be a pyometra. In another situation, no 
discharge was ever reported. For all the four cases, the histopathological analysis 
excluded abortion and evidenced the existence of serous papillary adenocarcinoma 
of the endometrium.  
 
CASE PRESENTATION 
 
CLINICAL PRESENTATION 
In a twelve months period (from May 2011 to May 2012) four cases of feline 
endometrial adenocarcinoma in female cats under one year of age were submitted 
to the Laboratory of Histology and Anatomical Pathology at UTAD (LHAP-UTAD), 
Vila Real. They all came from different practices in the north of Portugal that also 
provided the available clinical information. Clinical symptoms ranged from absent to 
a haemorrhagic or brownish discharge easily confused to pyometra or abortion. For 
most the situations, the owners were unaware of the existence of regular oestrous 
activity. Nevertheless, in all the cases, active corpora lutea were found in the 
ovaries, and the oestrous cycle was staged as dioestrus. A distended, firm uterus in 
such young individuals was the motive for submitting of the excised genitalia to the 
histopathology laboratory that emitted the final diagnosis of feline endometrial 
adenocarcinoma of the papillary type. 
 
TABLE 1: Selected clinical details of the 4 cases of feline endometrial adenocarcinoma in animals 
under one year old. 
CASE 
NUMBER 
REGION BREED AGE MAIN CLINICAL 
COMPLAINT AT 
SURGERY 
LAST EVALUATION 
POST-SURGICAL 
1 Vila Real 
Domestic 
shorthair 
8 months old Intermittent 
bloody vulvar 
discharge 
12 months – 
uneventfully 
2 Águeda 7 months old No clinical 
symptoms 
8 months – 
uneventfully 
3 Aveiro 10 months old Dark vulvar 
discharge 
15 months – after an 
8-month period, an 
intermittent bloody 
vulvar discharge 
appeared 
4 Vila Real 11 months old Intermittent 
mucous vulvar 
discharge that 
sporadically turns 
reddish in colour 
14 months - 
uneventfully 
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Case 1 
A domestic shorthair female cat with 8 months old was presented to 
consultation at the veterinary practice #1 (Vila Real, Portugal), with complaint of 
episodic bloody vulvar discharge for the preceding two weeks. The animal had been 
recently adopted from a free-ranging rescue program, and was not adequately 
vaccinated or dewormed. The queen was found in good physical condition, alert and 
with normal appetite. The previous reproductive history for the animal was unclear. 
When inquired, the owner ignored if she had already passed her first oestrus. 
Besides the periodic bloody discharge, no other symptoms were observed. 
At the physical examination the queen fur was dull, with symmetrical, bilateral 
areas of alopecia in the neck (suggestive of previous breeding), and in the perivulvar 
area the hair was stuck and stained in dark red. At the moment, no vulvar discharge 
was observed. The body temperature was 39 °C, the heart and respiratory rates 
were within normal limits and the capillary refill time under 2 seconds. There were 
no indicators of dehydration. Abdominal palpation showed a slightly increase of the 
uterine volume, but was not associated neither to an increase in the vulvar discharge 
nor to abdominal pain. 
A basic complete blood count (CBC) and preliminary biochemistry analysis 
were performed (TABLE 2). Haematological changes included an increase in the 
leucocyte counts due to neutrophilia and eosinophilia. The haematocrit was near 
the lower reference value for the species (30.8%), and the biochemical parameters 
were within normal range values, with only an increase in ALT (204U/L; reference 
values = 10 to 75 U/L).  
Abdominal ultrasonography showed a slightly enlarged, compact uterus. The 
uterine horns were faintly lobulated (FIGURE 1). Increased thickness of the uterine 
walls extended from the corpus to both cornua. In US images the thick walls nearly 
apposed, only separated by a very thin anechoic line corresponding to the uterine 
cavum, which was not distended by fluid (FIGURE 1). 
Given the clinical signs and on ultrasound observations, together with the 
possibility of mating in its putative first oestrus, the differential diagnoses raised for 
the bloody discharge was abortion and endometrial adenocarcinoma. The 
occurrence of intermittent episodes of bloody discharge directed the diagnosis 
towards FEA, as for abortion it would be expected the vulvar discharge to be more 
frequent. It was further supported by the observation of uterine wall thickening in the 
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absence of fluid accumulation. The final tentative diagnosis was feline endometrial 
adenocarcinoma and ovariohysterectomy was advised. 
Twelve months have past from the surgery, and no signs of relapses have 
been reported. 
 
TABLE 2: Haematological and biochemical parameters at admittance for the queen in case 1. 
PARAMETER (UNITS) 
VALUE AT 
ADMITTANCE 
LABORATORY REFERENCE 
VALUES 
Haematocrit (%)  
RBC (91012/l)  
WBC (9109/l)  
Neutrophils (x109/l)  
Eosinophils (x109/l)  
Lymphocytes (x109/l)  
Monocytes (x109/l)  
ALT (U/l)  
BUN (mM)  
Creatinine (μM)   
Total proteins (g/l)  
Albumin (g/l)  
30.8 
6.48 
25.12 
21.03 
1.47 
1.65 
0.9 
204 
13.03 
72.49 
64.1 
26.7 
30–45 
5–10 
5.50–19.50 
2.5–12.5 
0.10–0.79 
0.4–6.8 
0.15–1.70 
10–75 
10.71–21.42 
74.26–180.34 
60–82 
25–39 
Values outside the reference values are in bold. 
 
 
FIGURE 1: Abdominal ultrasound image at the day of admittance showed uterine (Ut) enlargement 
(white double-ended arrow), due to increased uterine wall thickness. In some scans, the anechoic 
uterine cavum (white arrow) presented an eccentric position as consequence of asymmetrical uterine 
wall width (red double-ended arrow). 
 
Case 2 
A 7 months old domestic shorthair female cat was presented to consultation 
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at the veterinary practice #2 (Águeda, Portugal), for routine OVH. Except for a 
respiratory disease episode and stromal keratitis associated to herpesvirus infection 
when she was a baby, this queen was healthy and never evidenced signs of uterine 
disease. Nevertheless, the growing rate was slower than the expected and she was 
a small queen for the age. According to the owner, no oestrus signs have been 
perceived previous to surgery. At admittance for surgery, the temperature was 
38.3ºC and the heart and respiratory rates were within the normal parameters; the 
physical examination was declared normal, and no complementary analyses were 
required. At surgery, the uterus was found enlarged and slightly thickened and thus 
assumed to have a pyometra. Due to her age, the altered excised genital tract was 
sent for analysis.  
From the surgery to this moment (10 months), the female health remains 
uneventfully. After the histopathology diagnosis, a set of complementary methods 
for detection of putative metastases was requested: blood analysis (Haematological 
and biochemical parameters), urinalysis, abdominal and thoracic radiology and 
ultrasonography. The results for the analysis were within normal values and 
imagiological exams devoid of evidences suggesting the presence of metastases. 
 
Case 3  
A 10 months old domestic shorthaired female cat was presented to 
consultation at the veterinary practice #3 (Aveiro, Portugal), with complaints of 
intermittent brownish vulvar discharge. The female was adopted while a baby. 
Previous medical history included episodic gastrointestinal problems and slow 
growing rate. The owner could not provide information on the occurrence of previous 
oestrus. The physical examination showed the perivulvar fur soiled in dark. The 
owner had noticed an intermittent dark vulvar discharge not associated to any 
clinical symptoms, but disregarded it. The temperature was within normal values for 
the species (38.0ºC), as well as the heart and respiratory rate and the capillary refill 
time. Due to economic constraints, complementary analyses were not performed, 
and ovariohysterectomy was decided under the suspicion of pyometra. At surgery, 
the uterus was found enlarged, firm and fluid-filled, and presented small nodules 
projecting towards the serosa. Due to its striking appearance the histopathological 
analysis was requested.  
Surgery recovering was uneventfully, but eight months after the OVH the 
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female was presented once more due to recurrence of the intermittent bloody 
discharge. The haematology and biochemistry analysis were within the reference 
range for the species. At ultrasonography, no signs of intra-abdominal mass were 
found and the uterine stump was not visible. Vaginal cytology was requested but the 
material was insufficient for diagnosis. Afterwards, the owners elected against any 
additional intervention, even if maintaining the female under vigilance. 
 
Case 4 
An 11 months old domestic shorthaired female cat was presented for 
consultation at the veterinary practice #4 (Vila Real, Portugal), for routine OVH. The 
female exhibit her first heat three months prior to surgery. No additional oestrus was 
detected since. The main complaint was the existence of intermittent mucous vulvar 
discharge for the past 2 to 3 weeks, which occasionally was reddish in colour. 
Previous medical history is unknown. No contraceptive treatment was performed at 
home. Occurrence of male contact was possible, as the female had free access to 
a garden. At consultation, the heart and respiratory rates were within the normal 
parameters for the species, but the body temperature was 39.7ºC. Due to economic 
constraints, the complementary diagnostic assessments (blood analysis and 
ultrasound) were not requested. The preliminary tentative diagnoses were pyometra 
and abortion, and surgery was recommended. Fourteen months over the surgery 
the animal is in good fitness and no signs of genital disease were perceived. 
 
HISTOPATHOLOGICAL EVALUATION 
All the four surgical specimens were received fixed in 4% buffered formalin 
and analysed at the LHAP-UTAD, under routine haematoxylin-eosin staining. The 
uterus was longitudinally cut for better examination, and 4 to 7 blocks were prepared 
to cover a representative area of the altered morphology and neighbouring zone. 
None of the lesions showed a nodular pattern, but rather extended through both 
uterine horns. On TABLE 3, it is provided a brief summary of the content of 
histopathological records. 
The major macroscopic finding was the uterine enlargement (FIGURES 2 A-D). 
In all the situations, a two to five-fold increase in the normal uterine horn diameter 
was present. Also, changes in the usual trajectory for the cat uterine horns were 
found, changing from slightly lobulated (cases 1 and 4; respectively FIGURES 2 A-D)  
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to moderately tortuous (cases 2 and 3; FIGURES 2 B-C, respectively). The uterine 
horns were firmer than the usual. The uterine wall was smooth (FIGURES 2 A-B and 
2 D), except for case 3 that presented several umbilicated nodular areas spotting in 
both uterine horns (FIGURE 2 C). Limited collection of purulent fluid was also found 
for cases 2 and 3. In case 4, both uterine horns presented portions of vesicular 
distension of the uterus, filled of purulent content, intermingled with areas of 
increased density (FIGURE 2 D).  
On transversal cuts of the uterine horns and body, an increased thickness of 
the endometrium was the major evidence (FIGURES 2 E-H). For most cases it 
extended through the entire wall. Restricted areas of uterine dilatation were present 
only in cases 2 and 4, which in the former was limited to the apex of one uterine 
horn. 
 
FIGURE 2: Macroscopic features of the Feline Endometrial Adenocarcinoma: A-D – Gross 
external morphology of the uterus in the cases described. A. Asymmetrical, nearly regular and 
bilateral enlargement of the uterine horns. B. Irregular enlargement of the uterine horns showing an 
increase in size in the cranial portion of the uterus; the ovary is laterally displayed. C. Enlarged uterine 
horns of irregular surface with exofitic prominences (arrows). D. Bilateral enlargement of both uterine 
horns showing 3 vesicular dilatations (arrowhead). E-H. Internal morphology of the uterus shown in 
sagittal sections. E. Uniform thickness of the endometrium, and necrotic/haemorrhagic areas (black 
tissues) were observed, along with endometrial areas invading the myometrium (arrow). F. In the 
dilated portions of the cranial uterine horn, it was observed the thinness of the wall (arrow) and 
nodular irregular proliferations, while in the other portions the uterus showed increased thickness. G. 
Increase thickness of the uterine wall showing haemorrhage and invasion of the myometrium up to 
near the serosa (arrow). H. Alternate disposition of the wall thinness matching the vesicular areas of 
dilatation (arrowhead) and thickness with exofitic endometrial proliferation (arrow) being more 
pronounced in the uterine body. 
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In areas of increased thickness, the uterine wall displayed yellowish 
proliferation of the endometrium, which seemed to deepen in some areas towards 
the myometrium (FIGURES 2 E and 2 G). In sections devoid of fluid, the uterine cavum 
was narrow, and opposing endometrium was closer than the normal. Further, it was 
perceived a papillary growth of the endometrium into the narrowed uterine lumen. 
Haemorrhage was sporadically found within both uterine horns for cases 1 and 4 
(FIGURES 2 E and 2 H). 
The ovaries presented a variable number of corpora lutea, attesting for the 
previous occurrence of an oestrus and possible mating. 
Histologically, uterine sections evidenced an extensive branched papillary 
proliferation of the endometrium, which were displayed in an irregular arboriform 
papillae and a complex cystic patterns arising from both the superficial and deep 
glandular endometrial epithelia (FIGURES 3 A-D). The tumour cells were columnar 
and loosed their polarity towards a thin stromal axis and frequently display a 
stratified disposition (FIGURE 3 E). Only for case 2, the deep endometrial glandular 
layer remained closer to normal, even if presenting serous, proteinaceous content. 
For case 1 and 3, areas of glomeruloid differentiation (FIGURES 3 C and 3 G) were 
reported, with multinucleated and aberrant cells. The stroma adjacent to the 
adenocarcinoma lesions exhibited a desmoplastic reaction (FIGURE 3 A). Epithelial 
cells in the tumour showed anisocytosis, anisocariosis and intense cell 
pleomorphism (FIGURES 3 E-F), evidenced by severe atypia, irregular chromatin 
clumping, and aberrant, prominent nucleoli. Atypical mitoses were reported in cases 
2, 3 and 4, even if mitotic activity was limited to 1 to 3 mitoses per 40x field.  
The stromal axis and the endometrial stroma contained scattered 
inflammatory cells infiltrate, whose number was increased in areas with co-existing 
pyometra (cases 2 to 4). Pyometra with decreased thickness of the endometrium 
was limited to the cranial apex of one uterine horn in case 2, and to the dilated 
portions of the uterine horns in case 4. On the remainder portions of the uterus, as 
for the others cases, endometritis was referred in the histological report. 
Myometrial invasion by the tumour was found in cases 1 and 3. Yet, in case 
3, invasion of the myometrium was more pronounced, being particularly evident in 
the nodular areas where focal infiltration of the uterine wall by tumour cells reached 
the uterine serosa and was accompanied by granulation tissue proliferation. In none 
of the cases vascular permeation was mentioned. 
Contribution to the Study of Feline Endometrial Adenocarcinomas | 159 
 
 
FIGURE 3: Microscopic features of Feline Endometrial Adenocarcinoma. [Hematoxilin and eosin; A-
D: lower magnification – bar= 300µm; E,F: moderate magnification – bar= 100µm] A. Extensive and 
irregularly branched papillary proliferation of the endometrium, supported by a central conjunctive 
stroma; haemorrhages were observed in the superficial area (Case 1). B. Irregular, parallel papillary 
proliferation of the endometrium, with inward areas of solid and glomeruloid pattern (Case 2). C. 
Severe disarrangement of the endometrial glands that presented irregular papillary ingrowths with 
prevalent glomeruloid pattern; sub-surface haemorrhage was evident (Case 3). D. Proliferation of 
the endometrial glands into a solid and papillary pattern supported by a central fibrovascular stroma; 
the increased density of the cells lining the papilla is characteristic of anisocariosis. Mucous, cellular 
debris and neutrophils were found in the lumen (Case 4). E. The papillary ingrowths were often lined 
by epithelial cells displaying stratified disposition (arrow). F. Detail of D tumour showing anisocytosis, 
anisocariosis and cellular pleomorphism, severe atypia, and aberrant and multinucleated cells. 
Apoptosis and necrosis were present. 
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In addition, areas of haemorrhage were found in cases 1 and 4, as well as 
areas of papillary hyperplasia, peripherals to the tumour. The endometrial 
carcinoma extended throughout the uterus and was invading the oviducts in case 3. 
For all the four specimens, the histological diagnosis was primary feline endometrial 
adenocarcinoma of serous papillary type.  
 
DISCUSSION 
 
Epithelial tumours of the feline uterus are considered rare (Cotchin, 1964; 
Kennedy et al., 1998; McEntee and Nielsen, 1976). Yet, incidence of feline 
endometrial adenocarcinomas may be underestimated due to the current practice 
of spaying young female cats. However, this procedure may not guarantee freedom 
from this disease, since some reports exist on adenocarcinoma in the uterine stump 
of spayed cats (Anderson and Pratschke 2011; Miller et al., 2003). Most frequently 
FEA are reported in older queens, over 9 years of age (Belter et al., 1968; Klein 
2007; McEntee, 1990; Morris and Dobson, 2001; Preiser, 1964), and described 
clinical signs often correspond to the existence of metastasis (Anderson and 
Pratschke, 2011; Belter et al., 1968; Preiser, 1964). Nonetheless, in a recent report, 
a case of uterine adenocarcinoma has been described in a young 2 years old 
Persian queen with feline leukaemia virus infection (Cho et al., 2011); the authors 
raised the hypothesis that immunodepression associated to the viral infection would 
contribute to the process of tumorigenesis. 
In the cases described herein, the animals were yearling females, with ages 
ranging from 7 to 12 months that recently acquired sexual maturity. All of them had 
access to the exterior and contact to other cats. None of the females was under 
contraceptive treatment. Unfortunately, at the time of surgery the animals were not 
tested for any of the most current feline virus (such as FeLV and PIF) and it was not 
possible to ascertain for a possible involvement of a viral infection on the 
carcinogenic process. Yet, in one of the cases described (Case 2), herpesvirus 
infection was referred earlier in the cat life. 
If, in particular situations, some retrovirus have being implicated as trigger for 
proliferative diseases (Khan et al., 1993), it might also be needed that, in regard to 
the uterus, a specific endocrine environment must exit. In fact, in the report by Belter 
et al. (1968) and the one by Cho (2011) the diseased animals were in dioestrus, and 
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displayed corpora lutea in the ovaries, as it was the case for the 4 females from the 
present study. Also Sontas et al. (2013) refer to the existence of luteal cysts (that 
might be cavitary corpora lutea from recent ovulation) in one of the females with 
FEA. The work of Saraiva et al. (2012b) showed that all the fifty FEA analysed were 
positive for the progesterone receptor, supporting the earlier observations by Gil da 
Costa et al. (2009) that found progesterone receptors in 5 of 6 endometrial 
adenocarcinoma samples. In two of the cases described in previously neutered 
queens administration of exogenous progesterone for a variable period prior FEA 
diagnosis was reported (Anderson and Pratschke, 2011; Miller et al., 2003). Such 
findings raise the question on the eventual role for progesterone in the invasiveness 
and progression of the epithelial tumours of the cat endometrium, highlighting the 
fact that the species is an induced ovulator. Taken together, the above-mentioned 
information suggests that progesterone may favour the abnormal proliferation of the 
endometrial glands that, with an adequate stimulus (ex. a viral infection), might 
become uncontrolled. In the cases described herein, the number of oestrous cycle 
with a luteal stage was limited by the animal age, and no contraceptive treatment 
was previously used. So it is improbable that the endometrial carcinoma may be 
associated to prolonged progesterone overstimulation of the uterus. Still, cats are 
prone to present highly proliferative lesions in the mammary glands under 
progestagenic stimulation - mammary fibroepithelial hyperplasia (Johnston et al., 
2001b) – suggesting that the species may be particularly sensible to progesterone 
influences, even if no evidences exist about those hyperplasic reactions (mammary 
or uterine) may acting as pre-neoplasic phenomena. 
Despite being rarely reported, FEA are believed to be locally invasive, and 
the occurrence of metastasis are commonly reported and often associated to the 
development of FEA symptoms (Anderson and Pratschke, 2011; Belter et al. 1968; 
Preiser, 1964). In the absence of metastatic disease, FEA clinical signs are often 
discrete and the disease frequently develops silently. When analysing the available 
FEA descriptions (Anderson and Pratschke, 2011; Belter et al., 1968; Miller et al., 
2003; Sapierzynski et al., 2009), it seems that clinical signs in this kind of tumours 
may vary with the size of the neoplasic lesions and the age of the process, which 
might determine the most prevalent clinical sign.  
In the absence of metastases, vague and unspecific signs of uterine disease 
are often reported, such as infertility (Miller et al. 2003), weight loss and vaginal 
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discharge (Cotchin, 1964; Miller et al., 2003; Sapierzynski et al. 2009). In available 
reports, the vaginal discharge has been described as being mucous (Cotchin, 1964), 
malodorous (Miller et al., 2003) or haemorrhagic (Miller et al., 2003; Sapierzynski et 
al., 2009; Sontas et al., 2013), and may be constant (Miller et al., 2003; Sontas et 
al., 2013) or intermittent (Meier 1956, cited by McEntee, 1990; Sapierzynski et al., 
2009). A vaginal discharge was noticed in three of our four cases, varying from 
mucous to bloody or purulent-hemorrhagic. In all the cases it was intermittent. All 
the females were considered to have an adequate body condition, except for the 
queens in cases 2 and 3, whose previous clinical history included reference to slow 
growing rate. However, in none of the cases described in the present work, 
inconspicuous signs such as lethargy and inhappetence were observed. Vomiting 
(Anderson and Pratschke, 2011; Cho et al., 2011), irregular appetite (Sapierzynski 
et al., 2009), polyuria/polydipsia, and lethargy are also possible to found in animals 
with FEA, but it often suggest the existence of a co-existing chronic inflammation in 
the uterus in moderately advanced situations. Frequently, these symptoms lead to 
a putative diagnosis of uterine disease, like pyometra, or abortion in queens that 
have been mated (Taylor, 2010). 
Enlargement of the uterus, causing abdominal distension and compression 
of adjacent viscera with concurrent constipation or dysuria have been described 
(Johnston et al., 2001a; Klein, 2007; Taylor, 2010) whenever larger tumours exist. 
Enlargement of the uterus is easily found during abdominal palpation, and may elicit 
abdominal distress or pain during the procedure (Anderson and Pratschke, 2011). 
If metastases exist, depending on the location of the metastasis, ascites, cough and 
respiratory distress or blindness and motor incoordination may be found (Klein, 
2007; Taylor, 2010). These symptoms are often present together with anorexia and 
important weight loss, fever, anaemia and dehydration (Belter et al., 1968; Johnston 
et al. 2001a; Meier 1956 quoted by McEntee, 1990; Miller et al., 2003). Seldom, 
recurrent oestrus has been reported (Anderson and Pratschke, 2011).  
Amongst the cases reported in the present study, only the queen in case 3 
developed signs compatible with possible persistency of the adenocarcinoma 
following OVH. Further, samples from this female also showed that FEA lesions 
deeply invaded the myometrium and reached the serosa, which increase the chance 
for subsequent abdominal metastization through the omentum or through the uterine 
stump, as it was described by Cho et al. (2011). If Taylor (2010) defends that most 
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cats develop metastatic disease within 6 months of diagnosis if OVH is not 
performed, one should be aware that this period would greatly vary with the stage 
of the disease at surgery and also with FEA aggressiveness, and thereby this period 
should be considered as indicative. For the two cases described by Sontas and 
colleagues (2013) 21 and 23 months after OVH the animals remained free of clinical 
uterine disease. For our four cases, only the case 3 showed reappearance of the 
intermittent bloody discharge, suggesting dissemination of the neoplastic lesions at 
the uterine stump. For all the other cases, the females remain asymptomatic.  
The usefulness of the clinical blood analysis for diagnosing FEA is limited, 
particularly in early situations. On regards to clinical blood analysis in the cases 
reported herein, in part due to economic constraints. In case 1, besides an increased 
in white cells counting, due to increased values for neutrophils and eosinophils, the 
sole disturbed biochemical parameter was ALT (alanine aminotransferase), which 
almost triple the normal range values. Sapierzynski et al. (2009) found a similar rose 
in the case they described. Regenerative anaemia and neutrophilia are common 
findings in FEA situations (Klein, 2007; Morris and Dobson, 2001; Sontas et al., 
2013). 
The ultrasonography may be helpful for the initial assessment of the clinical 
situation, although the most often described ultrasound images are similar to those 
of pyometra. However, irregular coiling or increased thickness of uterine wall in the 
absence of limited collection of the fluid in the uterus or narrowing of the uterine 
cavum, co-existing with bloody vaginal discharge should lead to suspicion of 
endometrial adenocarcinoma. Ultrasonography may further be useful to define the 
origin of the mass or to evaluate regional metastasis in more advanced situations 
(Klein, 2007; Morris and Dobson, 2001).  
Bloody or intermittent vulvar discharge whatever the queen´s age or the 
sexual status should always lead to include FEA in the differential diagnosis list. 
Yet, a definitive diagnosis is only obtained through histological examination 
of surgically excised specimens (Klein, 2007). In FEA, the mitotic index (MI) seems 
not to be useful in distinguishing FEA with different invasiveness ability, as in 
general, MI below 5 mitoses per field have been referred (Anderson and Pratschke, 
2011; Gil da Costa et al., 2009; Sapierzynski et al. 2009). According to Miller et al. 
(2003) in feline endometrial adenocarcinoma the mitotic index does correlated with 
invasiveness of the tumour or the outcome of the case. Loss of oestrogen and 
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progesterone receptors has been referred as sign of malignancy for feline 
endometrial carcinomas (Gil da Costa et al., 2009; Miller et al., 2003) and it may be 
important when searching for prognosis markers. Hormone-dependent FEAs may 
benefit from medical management of metastatic spread after ovariohysterectomy 
(Gil da Costa et al., 2009). Additional studies are needed to highlight the possible 
involvement of progesterone on the initial FEA development.  
Intermittency of bloody vaginal discharge should be foreseen as a strong 
indicator of the initial stages of FEA, as it is seldom saw during other uterine 
diseases. Further, in case of abortion, despite the presence of haemorrhagic 
discharge, this tend to decrease with time and often corresponds to a dark bloody 
secretion containing cell debris corresponding to placental or embryonic necrotic 
material. Moreover the vaginal discharge, a disturbed appearance of the uterus on 
ultrasound images or at surgery should be deemed as indicators for 
histopathological evaluation of the excised specimen, independently of the female 
age. Recently, growing evidences points to the fact that, in cats, endometrial 
adenocarcinomas do not show a predisposition for a sexual status (intact vs. 
spayed) or age (Saraiva et al., 2012a) 
 
CONCLUSIONS 
 
In this report, four cases of endometrial carcinoma in yearling cats under 
without major clinical findings are reported. In all of them, there were uterine 
enlargement and increased uterine wall thickness; often uterine dilatation by fluid 
accumulation was recorded. For all the cases, corpora lutea were present within the 
ovaries. Underlying mechanism for FEA tumourigenesis remains unclear, and 
request additional studies in larger series of tumours. Also, due to its rarity, detailed 
reports on clinical cases would be needed to highlight the clinical course and 
outcome, as well as additional diagnosis approaches to FEA. 
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